Page last updated: 2024-10-27

fluorouracil and Stomatitis

fluorouracil has been researched along with Stomatitis in 371 studies

Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.

Stomatitis: INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP.

Research Excerpts

ExcerptRelevanceReference
"to evaluate the effect of oral cryotherapy compared to physiological serum on the development of oral mucositis in outpatient cancer patients using the 5-fluorouracil antineoplastic agent."9.34Effect of cryotherapy in preventing mucositis associated with the use of 5-fluorouracil. ( Aguiar, MIF; Alves, NP; Lopes, TSS; Oliveira, PP; Rodrigues, AB; Silva, RA; Vitorino, WO, 2020)
"We assessed adding the multikinase inhibitor sorafenib to gemcitabine or capecitabine in patients with advanced breast cancer whose disease progressed during/after bevacizumab."9.17Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. ( Beck, JT; Bell-McGuinn, K; Eisenberg, P; Emanuelson, R; Hermann, RC; Hudis, CA; Isaacs, C; Kaklamani, V; Keaton, M; Kirshner, JJ; Levine, E; Lokker, NA; Makari-Judson, G; Medgyesy, DC; Qamar, R; Ro, SK; Rugo, HS; Schwartzberg, LS; Starr, A; Stepanski, EJ; Tauer, KW; Wang, W, 2013)
"We measured the effectiveness of the prophylactic administration of a polaprezinc suspension dispersed in sodium alginate solution (P-AG) by dividing it into two courses in the same patients, and measured the stomatitis induced by Docetaxel/Cisplatin/Fluorouracil (DCF) chemotherapy."9.15[Preventive effect of polaprezinc suspension dispersed in sodium alginate solution (P-AG) for stomatitis induced by Docetaxel/Cisplatin/Fluorouracil (DCF) chemotherapy in patients with head and neck cancer]. ( Fujiki, Y; Hama, T; Hatake, K; Ishibashi, M; Kawakami, K; Kawata, K; Mishima, Y; Nemoto, M; Sugisaki, T; Takahashi, S; Yokoyama, M, 2011)
"Stomatitis is a common adverse effect of intravenously infused 5-fluorouracil (5FU)."9.12Prevention of 5-fluorouracil-related stomatitis by oral cryotherapy: a randomized controlled study. ( Kalofonos, Ch; Naxakis, S; Papadeas, E; Riga, M, 2007)
" Oral glutamine supplements (OGS) may have a role in the prevention of chemotherapy-induced mucositis/stomatitis."9.12The effect of oral glutamine on 5-fluorouracil/leucovorin-induced mucositis/stomatitis assessed by intestinal permeability test. ( Choi, K; Jeon, WK; Kim, JW; Lee, SS; Lim, SY; Oh, SJ; Oh, TY, 2007)
"To characterize the efficacy and safety of palifermin in reducing the incidence of oral mucositis (OM) and diarrhea when administered to patients with metastatic colorectal cancer (CRC) receiving fluorouracil/leucovorin (FU/LV) chemotherapy."9.12Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. ( Abdi, E; Cesano, A; Chen, MG; Clarke, S; Davis, ID; Gayko, U; Gutheil, J; Rosen, LS; Schnell, FM; Zalcberg, J, 2006)
"This multicentre phase I/II study was designed to determine the maximum tolerated dose of irinotecan when combined with 5-fluorouracil and folinic acid according to the Mayo Clinic schedule and to evaluate the activity of this combination as first-line therapy in patients with advanced colorectal cancer."9.11Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer. ( Boussard, B; Carmichael, J; Daniel, F; Davidson, N; Falk, S; Jacobs, C; Kuehr, T; Rapoport, BL; Ruff, P; Thaler, J, 2004)
"To evaluate the safety and efficacy of irinotecan (CPT-11) alternated with a weekly treatment for 4 weeks of oxaliplatin (L-OHP), high-dose leucovorin (LV) and a 48-hour 5-fluorouracil infusion (5-FU 48 h) as first-line chemotherapy for patients with advanced colorectal cancer (ACC)."9.11A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer. ( Colarusso, D; Manzione, L; Pizza, C; Reggiardo, G; Rinaldi, A; Rosati, G; Tucci, A, 2004)
"To assess the activity and safety of combined folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC) in metastatic breast cancer patients previously treated with at least two chemotherapy regimens."9.10Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens. ( Correale, P; Fiaschi, AI; Francini, G; Marsili, S; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M, 2002)
"We investigated the activity of irinotecan given with a more convenient modified bimonthly de Gramont regimen of bolus and infusional 5-fluorouracil [IrMdG] in advanced or metastatic colorectal cancer in the first and second line setting."9.10Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer. ( Hochhauser, D; James, R; Ledermann, JA; Leonard, P; Seymour, MT, 2002)
"The present study was conducted to evaluate the effect of allopurinol spray on stomatitis induced by chemotherapy for esophageal cancer."9.10[The preventive effect of allopurinol spray on stomatitis induced by anti-cancer drugs]. ( Fujii, E; Hanawa, T; Ito, A, 2002)
"The combination of fluorouracil and leucovorin has until recently been standard therapy for metastatic colorectal cancer."9.09Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. ( Ackland, SP; Blanke, C; Cox, JV; Elfring, GL; Fehrenbacher, L; Locker, PK; Maroun, JA; Miller, LL; Moore, MJ; Pirotta, N; Rosen, LS; Saltz, LB, 2000)
"To compare the response rate, efficacy parameters, and toxicity profile of oral capecitabine with bolus intravenous (IV) fluorouracil plus leucovorin (5-FU/LV) as first-line treatment in patients with metastatic colorectal cancer."9.09Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. ( Ansari, R; Batist, G; Burger, HU; Cox, J; Harrison, E; Hoff, PM; Kocha, W; Kuperminc, M; Maroun, J; Osterwalder, B; Walde, D; Weaver, C; Wong, AO; Wong, R, 2001)
"We have reported that an alternating regimen of bolus and continuous infusion 5-fluorouracil (FU) was superior to bolus FU in terms of response rate and progression-free survival in advanced colorectal cancer."9.095-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer. ( Aschele, C; Caroti, C; Cirillo, M; Cortesi, E; Frassineti, GL; Gallo, L; Grossi, F; Guglielmi, A; Labianca, R; Pessi, MA; Ravaioli, A; Recaldin, E; Sobrero, A; Testore, P; Turci, D, 2001)
"The aim of this study was to investigate the effects of adding interferon alfa-2b (IFN) to protracted venous infusion fluorouracil (PVI 5-FU) from the start of treatment in patients with advanced colorectal cancer."9.08Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer. ( Ahmed, F; Cunningham, D; Findlay, M; Hickish, T; Hill, M; Middleton, G; Nicolson, V; Norman, A; Watson, M; Webb, A, 1995)
"A clinical trial was conducted in order to evaluate the anti-tumor effect and toxicity of a continuous infusion of 5-fluorouracil (5-FU) for metastatic colorectal cancer."9.08Clinical trial of continuous infusion of 5-fluorouracil using an ambulatory pump for metastatic colorectal cancer. ( Kondo, H; Ohkura, H; Saito, D; Shimada, Y; Shirao, K; Sugano, K; Yamao, T; Yokota, T; Yoshida, S, 1995)
"No effective systemic salvage therapy exists for patients with advanced colorectal cancer who progress after receiving bolus fluorouracil (FU) and leucovorin (LV) chemotherapy."9.08Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer. ( André, AM; Bertino, JR; Conti, JA; Grossano, DD; Kemeny, NE; Saltz, LB, 1995)
"A phase I trial of 5-fluorouracil (5-FU), leucovorin (LV) and interferon (IFN) was conducted in 15 advanced colorectal cancer patients refractory to a bolus regimen of 5-FU/LV."9.08A phase I trial of 5-fluorouracil, leucovorin and interferon-alpha 2b administered by 24 h infusion in metastatic colorectal carcinoma. ( Cascinu, S; Catalano, G; Del Ferro, E; Ligi, M, 1996)
"Stomatitis is a major dose-limiting toxicity of bolus fluorouracil (5FU)-based chemotherapy regimens, despite the use of oral cryotherapy."9.08Phase III controlled evaluation of sucralfate to alleviate stomatitis in patients receiving fluorouracil-based chemotherapy. ( Camoriano, J; Gerstner, JB; Ghosh, C; Hatfield, AK; Loprinzi, CL; Michalak, JC; Novotny, PJ; Quella, SK; Schaefer, PL; Sloan, J; Steen, PD; White, DF, 1997)
"Stomatitis caused by a combined chemotherapy with 5-fluorouracil (5-FU) and cisplatin (CDDP) is a serious problem in the course of treatment for patients with oral carcinoma."9.08[Inhibition of 5-fluorouracil-cisplatin-induced stomatitis by oral cryotherapy: use of an ice-bar containing fibrinolysin and deoxyribonuclease combine (Elase)]. ( Kumagai, S; Mori, S; Morikawa, H; Sakaki, K; Sato, A; Song, ST, 1997)
"Recently, a randomised study demonstrated the utility of oral cooling (cryotherapy) in the prevention of 5-fluorouracil (5FU)-induced stomatitis."9.07Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis. ( Cascinu, S; Catalano, G; Fedeli, A; Fedeli, SL, 1994)
"This study was aimed at assessing the efficacy of allopurinol mouthwashes in the treatment of 5-fluorouracil-induced stomatitis."9.07Allopurinol mouthwashes in the treatment of 5-fluorouracil-induced stomatitis. ( Moroni, M; Nastasi, G; Porta, C, 1994)
"The authors previously reported that 30 minutes of oral cryotherapy inhibits 5-fluorouracil (5-FU)-induced stomatitis."9.07A randomized clinical trial of two different durations of oral cryotherapy for prevention of 5-fluorouracil-related stomatitis. ( Finck, G; Glaw, KC; Hatfield, AK; Iverson, RK; Kunselman, SJ; Lee, JK; Lifsey, D; Loprinzi, CL; Rocke, LK; Stevens, BA, 1993)
"We have reported that 5-fluorouracil (5-FU) and folinic acid increased response rate and survival in patients with metastatic colorectal cancer."9.07Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid. ( Erlichman, C; Fine, S; Gadalla, T; Steinberg, J; Wong, A, 1992)
"Pursuant to a promising report suggesting that an allopurinol mouthwash could have a protective effect against 5-fluorouracil (5-FU)-induced stomatitis, the authors performed a randomized, placebo-controlled, double-blind, crossover study."9.06A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5-fluorouracil-induced stomatitis. ( Athmann, LM; Burnham, NL; Cianflone, SG; Cross, M; Dose, AM; Etzell, PS; Gainey, DK; Hagen, L; Loprinzi, CL; Therneau, TM, 1990)
"Thirty patients with a diagnosis of metastatic adenocarcinoma of the lung were entered on a trial to evaluate the antitumor efficacy of 5-fluorouracil 370 mg/m2 daily for 5 days every four weeks in combination with folinic acid 200 mg/m2, 60 min prior to 5FU."9.065-Fluorouracil with folinic acid is not effective against metastatic adenocarcinoma of the lung. ( Aitken, SE; Evans, WK; Ezzat, A; Maroun, JA; Rusthoven, J; Shepherd, FA; Stewart, DJ; Wierzbicki, R, 1990)
"5-Fluorouracil (5-Fu) is one of the most commonly prescribed antineoplastic agents against gastric and colorectal cancers."8.98Oral fluoropyrimidine versus intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: Meta-analysis. ( Meng, F; Wang, Y; Xing, X; Zhang, L; Zhong, D, 2018)
"An electronic search was undertaken to identify randomized controlled trials comparing raltitrexed-based regimen to 5-fluorouracil-based regimen in patients with advanced colorectal cancer."8.90Raltitrexed-based chemotherapy for advanced colorectal cancer. ( Hong, W; Huang, Q; Liu, Y; Sun, X; Wu, J; Wu, W, 2014)
"The aim of this study was to evaluate systematically the efficacy and safety of oral uracil-tegafur (UFT) plus leucovorin (LV) compared with infusional fluorouracil (5-FU) plus LV for advanced colorectal cancer."8.87Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials. ( Bin, Q; Cao, Y; Gao, F; Li, J; Liao, C, 2011)
"A 66-year-old woman with metastatic mammary carcinoma, who was being treated with capecitabine, contracted a herpes zoster infection that was treated with the antiviral drug brivudin."8.86Interaction between capecitabine and brivudin in a patient with breast cancer. ( Baena-Cañada, JM; García-Olmedo, O; Jiménez-Bárcenas, R; Martínez, MJ; Muriel-Cueto, P, 2010)
" A phase III randomized trial, Xeloda in Adjuvant Colorectal Cancer Treatment, demonstrated that treatment with single-agent capecitabine was equivalent to bolus 5-fluorouracil with leucovorin with respect to disease-free survival and overall survival, with significantly less diarrhea, stomatitis, neutropenia, nausea and vomiting, and alopecia."8.83Capecitabine: a new adjuvant option for colorectal cancer. ( Berg, DT, 2006)
"A meta-analysis of six North Central Cancer Treatment Group (NCCTG) trials involving patients receiving their first ever fluorouracil (5-FU)-based chemotherapy was undertaken to explore the association of sex with reports of the incidence and severity of stomatitis."8.80Sex differences in fluorouracil-induced stomatitis. ( Barton, DL; Loprinzi, CL; Nair, S; Novotny, PJ; Okuno, S; Sloan, JA, 2000)
"Glutaryl melatonin exhibited mild anti-candidiasis and anti-inflammatory properties."7.96Glutaryl Melatonin Niosome Gel for Topical Oral Mucositis: Anti- Inflammatory and Anticandidiasis. ( Daduang, J; Damrongrungruang, T; Mahakunakorn, P; Panpitakkul, P; Panyatip, P; Priprem, A; Puthongking, P; Sangchart, P; Somudorn, J; Uthaiwat, P, 2020)
"We used 90 mice of the CF-1 strain in which oral mucositis was induced using a protocol with 5-fluorouracil (5-FU) chemotherapy."7.96Cannabidiol on 5-FU-induced oral mucositis in mice. ( Borghetti, RL; Cherubini, K; Cuba, LF; de Figueiredo, MAZ; Guimarães, FS; Salum, FG, 2020)
" In this study, we investigated spontaneous pain and mechanical allodynia in a preclinical model of oral ulcerative mucositis after systemic administration of the chemotherapy drug 5-fluorouracil, using our proprietary pain assay system for conscious rats."7.83Distinct TRPV1- and TRPA1-based mechanisms underlying enhancement of oral ulcerative mucositis-induced pain by 5-fluorouracil. ( Goto, T; Harano, N; Hitomi, S; Inenaga, K; Inoue, H; Ito, M; Matoba, M; Miyano, K; Nodai, T; Ono, K; Uezono, Y; Watanabe, S; Yamaguchi, K, 2016)
"5-Fluorouracil (FUra) modulated by leucovorin (LV) is active in the treatment of colorectal cancer."7.70Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer. ( Cao, S; Rustum, YM; Troutt, AB, 1998)
"A total of 44 women with advanced breast cancer who had failed first- and second-line chemotherapy were given combination chemotherapy consisting of folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC)."7.68Advanced breast cancer treatment with folinic acid, 5-fluorouracil, and mitomycin C. ( Aquino, A; Francini, G; Gonnelli, S; Petrioli, R, 1993)
"Twenty-nine patients with metastatic breast cancer were treated with fluorouracil, adriamycin, cyclophosphamide (FAC), and methotrexate (MTX), with or without leukovorin rescue."7.67Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate. ( Aboud, A; Blumenschein, GR; Buzdar, AU; Hortobagyi, GN; Yap, HY, 1984)
"The authors assessed the value of protracted low-dose 5-fluorouracil (5-FU) infusion (250 mg/m2/day) in refractory breast cancer."7.675-Fluorouracil rechallenge by protracted infusion in refractory breast cancer. ( Holmes, FA; Hortobagyi, G; Jabboury, K, 1989)
"Sixty breast cancer patients undergoing an FEC60 regimen were enrolled, 37 patients completed the study."6.78The effects of fluorouracil, epirubicin, and cyclophosphamide (FEC60) on the intestinal barrier function and gut peptides in breast cancer patients: an observational study. ( Campanella, G; Clemente, C; D'Attoma, B; Giotta, F; Linsalata, M; Orlando, A; Riezzo, G; Russo, F, 2013)
" Patients exhibited high compliance in dosing administration."6.74Phase II, randomized, double-blind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fluorouracil-based chemotherapy. ( Akhmadullina, LI; Barker, NP; Davidenko, IS; Firsov, I; Gertner, JM; Gotovkin, EA; Kopp, MV; Kulikov, EP; Moiseyenko, VM; Peterson, DE; Rakovskaya, GN; Rodionova, I; Sherman, NZ; Shinkarev, SA; Tuleneva, T; Woon, CW; Yarosh, A, 2009)
"All patients had metastatic colorectal cancer, with adjuvant or palliative chemotherapy given to six patients (22%) on schedule A and 12 patients on schedule B (41%)."6.69Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion. ( Adam, R; Bismuth, H; Dallemagne, B; Focan, C; Focan-Henrard, D; Jasmin, C; Jehaes, C; Kreutz, F; Levi, F; Lobelle, JP; Markiewicz, S; Misset, JL; Weerts, J, 1999)
"Thirty-two patients (76%) had no oral mucositis."6.68Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma. ( Chan, WK; Chen, KY; Chen, SY; Chi, KH; Law, CK; Shu, CH; Yen, SH, 1995)
"Mucositis is a common toxicity of cancer chemotherapy."6.68Oral glutamine to prevent chemotherapy induced stomatitis: a pilot study. ( Anderson, PM; Skubitz, KM, 1996)
"Capecitabine (Xeloda) is an oral prodrug that is enzymatically converted to fluorouracil (5-FU) within cancer cells."6.41Current status of capecitabine in the treatment of colorectal cancer. ( Rothenberg, ML, 2002)
"Chemotherapy-induced oral mucositis (COM) is a common adverse effect of cancer chemotherapy."5.91Preparation and pharmaceutical properties of Hangeshashinto oral ointment and its safety and efficacy in Syrian hamsters with 5-fluorouracil-induced oral mucositis. ( Hira, D; Imai, S; Ito, M; Itohara, K; Kagawa, M; Matsubara, K; Nakagawa, S; Nakagawa, T; Ogihara, T; Terada, T; Yamanaka, R; Yonezawa, A, 2023)
"The current idea of how oral mucositis (OM) develops is primarily based on hypotheses and the early events which precede clinically established OM remain to be demonstrated."5.91Moderate temperature reduction is sufficient for prevention of 5-fluorouracil-induced oral mucositis: an experimental in vivo study in rats. ( Aydogdu, Ö; Dankis, M; Jontell, M; Walladbegi, J; Winder, M, 2023)
"Elental reduced oral mucositis and dermatitis more effectively than dextrin in the animal model."5.48Elemental Diet Accelerates the Recovery From Oral Mucositis and Dermatitis Induced by 5-Fluorouracil Through the Induction of Fibroblast Growth Factor 2. ( Ferdous, T; Harada, K; Kobayashi, H; Ueyama, Y, 2018)
"Population-based studies of adverse events are scarce."5.38Comparison of toxicity profiles of fluorouracil versus oxaliplatin regimens in a large population-based cohort of elderly patients with colorectal cancer. ( Cen, P; Du, XL; Liu, C, 2012)
"to evaluate the effect of oral cryotherapy compared to physiological serum on the development of oral mucositis in outpatient cancer patients using the 5-fluorouracil antineoplastic agent."5.34Effect of cryotherapy in preventing mucositis associated with the use of 5-fluorouracil. ( Aguiar, MIF; Alves, NP; Lopes, TSS; Oliveira, PP; Rodrigues, AB; Silva, RA; Vitorino, WO, 2020)
"However, stomatitis is one of the limiting side effects."5.28Treatment of 5-fluorouracil-induced stomatitis by allopurinol mouthwashes. ( Elzawawy, A, 1991)
"Aflibercept combined with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) as second-line treatment of metastatic colorectal cancer (mCRC) significantly improved survival compared with FOLFIRI alone in the pivotal VELOUR (aflibercept vs."5.27Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study. ( Antoniotti, C; Aprile, G; Bordonaro, R; Ciuffreda, L; Di Bartolomeo, M; Di Costanzo, F; Fasola, G; Frassineti, GL; Iaffaioli, V; Leone, F; Maiello, E; Marchetti, P; Pastorino, A; Sobrero, A; Zaniboni, A; Zilocchi, C, 2018)
"We assessed adding the multikinase inhibitor sorafenib to gemcitabine or capecitabine in patients with advanced breast cancer whose disease progressed during/after bevacizumab."5.17Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. ( Beck, JT; Bell-McGuinn, K; Eisenberg, P; Emanuelson, R; Hermann, RC; Hudis, CA; Isaacs, C; Kaklamani, V; Keaton, M; Kirshner, JJ; Levine, E; Lokker, NA; Makari-Judson, G; Medgyesy, DC; Qamar, R; Ro, SK; Rugo, HS; Schwartzberg, LS; Starr, A; Stepanski, EJ; Tauer, KW; Wang, W, 2013)
"The purpose of this multicenter phase II study was to evaluate the efficacy and safety of a combination of irinotecan, 5-fluorouracil (5-FU), and leucovorin (FOLFIRI) plus bevacizumab as first-line chemotherapy in Japanese patients with metastatic colorectal cancer."5.17FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study. ( Akiyama, Y; Aoki, T; Fujii, M; Hagiwara, K; Hironaka, K; Kochi, M; Nakajima, T; Osuka, F; Takahashi, T; Takeuchi, M; Teranishi, F, 2013)
"We measured the effectiveness of the prophylactic administration of a polaprezinc suspension dispersed in sodium alginate solution (P-AG) by dividing it into two courses in the same patients, and measured the stomatitis induced by Docetaxel/Cisplatin/Fluorouracil (DCF) chemotherapy."5.15[Preventive effect of polaprezinc suspension dispersed in sodium alginate solution (P-AG) for stomatitis induced by Docetaxel/Cisplatin/Fluorouracil (DCF) chemotherapy in patients with head and neck cancer]. ( Fujiki, Y; Hama, T; Hatake, K; Ishibashi, M; Kawakami, K; Kawata, K; Mishima, Y; Nemoto, M; Sugisaki, T; Takahashi, S; Yokoyama, M, 2011)
"Stomatitis is a common adverse effect of intravenously infused 5-fluorouracil (5FU)."5.12Prevention of 5-fluorouracil-related stomatitis by oral cryotherapy: a randomized controlled study. ( Kalofonos, Ch; Naxakis, S; Papadeas, E; Riga, M, 2007)
" Oral glutamine supplements (OGS) may have a role in the prevention of chemotherapy-induced mucositis/stomatitis."5.12The effect of oral glutamine on 5-fluorouracil/leucovorin-induced mucositis/stomatitis assessed by intestinal permeability test. ( Choi, K; Jeon, WK; Kim, JW; Lee, SS; Lim, SY; Oh, SJ; Oh, TY, 2007)
"To characterize the efficacy and safety of palifermin in reducing the incidence of oral mucositis (OM) and diarrhea when administered to patients with metastatic colorectal cancer (CRC) receiving fluorouracil/leucovorin (FU/LV) chemotherapy."5.12Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. ( Abdi, E; Cesano, A; Chen, MG; Clarke, S; Davis, ID; Gayko, U; Gutheil, J; Rosen, LS; Schnell, FM; Zalcberg, J, 2006)
"This multicentre phase I/II study was designed to determine the maximum tolerated dose of irinotecan when combined with 5-fluorouracil and folinic acid according to the Mayo Clinic schedule and to evaluate the activity of this combination as first-line therapy in patients with advanced colorectal cancer."5.11Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer. ( Boussard, B; Carmichael, J; Daniel, F; Davidson, N; Falk, S; Jacobs, C; Kuehr, T; Rapoport, BL; Ruff, P; Thaler, J, 2004)
"To evaluate the safety and efficacy of irinotecan (CPT-11) alternated with a weekly treatment for 4 weeks of oxaliplatin (L-OHP), high-dose leucovorin (LV) and a 48-hour 5-fluorouracil infusion (5-FU 48 h) as first-line chemotherapy for patients with advanced colorectal cancer (ACC)."5.11A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer. ( Colarusso, D; Manzione, L; Pizza, C; Reggiardo, G; Rinaldi, A; Rosati, G; Tucci, A, 2004)
"To assess the activity and safety of combined folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC) in metastatic breast cancer patients previously treated with at least two chemotherapy regimens."5.10Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens. ( Correale, P; Fiaschi, AI; Francini, G; Marsili, S; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M, 2002)
"We investigated the activity of irinotecan given with a more convenient modified bimonthly de Gramont regimen of bolus and infusional 5-fluorouracil [IrMdG] in advanced or metastatic colorectal cancer in the first and second line setting."5.10Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer. ( Hochhauser, D; James, R; Ledermann, JA; Leonard, P; Seymour, MT, 2002)
"To test the activity of subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF) administration in patients with colorectal cancer treated with adjuvant 5-fluorouracil (5-FU) plus leucovorin (LV) and suffering from mucositis."5.10Subcutaneous granulocyte-macrophage colony-stimulating factor in mucositis induced by an adjuvant 5-fluorouracil plus leucovorin regimen. A phase II study and review of the literature. ( Colarusso, D; Manzione, L; Rosati, G; Rossi, A, 2003)
"The present study was conducted to evaluate the effect of allopurinol spray on stomatitis induced by chemotherapy for esophageal cancer."5.10[The preventive effect of allopurinol spray on stomatitis induced by anti-cancer drugs]. ( Fujii, E; Hanawa, T; Ito, A, 2002)
"Diarrhea is dose-limiting with weekly 5-fluorouracil (5-FU) plus high-dose leucovorin (LV)."5.09Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant. ( Blumenson, LE; Creaven, PJ; Frank, C; Meropol, NJ; Rustum, YM, 1999)
"The combination of fluorouracil and leucovorin has until recently been standard therapy for metastatic colorectal cancer."5.09Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. ( Ackland, SP; Blanke, C; Cox, JV; Elfring, GL; Fehrenbacher, L; Locker, PK; Maroun, JA; Miller, LL; Moore, MJ; Pirotta, N; Rosen, LS; Saltz, LB, 2000)
"To compare the response rate, efficacy parameters, and toxicity profile of oral capecitabine with bolus intravenous (IV) fluorouracil plus leucovorin (5-FU/LV) as first-line treatment in patients with metastatic colorectal cancer."5.09Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. ( Ansari, R; Batist, G; Burger, HU; Cox, J; Harrison, E; Hoff, PM; Kocha, W; Kuperminc, M; Maroun, J; Osterwalder, B; Walde, D; Weaver, C; Wong, AO; Wong, R, 2001)
"We have reported that an alternating regimen of bolus and continuous infusion 5-fluorouracil (FU) was superior to bolus FU in terms of response rate and progression-free survival in advanced colorectal cancer."5.095-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer. ( Aschele, C; Caroti, C; Cirillo, M; Cortesi, E; Frassineti, GL; Gallo, L; Grossi, F; Guglielmi, A; Labianca, R; Pessi, MA; Ravaioli, A; Recaldin, E; Sobrero, A; Testore, P; Turci, D, 2001)
"The aim of this study was to investigate the effects of adding interferon alfa-2b (IFN) to protracted venous infusion fluorouracil (PVI 5-FU) from the start of treatment in patients with advanced colorectal cancer."5.08Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer. ( Ahmed, F; Cunningham, D; Findlay, M; Hickish, T; Hill, M; Middleton, G; Nicolson, V; Norman, A; Watson, M; Webb, A, 1995)
"A clinical trial was conducted in order to evaluate the anti-tumor effect and toxicity of a continuous infusion of 5-fluorouracil (5-FU) for metastatic colorectal cancer."5.08Clinical trial of continuous infusion of 5-fluorouracil using an ambulatory pump for metastatic colorectal cancer. ( Kondo, H; Ohkura, H; Saito, D; Shimada, Y; Shirao, K; Sugano, K; Yamao, T; Yokota, T; Yoshida, S, 1995)
"No effective systemic salvage therapy exists for patients with advanced colorectal cancer who progress after receiving bolus fluorouracil (FU) and leucovorin (LV) chemotherapy."5.08Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer. ( André, AM; Bertino, JR; Conti, JA; Grossano, DD; Kemeny, NE; Saltz, LB, 1995)
"Stomatitis has been found to be a major dose-limiting toxicity from bolus 5-fluorouracil-based (5-FU) chemotherapy regimens, despite the use of oral cryotherapy."5.08Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis. ( Bartel, J; Clemens-Schutjer, D; Fidler, P; Hayes, DL; Lee, JK; Leitch, JM; Loprinzi, CL; Michalak, JC; Novotny, P; O'Fallon, JR, 1996)
"A phase I trial of 5-fluorouracil (5-FU), leucovorin (LV) and interferon (IFN) was conducted in 15 advanced colorectal cancer patients refractory to a bolus regimen of 5-FU/LV."5.08A phase I trial of 5-fluorouracil, leucovorin and interferon-alpha 2b administered by 24 h infusion in metastatic colorectal carcinoma. ( Cascinu, S; Catalano, G; Del Ferro, E; Ligi, M, 1996)
"Stomatitis is a major dose-limiting toxicity of bolus fluorouracil (5FU)-based chemotherapy regimens, despite the use of oral cryotherapy."5.08Phase III controlled evaluation of sucralfate to alleviate stomatitis in patients receiving fluorouracil-based chemotherapy. ( Camoriano, J; Gerstner, JB; Ghosh, C; Hatfield, AK; Loprinzi, CL; Michalak, JC; Novotny, PJ; Quella, SK; Schaefer, PL; Sloan, J; Steen, PD; White, DF, 1997)
"Stomatitis caused by a combined chemotherapy with 5-fluorouracil (5-FU) and cisplatin (CDDP) is a serious problem in the course of treatment for patients with oral carcinoma."5.08[Inhibition of 5-fluorouracil-cisplatin-induced stomatitis by oral cryotherapy: use of an ice-bar containing fibrinolysin and deoxyribonuclease combine (Elase)]. ( Kumagai, S; Mori, S; Morikawa, H; Sakaki, K; Sato, A; Song, ST, 1997)
"Recently, a randomised study demonstrated the utility of oral cooling (cryotherapy) in the prevention of 5-fluorouracil (5FU)-induced stomatitis."5.07Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis. ( Cascinu, S; Catalano, G; Fedeli, A; Fedeli, SL, 1994)
"Pharmacokinetics of total platinum, 5-fluorouracil, l-folinic and d-folinic acid, and 5-methyltetrahydrofolate were studied in plasma from nine patients with advanced colorectal cancer treated with oxaliplatin (20 mg/m2/day), 5-fluorouracil (600 mg/m2/day), and folinic acid (300 mg/m2/day)."5.07Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in patients with cancer. ( Bastian, G; Brienza, S; Comisso, M; Etienne, MC; Lévi, F; Massari, C; Metzger, G; Milano, G; Misset, JL; Touitou, Y, 1994)
" Leukopenia was severe in the first two steps of treatment, with WHO grade IV toxicity occurring in 41% of patients; however, this decreased to 10% when vindesine was deleted from the chemotherapy regimen in the last two steps."5.07Rapidly alternating chemotherapy and hyperfractionated radiotherapy in the management of locally advanced head and neck carcinoma: four-year results of a phase I/II study. ( Bauer, J; Bernasconi, S; Leyvraz, S; Monnier, P; Pasche, P, 1994)
"This study was aimed at assessing the efficacy of allopurinol mouthwashes in the treatment of 5-fluorouracil-induced stomatitis."5.07Allopurinol mouthwashes in the treatment of 5-fluorouracil-induced stomatitis. ( Moroni, M; Nastasi, G; Porta, C, 1994)
"The authors previously reported that 30 minutes of oral cryotherapy inhibits 5-fluorouracil (5-FU)-induced stomatitis."5.07A randomized clinical trial of two different durations of oral cryotherapy for prevention of 5-fluorouracil-related stomatitis. ( Finck, G; Glaw, KC; Hatfield, AK; Iverson, RK; Kunselman, SJ; Lee, JK; Lifsey, D; Loprinzi, CL; Rocke, LK; Stevens, BA, 1993)
"We have reported that 5-fluorouracil (5-FU) and folinic acid increased response rate and survival in patients with metastatic colorectal cancer."5.07Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid. ( Erlichman, C; Fine, S; Gadalla, T; Steinberg, J; Wong, A, 1992)
"148 patients with advanced untreated colorectal cancer were randomised to receive a weekly bolus of 5-fluorouracil (5-FU) 600 mg/m2 alone, with or without leucovorin (LV) 500 mg/m2."5.07Randomised comparison of weekly bolus 5-fluorouracil with or without leucovorin in metastatic colorectal carcinoma. ( Canobbio, L; Fassio, T; Gallo, L; Guglielmi, A; Nobile, MT; Rosso, R; Rubagotti, A; Sertoli, MR; Venturini, M; Vidili, MG, 1992)
"Pursuant to a promising report suggesting that an allopurinol mouthwash could have a protective effect against 5-fluorouracil (5-FU)-induced stomatitis, the authors performed a randomized, placebo-controlled, double-blind, crossover study."5.06A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5-fluorouracil-induced stomatitis. ( Athmann, LM; Burnham, NL; Cianflone, SG; Cross, M; Dose, AM; Etzell, PS; Gainey, DK; Hagen, L; Loprinzi, CL; Therneau, TM, 1990)
"Thirty patients with a diagnosis of metastatic adenocarcinoma of the lung were entered on a trial to evaluate the antitumor efficacy of 5-fluorouracil 370 mg/m2 daily for 5 days every four weeks in combination with folinic acid 200 mg/m2, 60 min prior to 5FU."5.065-Fluorouracil with folinic acid is not effective against metastatic adenocarcinoma of the lung. ( Aitken, SE; Evans, WK; Ezzat, A; Maroun, JA; Rusthoven, J; Shepherd, FA; Stewart, DJ; Wierzbicki, R, 1990)
"A randomized control trial study was carried out to evaluate the effect of allopurinol mouth wash on stomatitis induced by chemotherapy in gynecologic patients."5.06[Prevention of stomatitis induced by anti-cancer drugs]. ( Dozono, H; Ishibashi, M; Miwa, K; Motoya, T; Nagata, Y; Nakamura, K; Nakamura, S; Shinmura, R, 1989)
"5-Fluorouracil (5-Fu) is one of the most commonly prescribed antineoplastic agents against gastric and colorectal cancers."4.98Oral fluoropyrimidine versus intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: Meta-analysis. ( Meng, F; Wang, Y; Xing, X; Zhang, L; Zhong, D, 2018)
"An electronic search was undertaken to identify randomized controlled trials comparing raltitrexed-based regimen to 5-fluorouracil-based regimen in patients with advanced colorectal cancer."4.90Raltitrexed-based chemotherapy for advanced colorectal cancer. ( Hong, W; Huang, Q; Liu, Y; Sun, X; Wu, J; Wu, W, 2014)
"The aim of this study was to evaluate systematically the efficacy and safety of oral uracil-tegafur (UFT) plus leucovorin (LV) compared with infusional fluorouracil (5-FU) plus LV for advanced colorectal cancer."4.87Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials. ( Bin, Q; Cao, Y; Gao, F; Li, J; Liao, C, 2011)
"We analyzed individual data on 6,284 patients from nine phase III trials of advanced colorectal cancer (aCRC) that used fluorouracil-based single-agent and combination chemotherapy."4.87Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials. ( Blanke, CD; Bleyer, A; Bot, BM; de Gramont, A; Goldberg, RM; Kohne, CH; Sargent, DJ; Seymour, MT; Thomas, DM, 2011)
"A 66-year-old woman with metastatic mammary carcinoma, who was being treated with capecitabine, contracted a herpes zoster infection that was treated with the antiviral drug brivudin."4.86Interaction between capecitabine and brivudin in a patient with breast cancer. ( Baena-Cañada, JM; García-Olmedo, O; Jiménez-Bárcenas, R; Martínez, MJ; Muriel-Cueto, P, 2010)
"We reviewed published studies reporting phase II and III clinical trials of dose-dense regimens for breast cancer and NHL, TAC (docetaxel, adriamycin, cyclophosphamide) chemotherapy for breast cancer, and infusional 5-fluorouracil-based regimens for colorectal cancer."4.83Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. ( Avritscher, EB; Bekele, BN; Cooksley, CD; Elting, LS; Jones, JA; Michelet, M, 2006)
" A phase III randomized trial, Xeloda in Adjuvant Colorectal Cancer Treatment, demonstrated that treatment with single-agent capecitabine was equivalent to bolus 5-fluorouracil with leucovorin with respect to disease-free survival and overall survival, with significantly less diarrhea, stomatitis, neutropenia, nausea and vomiting, and alopecia."4.83Capecitabine: a new adjuvant option for colorectal cancer. ( Berg, DT, 2006)
"A meta-analysis of six North Central Cancer Treatment Group (NCCTG) trials involving patients receiving their first ever fluorouracil (5-FU)-based chemotherapy was undertaken to explore the association of sex with reports of the incidence and severity of stomatitis."4.80Sex differences in fluorouracil-induced stomatitis. ( Barton, DL; Loprinzi, CL; Nair, S; Novotny, PJ; Okuno, S; Sloan, JA, 2000)
" Pain is measured by facial grooming behavior stimulated by capsaicin, the alternation of body weight and food intake was also recorded to reflect the OM pain."4.31Sprayable NAHAO® hydrogel alleviates pain and accelerates rat oral mucositis wound healing. ( Ma, H; Mao, R; Tang, Y; Yan, H; Zhang, Y; Zhao, Y, 2023)
"In this study, the oral mucosa of mice was burned with 90% phenol and intraperitoneal injection of 5-fluorouracil to establish the model of stomatitis mice."4.12Dual roles of ANGPTL4 in multiple inflammatory responses in stomatitis mice. ( Tian, MM; Wang, YS; Xiao, HB, 2022)
"The aim of this study was to analyze the effects of three different Photobiomodulation Therapy (PBMT) protocols in the treatment of 5-fluorouracil-induced oral mucositis in hamsters."4.02Wound healing process with different photobiomodulation therapy protocols to treat 5-FU-induced oral mucositis in hamsters. ( Arana-Chavez, VE; Calarga, CC; Cotomacio, CC; Simões, A; Yshikawa, BK, 2021)
"Glutaryl melatonin exhibited mild anti-candidiasis and anti-inflammatory properties."3.96Glutaryl Melatonin Niosome Gel for Topical Oral Mucositis: Anti- Inflammatory and Anticandidiasis. ( Daduang, J; Damrongrungruang, T; Mahakunakorn, P; Panpitakkul, P; Panyatip, P; Priprem, A; Puthongking, P; Sangchart, P; Somudorn, J; Uthaiwat, P, 2020)
"We used 90 mice of the CF-1 strain in which oral mucositis was induced using a protocol with 5-fluorouracil (5-FU) chemotherapy."3.96Cannabidiol on 5-FU-induced oral mucositis in mice. ( Borghetti, RL; Cherubini, K; Cuba, LF; de Figueiredo, MAZ; Guimarães, FS; Salum, FG, 2020)
"The intent of this article is to evaluate the effect of oral cryotherapy on the prevention of oral mucositis and pain among patients with colorectal cancer undergoing fluorouracil-based chemotherapy."3.88Oral Cryotherapy: Prevention of Oral Mucositis and Pain Among Patients With Colorectal Cancer Undergoing Chemotherapy. ( Hsien Chan, CM; Idayu Mat Nawi, R; Lei Chui, P; Wan Ishak, WZ, 2018)
" In this study, we investigated spontaneous pain and mechanical allodynia in a preclinical model of oral ulcerative mucositis after systemic administration of the chemotherapy drug 5-fluorouracil, using our proprietary pain assay system for conscious rats."3.83Distinct TRPV1- and TRPA1-based mechanisms underlying enhancement of oral ulcerative mucositis-induced pain by 5-fluorouracil. ( Goto, T; Harano, N; Hitomi, S; Inenaga, K; Inoue, H; Ito, M; Matoba, M; Miyano, K; Nodai, T; Ono, K; Uezono, Y; Watanabe, S; Yamaguchi, K, 2016)
" We retrospectively examined the progression of oral mucositis in 91 patients with breast cancer who received the 5-fluorouracil, epirubicin, and cyclophosphamide (FEC)-100 regimen between September 2007 and August 2008."3.80[Therapeutic effect of rebamipide for oral mucositis associated with FEC therapy for breast cancer]. ( Abe, M; Bamba, N; Enami, A; Makihara, K; Masaoka, M; Masuda, N; Mizutani, M; Shikata, A; Takada, S; Yamamoto, M; Yamamura, J; Yasojima, H, 2014)
"From June 2007 to July 2008, 61 breast cancer patients eligible for this study received anthracycline-based chemotherapy(FEC100: 5-FU 500mg/m / / 2, epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2)at National Kyushu Cancer Center and Iwate Medical University Hospital."3.78[High incidence-rate of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy (FEC100)]. ( Fukazawa, M; Kashiwaba, K; Kawaguchi, H; Koga, C; Mori, E; Nakamura, Y; Nishimura, S; Ohno, S; Satou, S; Sawamura, K; Shigematsu, H, 2012)
"Atorvastatin prevented mucosal damage and inflammation associated with 5-FU-induced OM, but the association of a higher dose of ATV with 5-FU induced hepatotoxicity and amplified leukopenia."3.77Effect of atorvastatin on 5-fluorouracil-induced experimental oral mucositis. ( Alencar, NM; Barboza, DR; Brito, GA; Gomes, AS; Leitão, RF; Macedo, RN; Medeiros, CA; Nogueira, NA; Ribeiro, RA, 2011)
" The aim of the present report was to evaluate real-life drug adherence in a prospective cohort analysis of patients with gastrointestinal or breast cancer treated with capecitabine-based chemotherapy."3.77Self-reported compliance with capecitabine: findings from a prospective cohort analysis. ( Bressoud, A; Delmore, G; Hermann, F; Hoesli, P; Pederiva, S; von Moos, R; Winterhalder, R, 2011)
" We conducted a study using FOLFOX-4 (oxaliplatin, fluorouracil, folinic acid) in pre-treated advanced bladder cancer patients."3.72FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder. ( Autorino, R; Bianco, AR; D'Armiento, M; De Placido, S; Di Lorenzo, G; Giordano, A; Giuliano, M, 2004)
"One hundred and three patients with recurrent adenocarcinoma of the rectum underwent reirradiation with concurrent 5-fluorouracil-based chemotherapy."3.71Long-term results of reirradiation for patients with recurrent rectal carcinoma. ( Marks, G; Marks, J; Mohiuddin, M, 2002)
"5-Fluorouracil (FUra) modulated by leucovorin (LV) is active in the treatment of colorectal cancer."3.70Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer. ( Cao, S; Rustum, YM; Troutt, AB, 1998)
" Results indicated that the chemotherapy agent 5-fluorouracil (5-FU) administered to hamsters on days 0 and 2 produced severe leukopenia between days 4 and 7 of the trial, and that severity of oral mucositis coincided with the suppressed immune state in these animals."3.70Evaluation of bovine lactoferrin as a topical therapy for chemotherapy-induced mucositis in the golden Syrian hamster. ( Clarke, J; Edwards, B; Regester, G; Srpek, L, 1999)
" Administration of topical TGF-beta 3 prior to chemotherapy with 5-fluorouracil (5-FU) significantly reduced the severity of mucositis with respect to time, reduced chemotherapy-associated weight loss and increased survival."3.69Transforming growth factor-beta 3 mediated modulation of cell cycling and attenuation of 5-fluorouracil induced oral mucositis. ( Brien, JP; Bruskin, AM; Haley, JD; Muska, AD; Rose, A; Sonis, ST; Van Vugt, AG, 1997)
"A total of 44 women with advanced breast cancer who had failed first- and second-line chemotherapy were given combination chemotherapy consisting of folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC)."3.68Advanced breast cancer treatment with folinic acid, 5-fluorouracil, and mitomycin C. ( Aquino, A; Francini, G; Gonnelli, S; Petrioli, R, 1993)
"In a previous trial in which methotrexate and N-phosphonacetyl-L-aspartate (PALA) were used to modulate 5-fluorouracil (5-FU), four of six patients could not tolerate treatment at the 600 mg/m2 5-FU dose level because of mucositis, diarrhea, and a decrease in performance status."3.68Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin. ( Colofiore, J; Kemeny, N; Martin, D; Sawyer, R; Schneider, A; Seiter, K; Williams, L, 1993)
" This prospective cohort study investigated orofacial complications of combination chemotherapy (cyclophosphamide, methotrexate, fluorouracil, vincristine, and prednisone) in women with breast cancer."3.68Orofacial complications of chemotherapy for breast cancer. ( McCarthy, GM; Skillings, JR, 1992)
"7 mg/kg/d of dipyridamole, we examined the relationships between 5FUra dose and steady-state plasma concentration (Css) and the percentage reduction in WBCs, as well as the percentage frequency of stomatitis."3.68Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole. ( Egorin, MJ; Forrest, A; Remick, S; Trump, DL; Tutsch, KD; Willson, JK, 1991)
"Twenty-nine patients with metastatic breast cancer were treated with fluorouracil, adriamycin, cyclophosphamide (FAC), and methotrexate (MTX), with or without leukovorin rescue."3.67Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate. ( Aboud, A; Blumenschein, GR; Buzdar, AU; Hortobagyi, GN; Yap, HY, 1984)
"The authors assessed the value of protracted low-dose 5-fluorouracil (5-FU) infusion (250 mg/m2/day) in refractory breast cancer."3.675-Fluorouracil rechallenge by protracted infusion in refractory breast cancer. ( Holmes, FA; Hortobagyi, G; Jabboury, K, 1989)
"Two hundred and seventy-four consecutive patients with measurable metastatic breast cancer, without prior exposure to cytotoxic agents were treated with tamoxifen, 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC)."3.67Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. ( Ames, F; Buzdar, AU; Carrasco, CH; Ewer, MS; Fraschini, G; Frye, D; Hortobagyi, GN; Hug, V; Mackay, B; Montague, E, 1989)
"Thirty patients with an advanced bronchogenic carcinoma were treated with a combination of adriamycin and 5-fluorouracil; in eight the size of the tumour or its metastases was reduced by over 50%, and eight further patients experienced useful relief of symptoms."3.65Treatment of advanced bronchogenic carcinoma with adriamycin and 5-fluorouracil. ( Anderson, G; Bugaighis, A; Rees, GJ, 1975)
"The induction of oral mucositis occurred by the administration of intraperitoneal Fluorouracila (60 mg/kg) and trauma to the mucosa."3.30The chromatographic constitution of andiroba oil and his healing effects, compared to the LLLT outcomes, in oral mucositis induced in golden Syrian hamsters: a new treatment option. ( Alcantara, DDFA; Burbano, RMR; Gomes, JT; Júnior, SMA; Oliveira, CP; Rodrigues, EM; Soares, BM; Soares, RHFC; Tuji, FM; Wanzeler, AMV, 2023)
"Oral pain was assessed using a visual analogue scale alongside assessment of patients' perceptions and daily functional activities based on the Rotterdam Symptom Checklist."3.30Potential therapeutic effects of different mouthwashes for alleviation and treatment of oral complications of 5-fluorouracil-based chemotherapy in patients with colon cancer. ( Al-Taie, A; Koseoglu, A, 2023)
"Pentoxifylline (PTX) is a drug that has been shown to have multiple beneficial effects in cancer patients through its anti-inflammatory properties."3.01Effect of pentoxifylline on colon cancer patients treated with chemotherapy (Part I). ( Baider, L; Barak, V; Meirovitz, A; Peretz, T; Stephanos, S, 2021)
"To assess S-1 and 5-fluorouracil (5-FU)-related adverse events in patients with advanced gastric cancer and provide focused health care approaches to improve patient compliance and quality of survival."3.01S-1 and 5-Fluorouracil-related adverse events in patients with advanced gastric cancer: A meta-analysis. ( Chu, T; Hu, Q; Ke, J; Xu, J; Zhang, Z, 2023)
"Mucositis is a common and most debilitating complication associated with the cytotoxicity of chemotherapy."2.82Experimental Chemotherapy-Induced Mucositis: A Scoping Review Guiding the Design of Suitable Preclinical Models. ( Cirillo, N; Huang, J; Hwang, AYM; Iskandar, M; Jia, Y; Kim, B; Mohammed, AI, 2022)
" No difference in other treatment toxicity was observed between the two groups, and patients exhibited high compliance in dosing administration."2.80Double-blind, placebo-controlled, randomized phase II study of TJ-14 (Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer chemotherapy-induced oral mucositis. ( Aoyama, T; Kataoka, M; Kono, T; Matsuda, C; Mishima, H; Morita, S; Munemoto, Y; Nagata, N; Oshiro, M; Sakamoto, J, 2015)
"Patient survival in esophageal cancer (EC) remains poor."2.80A Phase 1/2 Study of Definitive Chemoradiation Therapy Using Docetaxel, Nedaplatin, and 5-Fluorouracil (DNF-R) for Esophageal Cancer. ( Hayashi, T; Hirakawa, M; Hori, M; Kato, J; Kobune, M; Miyanishi, K; Nakata, K; Ohnuma, H; Okagawa, Y; Osuga, T; Sagawa, T; Sakata, K; Sato, T; Sato, Y; Someya, M; Takayama, T; Takimoto, R, 2015)
"Potentiation of oral mucositis was achieved by scratching both cheek pouches of all animals with needles (days 5, 6, and 14)."2.78Protective effect of bilberry extract as a pretreatment on induced oral mucositis in hamsters. ( Asatourian, A; Davarmanesh, M; Garcia-Godoy, F; Haghnegahdar, S; Miri, R; Saghiri, MA; Tadbir, AA; Tanideh, N, 2013)
" The incidence and maximum severity of fluorouracil-induced oral mucositis and safety of the irsogladine dosing regimen were evaluated."2.78Irsogladine maleate reduces the incidence of fluorouracil-based chemotherapy-induced oral mucositis. ( Hayashi, K; Kamata, M; Kojima, H; Nomura, M; Sawada, S, 2013)
"Sixty breast cancer patients undergoing an FEC60 regimen were enrolled, 37 patients completed the study."2.78The effects of fluorouracil, epirubicin, and cyclophosphamide (FEC60) on the intestinal barrier function and gut peptides in breast cancer patients: an observational study. ( Campanella, G; Clemente, C; D'Attoma, B; Giotta, F; Linsalata, M; Orlando, A; Riezzo, G; Russo, F, 2013)
"Acute Grade 3 (G3) dysphagia was higher in DL2 (87% DL2 vs."2.77Dose-escalated intensity-modulated radiotherapy is feasible and may improve locoregional control and laryngeal preservation in laryngo-hypopharyngeal cancers. ( A'hern, R; Barbachano, Y; Bhide, SA; Bidmead, AM; Clark, C; Guerrero-Urbano, MT; Harrington, KJ; Hickey, J; Miah, AB; Newbold, KL; Nicol, R; Nutting, CM; St Rose, S; Tanay, M, 2012)
"Deleterious oral mucositis (OM) develops during radiotherapy (RT) or chemoradiotherapy for head-and-neck cancer (HNC) patients."2.77Phenylbutyrate mouthwash mitigates oral mucositis during radiotherapy or chemoradiotherapy in patients with head-and-neck cancer. ( Chung, YL; Jen, YM; Lin, YH; Wang, LW; Yen, SH, 2012)
"Gemcitabine was administered intravenously at 1,000 mg/m(2)/week (days 1, 8 and 15) and oral capecitabine from day 1 to day 21 at 1,660 mg/m(2)/day."2.77Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study. ( Bennouna, J; Chamorey, E; Douillard, JY; Etienne-Grimaldi, MC; Follana, P; Francois, E; Mari, V; Michel, C; Milano, G; Renée, N; Senellart, H, 2012)
"The peak prevalence of grade 3 dysphagia was higher and the recovery was slower in patients with lower OTT (median 38 days vs."2.75Characteristics of response of oral and pharyngeal mucosa in patients receiving chemo-IMRT for head and neck cancer using hypofractionated accelerated radiotherapy. ( Bhide, SA; Fowler, J; Gulliford, S; Harrington, KJ; Newbold, K; Nutting, CM; Rosenfelder, N, 2010)
" Patients exhibited high compliance in dosing administration."2.74Phase II, randomized, double-blind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fluorouracil-based chemotherapy. ( Akhmadullina, LI; Barker, NP; Davidenko, IS; Firsov, I; Gertner, JM; Gotovkin, EA; Kopp, MV; Kulikov, EP; Moiseyenko, VM; Peterson, DE; Rakovskaya, GN; Rodionova, I; Sherman, NZ; Shinkarev, SA; Tuleneva, T; Woon, CW; Yarosh, A, 2009)
"Forty patients with colorectal cancer were included in this randomized prospective study."2.73Effect of oral administration of kefir on serum proinflammatory cytokines on 5-FU induced oral mucositis in patients with colorectal cancer. ( Aydiner, A; Aykan, F; Can, G; Cevikbaş, A; Cinar, S; Deniz, G; Derin, D; Dişçi, R; Durna, Z; Guney, N; Gürer, U; Kürklü, E; Saglam, S; Sakar, B; Tanyeri, H; Taş, F; Topuz, E, 2008)
"Seventy patients with advanced head and neck cancer were treated with vinorelbine and continuous 5-FU administered in a central venous catheter."2.73A phase II study using vinorelbine and continuous 5-fluorouracil in patients with advanced head and neck cancer. ( Adimi, P; Andersen, LJ; Bastholt, L; Larsen, S; Lindeløv, B; McCulloch, T; Serup-Hansen, E, 2007)
" The most frequent common adverse events were nausea, Grades 1 - 2 in 13 patients (81."2.72Chronomodulated chemotherapy with oxaliplatin, 5-FU and sodium folinate in metastatic gastrointestinal cancer patients: original analysis of non-hematological toxicity and patient characteristics in a pilot investigation. ( Farker, K; Hippius, M; Höffken, K; Hoffmann, A; Merkel, U; Wedding, U, 2006)
"Thirty-two patients with head-and-neck cancer were treated with chemoradiotherapy (CRT) (radiotherapy daily up to 70 Gy plus cisplatin/5-fluoruracil once a week) and were asked to participate."2.72Double-blinded, placebo-controlled trial on intravenous L-alanyl-L-glutamine in the incidence of oral mucositis following chemoradiotherapy in patients with head-and-neck cancer. ( Bonomi, M; Cabalar, ME; Castro, MA; Cerchietti, LC; Kirchuk, R; Lutteral, MA; Navigante, AH; Negretti, G; Roth, B; Sheinker, B; Uchima, P, 2006)
"Preoperative chemoradiotherapy in rectal cancer using chronomodulated 5-FU and LV is feasible."2.71Phase I study of 5-fluorouracil and leucovorin by continuous infusion chronotherapy and pelvic radiotherapy in patients with locally advanced or recurrent rectal cancer. ( Berry, S; Bjarnason, GA; Davey, P; de Marsh, RW; Mendenhall, W; Parulekar, W; Rout, WR; Wong, R; Zlotecki, R, 2004)
"Capecitabine was given twice daily, 7 days a week at a dose starting at 350 mg/m(2) bid."2.71Results of a phase I study to determine the maximum tolerated dose of capecitabine when given concurrently with radical radiotherapy in the treatment of squamous cell carcinoma of the head and neck. ( Ironside, JA; MacDougall, RH; Mais, KL; Slevin, NJ; Sykes, AJ, 2004)
"Oral mucositis is a frequent and potentially severe complication of radiation or chemotherapy for cancer."2.71Chitosan delivery systems for the treatment of oral mucositis: in vitro and in vivo studies. ( Aksungur, P; Iskit, AB; Senel, S; Squier, CA; Sungur, A; Unal, S, 2004)
"Capecitabine was administered orally on day 1 of radiotherapy by an intermittent schedule (14 days treatment; 7-day rest) at 3 weekly intervals for two cycles."2.71[Phase I study of capecitabine with concurrent radiotherapy in early-stage nasopharyngeal carcinoma]. ( Guo, L; Guo, X; Hong, MH; Li, FY; Li, Q; Lin, HX; Luo, DH; Qiu, F, 2004)
"Capecitabine was administered in twice daily divided doses, and CI-994 was given as a single daily dose."2.71A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. ( Janisch, L; Kimmel, KA; Kindler, HL; Macek, TA; Olson, SC; Ratain, MJ; Schilsky, RL; Undevia, SD; Vogelzang, NJ, 2004)
"Oral mucositis was assessed by nurses prior to each of the three chemotherapy cycles and 15 days after each intervention."2.71Comparison of plain ice and flavoured ice for preventing oral mucositis associated with the use of 5 fluorouracil. ( Hyde, S; Kristjanson, LJ; Myers, H; Nikoletti, S; Shaw, T, 2005)
" This regimen is under way in which chemotherapy with 5-FU 500 mg/day on days 1 to 5 and superselective intra-arterial infusion of CDGP on day 6 combined with radiation therapy is being evaluated for locally advanced oral cancer."2.71[Clinical trial of chemotherapy by superselective intra-arterial infusion of nedaplatin combined with radiotherapy for advanced oral cancer]. ( Goto, M; Shikimori, M; Yamshita, Y, 2005)
" We investigated the therapeutic and adverse drug reaction of intensive chemotherapy using cisplatin (CDDP), 5-FU and dl-leucovorin (LV) (PFL-therapy), which may be producing dual biochemical modulation effect of 5-FU for advanced colorectal carcinoma."2.70Investigation into the usefulness and adverse events of CDDP, 5-fU and dl-leucovorin (PFL-therapy) for advanced colorectal cancer. ( Arai, T; Fukahara, T; Ishikawa, T; Iwai, T; Kuwabara, H; Maruyama, S; Murase, N; Okabe, S; Ootsukasa, S; Tanami, H; Udagawa, M; Yamashita, H, 2002)
"The mean size of lesions of oral mucositis was 1."2.70Decrease of duration and symptoms in chemotherapy-induced oral mucositis by topical GM-CSF: results of a prospective randomised trial. ( Brodowicz, T; Hejna, M; Köstler, WJ; Raderer, M; Scheithauer, W; Steger, GG; Wiltschke, C; Zielinski, CC, 2001)
"Capecitabine is a novel fluoropyrimidine carbamate, orally administered and selectively activated to fluorouracil by a sequential triple-enzyme pathway in liver and tumor cells."2.70Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy. ( Kramer, G; Locker, GJ; Mader, R; Marberger, M; Rauchenwald, M; Schmidinger, M; Steger, GG; Wenzel, C; Zielinski, CC, 2002)
"Gemcitabine was administered as a 30-minute intravenous infusion weekly for 3 weeks followed by a 1-week break."2.70Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. ( Bertucci, D; Kindler, HL; Ratain, MJ; Schilsky, RL; Vogelzang, NJ, 2002)
"All patients had metastatic colorectal cancer, with adjuvant or palliative chemotherapy given to six patients (22%) on schedule A and 12 patients on schedule B (41%)."2.69Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion. ( Adam, R; Bismuth, H; Dallemagne, B; Focan, C; Focan-Henrard, D; Jasmin, C; Jehaes, C; Kreutz, F; Levi, F; Lobelle, JP; Markiewicz, S; Misset, JL; Weerts, J, 1999)
"Twenty-three patients with advanced head and neck cancer, mainly Stage III and IV, were treated with preoperative radiation (n = 1), pre- as well as postoperative radiotherapy (n = 5), postoperative radiation (n = 9) or combined postoperative radio-chemotherapy (n = 6)."2.69[Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors]. ( Altmann, S; Hoffmanns, H, 1999)
"Oral mucositis is a frequent side effect of cancer therapy."2.68A double-blind, randomized, placebo-controlled, crossover trial of pentoxifylline for the prevention of chemotherapy-induced oral mucositis. ( Burkhead, T; Garewal, HS; Koenig, LM; Vaughn, B; Verdi, CJ, 1995)
"Twenty patients with stage IV squamous cell carcinoma of head and neck were studied."2.68Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy. ( Chan, WK; Chang, CY; Chao, JY; Chen, CH; Chen, KY; Chen, SY; Chi, KH; Chow, KC; Yen, SH, 1995)
"Stomatitis was seen more in arm B and C than in arm A."2.68[A randomized early phase II study of l-leucovorin and 5-fluorouracil in gastric cancer. l-Leucovorin and 5-FU Study Group]. ( Akazawa, S; Konishi, T; Kumai, K; Kurihara, M; Ogawa, M; Ogawa, N; Ota, K; Sasaki, T; Taguchi, T; Tominaga, T, 1995)
" Patients who received Tomudex spent a substantially shorter time in hospital for dosing and had significantly lower rates of grade 3 and 4 toxicities such as leucopenia and mucositis."2.68'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The 'Tomudex' Colorectal Cancer Study Group. ( Cunningham, D; Harper, P; Kerr, D; Olver, I; Perez-Manga, G; Rath, U; Seitz, JF; Svensson, C; Van Cutsem, E; Zalcberg, JR, 1995)
"Thirty-two patients (76%) had no oral mucositis."2.68Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma. ( Chan, WK; Chen, KY; Chen, SY; Chi, KH; Law, CK; Shu, CH; Yen, SH, 1995)
"Mucositis is a common toxicity of cancer chemotherapy."2.68Oral glutamine to prevent chemotherapy induced stomatitis: a pilot study. ( Anderson, PM; Skubitz, KM, 1996)
"Thirty patients with recurrent primary brain tumors were treated with a combination of 5-fluorouracil and leucovorin."2.68Phase II study of 5-fluorouracil and leucovorin in recurrent primary brain tumor. ( Buckner, JC; Cascino, TL; Goldberg, RM; Kuross, SA; Levitt, R; Morton, RF; O'Fallon, JR; Scheithauer, BW; Veeder, MH; Wiesenfeld, M, 1996)
"Levamisole was administered orally (days 1-3 and 15-17) at doses from 30 to 470 mg/m2 per day."2.68A phase I study of 5-fluorouracil, leucovorin and levamisole. ( Alberti, D; Arzoomanian, R; Carbone, P; Cleary, JF; Feierabend, C; Storer, B; Wilding, G; Witt, P, 1997)
"Twelve patients with locally advanced breast carcinoma received HD-CT followed by peripheral stem cell reinfusion."2.68A new in vitro assay for quantitation of chemotherapy-induced mucositis. ( de Vries, EG; Mulder, NH; Sluiter, WJ; Spijkervet, FL; Timens, W; Timmer-Bosscha, H; van der Graaf, WT; Wymenga, AN, 1997)
"Grade 3-4 toxicities included oral mucositis in 19 patients, granulocytopenia in 16, fatigue in 8, and diarrhea in 3."2.67Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinoma. ( Abbruzzese, JL; Ajani, JJ; Belt, RJ; Dakhil, SR; Dubovsky, D; Graham, S; Levin, B; Pazdur, R; Pilat, S; Winn, R, 1992)
"Stomatitis was observed in 44/78 (56%) courses."2.67A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions. ( Alberti, D; Arzoomanian, RZ; Bailey, H; Grem, JL; Spriggs, DR; Tombes, MB; Tutsch, KD; Wilding, G, 1992)
"Oral hydroxyurea (HU) was added to a regimen of 5-fluorouracil (5-FU) plus leucovorin (LCV) administered as a continuous 24-hour infusion for 14 days."2.67Dual modulation of 5-fluorouracil using leucovorin and hydroxyurea. A phase I trial. ( Anderson, N; Bern, M; Coco, F; Gonsalves, L; Lokich, J; Moore, C; Zipoli, T, 1991)
"5-Fluorouracil was infused 24 hours per day throughout the period of radiation at a dose of 300 mg/m2/day for a median of 42 days (range, 28-56 days)."2.66Concomitant 5-fluorouracil infusion and high-dose radiation for stage III non-small cell lung cancer. ( Chaffey, J; Lokich, J; Neptune, W, 1989)
"Stomatitis was more frequent on the infusion arm but it was mild and reversible."2.66A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck. ( Al-Sarraf, M; Cummings, G; Ensley, JF; Jacobs, J; Kish, JA; Weaver, A, 1985)
"Ulcerative oral mucositis can be costly to healthcare systems, yet there are few preventive interventions proven to be beneficial."2.52Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy. ( Clarkson, JE; Glenny, AM; Littlewood, A; McCabe, MG; Riley, P; Worthington, HV, 2015)
"Adjuvant therapy for colorectal cancer has been one of the most important contributions of medical oncology to the health of the population, saving more lives annually than more effective therapy for less common cancers, such as Hodgkin's disease."2.42Adjuvant therapy for rectal cancer in the elderly. ( Cohen, SM; Neugut, AI, 2004)
" Hand-foot syndrome (HFS) is the only clinical adverse event occurring more often during capecitabine treatment."2.42Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda). ( Grothey, A; Marsé, H; Valverde, S; Van Cutsem, E, 2004)
"Capecitabine has a favourable safety profile, the most frequent adverse events being hand-foot syndrome, stomatitis and diarrhoea."2.42Development of and clinical experience with capecitabine (Xeloda) in the treatment of solid tumours. ( Holland, M; Reichardt, P; Sternberg, CN, 2004)
"Capecitabine (Xeloda) is an oral prodrug that is enzymatically converted to fluorouracil (5-FU) within cancer cells."2.41Current status of capecitabine in the treatment of colorectal cancer. ( Rothenberg, ML, 2002)
"Oral mucositis is a frequent and potentially severe complication of chemotherapy which has a considerable impact on patient quality of life."2.41Chemotherapy-induced oral mucositis. Prevention and management. ( Feld, R; Knox, JJ; Puodziunas, AL, 2000)
"Pursuant to this, the North Central Cancer Treatment Group has developed a series of clinical trials designed to study antidotes for these pathologic processes."2.39Alleviation of cytotoxic therapy-induced normal tissue damage. ( Foote, RL; Loprinzi, CL; Michalak, J, 1995)
"Chemotherapy-induced oral mucositis (COM) is a common adverse effect of cancer chemotherapy."1.91Preparation and pharmaceutical properties of Hangeshashinto oral ointment and its safety and efficacy in Syrian hamsters with 5-fluorouracil-induced oral mucositis. ( Hira, D; Imai, S; Ito, M; Itohara, K; Kagawa, M; Matsubara, K; Nakagawa, S; Nakagawa, T; Ogihara, T; Terada, T; Yamanaka, R; Yonezawa, A, 2023)
"The current idea of how oral mucositis (OM) develops is primarily based on hypotheses and the early events which precede clinically established OM remain to be demonstrated."1.91Moderate temperature reduction is sufficient for prevention of 5-fluorouracil-induced oral mucositis: an experimental in vivo study in rats. ( Aydogdu, Ö; Dankis, M; Jontell, M; Walladbegi, J; Winder, M, 2023)
"Oral and intestinal mucositis are debilitating inflammatory diseases observed in cancer patients undergoing chemo-radiotherapy."1.91Characterization of a novel dual murine model of chemotherapy-induced oral and intestinal mucositis. ( Celentano, A; Cirillo, N; Low, JT; McCullough, MJ; Mohammed, AI; O' Reilly, LA; Paolini, R, 2023)
"However, the β-cry effect on oral mucositis remains unclear."1.91Anti-Inflammatory Effects of β-Cryptoxanthin on 5-Fluorouracil-Induced Cytokine Expression in Human Oral Mucosal Keratinocytes. ( Kanamura, N; Kishimoto, S; Mazda, O; Nakai, K; Oseko, F; Yamamoto, K; Yamamoto, T; Yamanobe, H, 2023)
"5-Fluorouracil (5-FU)-induced oral mucositis has a severe negative impact on the patient's quality of life."1.72Protective effect of endoplasmic reticulum stress inhibition on 5-fluorouracil-induced oral mucositis. ( Cao, YN; Chen, C; Hou, Y; Li, M; Shan, E; Shan, J; Wang, J; Wang, Y; Zhang, L; Zhou, Y, 2022)
"Metformin (Met) is a first-line and essential treatment for type 2 diabetes, with anti-inflammatory effects."1.72Metformin protects 5-Fu-induced chemotherapy oral mucositis by reducing endoplasmic reticulum stress in mice. ( Chen, Y; Li, X; Ma, R; Shan, E; Shan, J; Sun, H; Zhang, J; Zhou, Y, 2022)
"Changes in body weight and white blood cell count were measured to determine the optimal dosing schedule."1.62Therapeutic Effects of GGsTop ( Makino, K; Takeuchi, I; Tanaka, K, 2021)
"Due to the worsening of oral mucositis, the patient may progress to a worse clinical condition and interrupt antineoplastic treatment."1.62Laser Therapy as a Preventive Approach for Oral Mucositis in Cancer Patients Undergoing Chemotherapy: The Potential Role of Superoxide Dismutase. ( Bissoli, NS; Bonela, LAS; Gonçalves, WL; Gouvea, SA; Menezes, BC; Oliveira, KG; Sartorio, CL; Thebit, MM, 2021)
"Oral mucositis was induced in ICR mice by 5-FU and randomly assigned to receive daily applications of the topical oral MNG, a fluocinolone acetonide gel, a blank niosome gel, or no treatment for 5 days in comparison with a normal group."1.62Topical Melatonin Niosome Gel for the Treatment of 5-FU-Induced Oral Mucositis in Mice. ( Boonsiri, P; Chio-Srichan, S; Daduang, J; Lee, YC; Mahakunakorn, P; Priprem, A; Settasatian, C; Uthaiwat, P, 2021)
" Given the known sex differences in fluoropyrimidine pharmacokinetics, sex-specific dosing of fluoropyrimidines warrants further investigation."1.62Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database. ( Alberts, SR; Allegra, CJ; Andre, T; Blanke, CD; de Gramont, A; Dixon, JG; Francini, E; George, TJ; Goldberg, RM; Grothey, A; Haller, DG; Kerr, R; Marsoni, S; O'Connell, MJ; Saltz, LB; Seitz, JF; Shi, Q; Taieb, J; Twelves, C; VanCutsem, E; Wagner, AD; Wolmark, N; Yothers, G, 2021)
"A chemoradiation-induced oral mucositis model was established by treating mice with concurrent 5-fluorouracil (100 mg/kg, i."1.561-Palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol ameliorates chemoradiation-induced oral mucositis. ( Choi, S; Kim, JW; Lee, HR; Shin, SH; Sohn, KY; Yoon, SY, 2020)
"Oral mucositis was induced in hamsters by administration of 5-fluorouracil (day 0, 2, 4) followed by mechanical trauma (day 1, 2, 4)."1.56Wound Healing Promoting Activity of Tonsil-Derived Stem Cells on 5-Fluorouracil-Induced Oral Mucositis Model. ( Jung, H; Kim, HS; Lee, JH; Lee, JJ; Park, HS, 2020)
"A model animal of oral mucositis was prepared by injecting an acetic acid aqueous solution into the buccal mucosa of rats to which a 5-FU solution had been previously administered."1.56A Rat Model of Oral Mucositis Induced by Cancer Chemotherapy for Quantitative Experiments. ( Kawamata, R; Makino, K; Takeuchi, I, 2020)
"Oral mucositis is a common inflammatory complication among patients with cancer."1.56Effect of Topical 2% Eucalyptus Extract on 5-FU-Induced Oral Mucositis in Male Golden Hamsters. ( Andisheh-Tadbir, A; Badie, A; Habibagahi, R; Haghnegahdar, S; Koohi-Hosseinabadi, O; Tanideh, N, 2020)
"Oral mucositis (OM) induced by cancer chemotherapy has a high incidence and serious symptoms, which often force chemotherapy to be stopped."1.51Therapeutic Effect of GGsTop, Selective Gamma-glutamyl Transpeptidase Inhibitor, on a Mouse Model of 5-Fluorouracil-induced Oral Mucositis. ( Makino, K; Shimamura, Y; Takeuchi, I; Terada, H, 2019)
"Oral mucositis is an important adverse effect of chemotherapy, and its severity, frequency, and impact on patient quality of life should not be underestimated."1.51Oral cryotherapy for prophylaxis of oral mucositis caused by docetaxel, cisplatin, and fluorouracil chemotherapy for esophageal cancer. ( Fushida, S; Kinoshita, J; Makino, I; Miyashita, T; Nakamura, K; Nakanuma, S; Ninomiya, I; Ohta, T; Okamoto, K; Tajima, H; Takamura, H; Terai, S; Yamaguchi, T, 2019)
"extract on oral mucositis (OM) induced by 5-fluorouracil (5-FU) in hamsters."1.51Mucoadhesive formulation containing Curcuma longa L. reduces oral mucositis induced by 5-fluorouracil in hamsters. ( Batista, AC; Curra, M; de Oliveira, AC; Marreto, RN; Martins, MAT; Martins, MD; Schmidt, TR; Valadares, MC; Wagner, VP, 2019)
"Elental reduced oral mucositis and dermatitis more effectively than dextrin in the animal model."1.48Elemental Diet Accelerates the Recovery From Oral Mucositis and Dermatitis Induced by 5-Fluorouracil Through the Induction of Fibroblast Growth Factor 2. ( Ferdous, T; Harada, K; Kobayashi, H; Ueyama, Y, 2018)
"Oral mucositis is a side effect of treatment regimens containing 5-fluorouracil (5-FU)."1.48Peroxisome proliferator activated receptor-gamma stimulation for prevention of 5-fluorouracil-induced oral mucositis in mice. ( Biti, G; Bonomo, P; Castiglione, F; Desideri, I; Francolini, G; Gerini, C; Grassi, R; Greto, D; Livi, L; Loi, M; Mangoni, M; Meattini, I; Perna, M; Salvatore, G; Sottili, M, 2018)
"Oral mucositis is a common side effect of cancer chemotherapy, with significant adverse impact on the delivery of anti-neoplastic treatment."1.48Chemotherapy-induced oral mucositis and associated infections in a novel organotypic model. ( Bertolini, M; Diaz, PI; Dongari-Bagtzoglou, A; Peterson, DE; Sobue, T; Thompson, A, 2018)
"The cytotoxic effect of chemotherapeutic agents to the oral mucosa, as a side effect of cancer treatment, is a major problem."1.48Cooling of the oral mucosa to prevent adverse effects of chemotherapeutic agents: An in vitro study. ( Colley, HE; Grayson, AK; Jontell, M; Murdoch, C; Smith, SA; Walladbegi, J, 2018)
"Oral mucositis is one of the most common side effects induced by cancer therapy, and the prevention or rapid treatment of the symptoms of oral mucositis can improve patients' quality of life and reduce the need for treatment interruption."1.48Therapeutic efficacy of rebamipide-loaded PLGA nanoparticles coated with chitosan in a mouse model for oral mucositis induced by cancer chemotherapy. ( Kamiki, Y; Makino, K; Takeuchi, I, 2018)
"Oral mucositis was induced in hamsters with 5-fluorouracil (5-FU; 60 mg/kg day 1 and 40 mg/kg day 2)."1.48Protective effect of angiotensin II receptor blocker against oxidative stress and inflammation in an oral mucositis experimental model. ( Araújo Junior, RF; Araújo, AA; Araújo, LS; Brito, GAC; Costa, DVDS; Garcia, VB; Guerra, GCB; Leitão, RFC; Lima, MLS; Medeiros, CACX, 2018)
"Chemotherapy-induced oral mucositis impairs the quality of life."1.48Oral mucositis associated with anti-EGFR therapy in colorectal cancer: single institutional retrospective cohort study. ( Dote, S; Hira, D; Itakura, S; Kamei, K; Kobayashi, Y; Noda, S; Terada, T, 2018)
" The frequency and severity of these adverse events vary from patient to patient and are partially explained by genetic polymorphism into the dihydropyrimidine dehydrogenase (DPYD) gene."1.46Fluoropyrimidine-Associated Toxicity in Two Gastrointestinal Cancer Patients: Potential Role of Common DPYD Polymorphisms. ( Cergnul, M; Cheli, S; Falvella, FS; Fava, S; Luoni, M, 2017)
"Oral mucositis was induced in hamsters using 5-fluorouracil (5-FU; 60 and 40 mg/kg; i."1.46Role of the route of leukotrienes in an experimental model of oral mucositis induced by 5-fluorouracil 1. ( Aragão, KS; Brito, GAC; Freire, GE; Freitas, MR; Leitão, RFC; Martins, CDS; Silva, VCD; Wanderley, CWS, 2017)
"Apigenin treatment may enhance healing of OM induced by 5-fluorouracil, thus suggesting that more extensive research in this area may be useful to assess the role of agents of natural origin capable of preventing OM."1.46The therapeutic effects of apigenin and dexamethasone on 5-fluorouracil-induced oral mucositis - a pilot study using a Syrian hamster model. ( Amaral Mendes, R; Gómez Garcia, F; Lopez-Jornet, P; Martinez Diaz, F; Molina Prats, P, 2017)
"Forty hamsters with oral mucositis induced by 5-fluorouracil administered on days 0, 5 and 10 and buccal mucosal scratching were randomly divided into four equal groups: group 1 received no additional treatment, group 2 received gel base, and groups 3 and 4 received gels containing 5% and 10% oil, respectively."1.46Healing acceleration of oral mucositis induced by 5-fluorouracil with Pistacia atlantica (bene) essential oil in hamsters. ( Andisheh-Tadbir, A; Davarmanesh, M; Koohi-Hosseinabadi, O; Mehriar, P; Ranjbar, Z; Tanideh, N, 2017)
"Twenty esophageal cancer patients receiving chemotherapy with 5-fluorouracil plus cisplatin were assigned randomly to one of the following two groups: (1) receiving elemental diet with Elental (one pack per day) for 14 days and (2) not receiving Elental during chemotherapy."1.46A prospective study of nutritional supplementation for preventing oral mucositis in cancer patients receiving chemotherapy. ( Hoshino, A; Kawada, K; Kawano, T; Miyawaki, Y; Nagai, K; Nakajima, Y; Nishikage, T; Okada, T; Ryotokuji, T; Tokairin, Y, 2017)
"Oral mucositis was induced through a combination of 5-FU treatment and mild abrasion of the cheek pouch with a wire brush."1.43Effect of a corticosteroid (triamcinolone) and chlorhexidine on chemotherapy-induced oxidative stress in the buccal mucosa of rats. ( Aynali, G; Başpınar, Ş; Gümüş, S; Nazıroğlu, M; Uğuz, AC; Yarıktaş, M, 2016)
"Chemotherapy-induced oral mucositis is a common adverse event in patients with oral squamous cell carcinoma, and is initiated through a variety of mechanisms, including the generation of reactive oxygen species (ROS)."1.42γ-Tocotrienol prevents 5-FU-induced reactive oxygen species production in human oral keratinocytes through the stabilization of 5-FU-induced activation of Nrf2. ( Aota, K; Azuma, M; Kani, K; Momota, Y; Takano, H; Yamamura, Y; Yamanoi, T, 2015)
"Oral mucositis is a reaction to chemoradiation therapy during cancer treatment."1.42Amniotic membrane as a biological dressing for 5-fluoruracil-induced oral mucositis in rats. ( Carvalho, MA; Gomes, MF; Lima, Gde M; Salgado, MA; Santana-Melo, Gde F; Severo, MC; Vilela-Goulart, Md, 2015)
" Severe toxic reactions to 5-FU have been associated with decreased levels of dihydropyrimidine dehydrogenase (DPD) enzyme activity."1.40A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach. ( Diasio, RB; Lee, AM; McConnell, K; Offer, SM; Relias, V; Saif, MW, 2014)
"The recovery stage of oral mucositis was evaluated through daily weighing, measurements of the ulcer area, histopathologic analysis, and a myeloperoxidase activity assay."1.40Platelet-rich fibrin has a healing effect on chemotherapy-induced mucositis in hamsters. ( Horii, K; Kanayama, T; Kohgo, T; Miyamoto, H; Shigetomi, T; Tsuchimochi, T; Yokoi, M, 2014)
"perforatum extract on oral mucositis."1.40Comparative assessment of the therapeutic effects of the topical and systemic forms of Hypericum perforatum extract on induced oral mucositis in golden hamsters. ( Andisheh Tadbir, A; Ebrahimi, H; Koohi-Hosseinabadi, O; Namazi, F; Tanideh, N, 2014)
"Oral mucositis was induced in male hamsters by two intraperitoneal administrations of 5-FU on the first and second days of the experiment (60 and 40 mg/kg, respectively) followed by mechanical trauma on the fourth day."1.40S-nitrosoglutathione accelerates recovery from 5-fluorouracil-induced oral mucositis. ( Baldim, V; Braga, CM; Brito, GA; Cavalcante, MM; Colombo, AP; de Oliveira, MG; Holanda-Afonso, RC; Leitão, RF; Moura-Neto, V; Ribeiro, RA; Silva-Boghossian, CM; Skeff, MA, 2014)
"Oral mucositis was induced in Syrian hamster cheek pouches by 5-fluorouracil treatment and mechanical scratching."1.39Effect of rice cell-derived human granulocyte-macrophage colony-stimulating factor on 5-fluorouracil-induced mucositis in hamsters. ( Ahn, KH; Choi, JM; Ha, HC; Han, K; Ji, JE; Kim, DK; Kim, HM; Kim, SK; Won, JH; Yun, CK, 2013)
"It has been reported that oral mucositis can reduce quality of life, as well as increasing the incidence of mortality."1.39Alteration of the redox state with reactive oxygen species for 5-fluorouracil-induced oral mucositis in hamsters. ( Lee, MC; Nakajima, A; Takahashi, SS; Wada-Takahashi, S; Yoshida, A; Yoshino, F, 2013)
"Weight gain was noted in the treatment groups compared with the gel base and control groups (P < ."1.39Healing acceleration in hamsters of oral mucositis induced by 5-fluorouracil with topical Calendula officinalis. ( Amanat, D; Garcia-Godoy, F; Saghiri, MA; Samani, SM; Tadbir, AA; Tamadon, A; Tanideh, N; Tavakoli, P, 2013)
"Oral mucositis was induced in hamsters through a combination of 5-FU treatment and mild abrasion of the cheek pouch."1.39Oral mucosal adhesive films containing royal jelly accelerate recovery from 5-fluorouracil-induced oral mucositis. ( Araki, H; Imai, K; Kaji, H; Suemaru, K; Takechi, K; Watanabe, S, 2013)
"Population-based studies of adverse events are scarce."1.38Comparison of toxicity profiles of fluorouracil versus oxaliplatin regimens in a large population-based cohort of elderly patients with colorectal cancer. ( Cen, P; Du, XL; Liu, C, 2012)
"Oral mucositis is an important dose-limiting and costly side effect of cancer chemotherapy."1.38Protein fraction of Calotropis procera latex protects against 5-fluorouracil-induced oral mucositis associated with downregulation of pivotal pro-inflammatory mediators. ( Bitencourt, FS; Brito, GA; de Alencar, NM; Freitas, AP; Lima-Júnior, RC; Ramos, MV; Ribeiro, RA; Vale, ML, 2012)
"Chamomile proved effective in the treatment of oral mucositis in a hamster model."1.37Healing action of topical chamomile on 5-fluoracil induced oral mucositis in hamster. ( Bussadori, SK; Fernandes, KP; Lopez, TC; Martins, MA; Martins, MD; Mesquita-Ferrari, RA; Pavesi, VC; Sant'Ana Filho, M, 2011)
"World Health Organization scores for oral mucositis were documented weekly and correlated with DSB repair."1.37The impact of individual in vivo repair of DNA double-strand breaks on oral mucositis in adjuvant radiotherapy of head-and-neck cancer. ( Derschang, S; Fleckenstein, J; Fricke, A; Gräber, S; Kühne, M; Melchior, P; Rübe, C; Rübe, CE; Seegmüller, K, 2011)
"Three patients (20%) had grade 3-4 dysphagia in weeks 3-4 and were continued on intravenous fluids and pain medications."1.37Toxicity data for preoperative concurrent chemoradiotherapy with oxaliplatin and continuous infusion 5-fluorouracil for locally advanced esophageal cancer. ( Ad, VB; Bar-Ad, V; Both, S; Hwang, WT; Metz, J; O'Dwyer, P; Plastaras, J; Thukral, A, 2011)
"Strictures were associated with tumor location (tonsil vs base of tongue; p = ."1.37Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma. ( Best, SR; Blanco, RG; Califano, JA; Ha, PK; Levine, MA; Messing, BP; Murakami, P; Pai, SI; Saunders, JR; Thompson, R; Trachta, J; Ulmer, K; Walker, M; Zinreich, ES, 2011)
"Stomatitis is a side effect caused frequently by chemotherapy in patients with esophageal cancer, but a standard treatment for it has not been established."1.37[Elental prevented and reduced oral mucositis during chemotherapy in patients esophageal cancer]. ( Fukui, T; Itoh, Y; Kawada, S; Orihara, M; Takeda, H; Yoshioka, T; Yoshizawa, K, 2011)
"A hamster cheek pouch model of oral mucositis was used with all animals receiving intraperitoneal 5-fluorouracil, followed by surface irritation."1.36Effects of low-level laser therapy on collagen expression and neutrophil infiltrate in 5-fluorouracil-induced oral mucositis in hamsters. ( Alves, MT; Chavantes, MC; da Silva, MA; Lalla, RV; Lopes, NN; Plapler, H; Yoshimura, EM, 2010)
"Oral mucositis was induced in hamsters through a combination of 5-fluorouracil and mild abrasions that were made on the cheek pouch."1.35Topical application of royal jelly has a healing effect for 5-fluorouracil-induced experimental oral mucositis in hamsters. ( Araki, H; Cui, R; Hashimoto, K; Li, B; Okihara, K; Suemaru, K; Watanabe, S; Yamada, H, 2008)
"Oral mucositis is a frequent and significant side effect of chemotherapy and/or radiation therapy."1.35Homogenous amniotic membrane as a biological dressing for oral mucositis in rats: histomorphometric analysis. ( Gomes, MF; Niccoli-Filho, W; Rangel, DC; Teixeira, RT; Vilela-Goulart, Md, 2008)
"A hamster cheek pouch model of oral mucositis was used with all animals receiving intraperitoneal 5-fluorouracil followed by surface irritation."1.35Cyclooxygenase-2 and vascular endothelial growth factor expression in 5-fluorouracil-induced oral mucositis in hamsters: evaluation of two low-intensity laser protocols. ( Alves, MT; Chavantes, MC; Lalla, RV; Lopes, NN; Plapler, H; Yoshimura, EM, 2009)
"We focused on the relationship between oral mucositis and keratinocyte injury and examined methotrexate and 5-fluorouracil-induced cytotoxicity in normal human epidermal keratinocyte cell lines."1.35Protective effects of amifostine and cyclooxygenase-1 inhibitor against normal human epidermal keratinocyte toxicity induced by methotrexate and 5-fluorouracil. ( Kaji, H; Maiguma, T; Makino, K; Teshima, D, 2009)
"Oral mucositis was induced in hamsters through a combination of 5-FU treatment and mild abrasion of the cheek pouch."1.35Effect of oral mucosal adhesive films containing ginsenoside Rb1 on 5-fluorouracil-induced oral mucositis in hamsters. ( Araki, H; Hidaka, N; Sakanaka, M; Suemaru, K; Watanabe, S; Yamaguchi, T, 2009)
"The 5-FU-induced oral mucositis significantly decreased the serum glutamine levels as well as the cheek pouch glutathione stores observed on day 10."1.35Glutamine and alanyl-glutamine accelerate the recovery from 5-fluorouracil-induced experimental oral mucositis in hamster. ( Bellaguarda, EA; Brito, GA; Leitão, RF; Lira, AM; Macedo, FD; Ribeiro, RA; Silva, LR; Sousa, RB, 2008)
"Oral mucositis was induced by two intraperitoneal (i."1.34Role of nitric oxide on pathogenesis of 5-fluorouracil induced experimental oral mucositis in hamster. ( Bellaguarda, EA; Brito, GA; Cunha, FQ; Leitão, RF; Macedo, FD; Oriá, RB; Ribeiro, RA; Silva, LR; Vale, ML, 2007)
" In May 2002, we devised a new regimen by intermittent dosage of 5-FU (-->S-1), CDDP and paclitaxel utilizing the difference of cell cycle between normal and cancer cells, and thirteen patients with advanced colorectal cancer (Stage IV) were treated with this regimen."1.34[The second report from Sapporo Tsukisamu hospital--chemotherapy for patients with advanced colorectal cancer]. ( Hirata, K; Hiyama, S; Inui, N; Kimura, H; Kimura, Y; Shirasaka, T; Yamada, Y; Yamamitsu, S, 2007)
"Oral mucositis is a frequent side-effect of cancer therapy."1.33Effects of the tumour necrosis factor-alpha inhibitors pentoxifylline and thalidomide in short-term experimental oral mucositis in hamsters. ( Augusto, RF; Brito, GA; Cunha, FQ; Falcão, BA; Leitão, BT; Lima, V; Rebouças, CG; Ribeiro, RA; Souza, ML, 2005)
"Oral mucositis was induced in hamsters through a combination treatment of 5-fluorouracil and mild abrasion of the cheek pouch."1.33Evaluation of topical external medicine for 5-fluorouracil-induced oral mucositis in hamsters. ( Araki, H; Cui, R; Li, B; Mitsuhashi, H; Suemaru, K, 2006)
"Oral mucositis is a common, treatment-limiting, and costly side effect of cancer treatments whose biological underpinnings remain poorly understood."1.32An engineered biopolymer prevents mucositis induced by 5-fluorouracil in hamsters. ( Baroukh, B; Barritault, D; Caruelle, JP; Godeau, G; Ledoux, D; Morvan, FO; Saffar, JL, 2004)
"Twenty patients with advanced gastric cancer received biweekly regimen of CF/5-FU/PTX (200 mg/m(2) of CF, intravenous infusion for 2 h, day 1; 500 mg/m(2) of 5-FU, intravenous injection, day 1; 1 500 mg/m(2) of 5-FU, intravenous infusion for 46 h, day 1, 2; 90 mg/m(2) of PTX, intravenous infusion for 3 h,day 1)."1.32[Biweekly regimen of high dose of leucovorin, 5-fluorouracil, and paclitaxel for patients with advanced gastric cancer]. ( Feng, JF; Lu, JW; Sun, XF, 2004)
"Oral mucositis was induced in Syrian golden hamsters through a combination treatment of the antimetabolite chemotherapy drug 5-fluorouracil (5-FU), and mild abrasion of the cheek pouch."1.31Exposure of oral mucosa to bioactive milk factors reduces severity of chemotherapy-induced mucositis in the hamster. ( Butler, R; Clarke, J; Howarth, G; Read, L; Regester, G, 2002)
"Improvement of oral mucositis was associated with a significant decrease of intestinal permeability to lactulose."1.31Intestinal permeability in patients with chemotherapy-induced stomatitis. ( Brátová, M; Kohout, P; Králícková, P; Melichar, B; Solichová, D; Zadák, Z, 2001)
"All of them had stage IV, unresectable squamous cell carcinoma of the pharynx and they received continuous bid radiotherapy (two daily fractions of 1."1.31[Concomitant bifractionated radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in locally progressive, non-resectable epidermoid carcinomas of the pharynx: ten years experience at the Antoine Lacassagne center]. ( Bensadoun, RJ; Chauvel, P; Courdi, A; Dassonville, O; Demard, F; Ettore, F; Falewee, MN; Lagrange, JL; Magné, N; Marcy, PY; Milano, G; Pivot, X; Poissonnet, G; Santini, J; Schneider, M; Vallicioni, J, 2001)
"Deficiency of dihydropyrimidine dehydrogenase (DPD), the rate-limiting enzyme in 5-fluorouracil (5-FU) catabolism, has been linked to toxic side effects of 5-FU."1.31Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. ( Behnke, D; Häusler, P; Höffken, K; Raida, M; Schwabe, W; Van Gennip, AH; Van Kuilenburg, AB, 2001)
"Oral mucositis is a dose-limiting toxicity of 5-fluorouracil (5-FU)."1.30Risk factors associated with mucositis in cancer patients receiving 5-fluorouracil. ( Awde, JD; Ghandi, H; Kocha, WI; McCarthy, GM; Vincent, M, 1998)
"Oral mucositis was induced in hamsters by intraperitoneal injection of 5-fluorouracil followed by superficial abrasion of the buccal mucosa."1.30Effect of local application of the antimicrobial peptide IB-367 on the incidence and severity of oral mucositis in hamsters. ( Embree, JR; Fiddes, JC; Loury, D; Sonis, ST; Steinberg, DA, 1999)
"Patients with head and neck cancer who chewed betel quid habitually seem to experience more severe chemotherapy-induced mucositis in our clinical practice."1.30Impact of oral submucous fibrosis on chemotherapy-induced mucositis for head and neck cancer in a geographic area in which betel quid chewing is prevalent. ( Chen, IH; Chen, JS; Liao, CT; Su, CL; Wang, CH; Wang, HM, 1999)
"Oral mucositis was induced in male Golden Syrian hamsters with 5-fluorouracil 60 mg/kg intraperitoneal, days 0 and 2."1.29IL-11, a pleiotropic cytokine: exciting new effects of IL-11 on gastrointestinal mucosal biology. ( Albert, L; Keith, JC; Pfeiffer, CJ; Schaub, RG; Sonis, ST, 1994)
"Hydroxyurea is an active single agent in squamous cell cancer of the head and neck."1.28Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer. ( Haraf, DJ; Panje, WR; Schilsky, RL; Vokes, EE; Weichselbaum, RR, 1992)
"However, stomatitis is one of the limiting side effects."1.28Treatment of 5-fluorouracil-induced stomatitis by allopurinol mouthwashes. ( Elzawawy, A, 1991)
"Oral mucositis is a major toxic effect related to 5-fluorouracil (5-FU) therapy."1.28Studies on the prevention of 5-fluorouracil-induced oral mucositis. ( Dose, AM; Loprinzi, CL, 1990)
" Thus, TMTX can be given with 5-FU (400 mg/m2) on a daily x 5-day bolus schedule at the 12 mg/m2 per day dose level, which was the recommended dose of TMTX as a single agent for phase II studies using the 5-day bolus schedule."1.28Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil. ( Catalano, R; Comis, RL; DeLap, RJ; Grillo-Lopez, AJ; Hudes, GR; LaCreta, F, 1989)
"Thirty-six patients with advanced colorectal cancer with unequivocal evidence of progression while treated with fluoropyrimidines were treated with a six-day continuous infusion of 500 mg/m2/d of folinic acid initiated 24 hours before a five-day course of 5-FU administered as an intravenous (IV) bolus of 370 mg/m2/d."1.27High-dose continuous infusion folinic acid and bolus 5-fluorouracil in patients with advanced colorectal cancer: a phase II study. ( Bertrand, M; Blayney, DW; Carr, BI; Cecchi, G; Doroshow, JH; Goldberg, D; Leong, L; Margolin, K; Metter, G; Multhauf, P, 1986)
"We treated 45 patients with advanced colon cancer with HDFA and 5-FU for 5 consecutive days."1.27High-dose folinic acid (HDFA) combined with 5-fluorouracil (5-FU) in first line chemotherapy of advanced large bowel cancer. ( Astone, A; Barone, C; Cassano, A; Cavallaro, A; Garufi, C; Grieco, A; Netri, G; Noviello, MR; Ricevuto, E; Rossi, S, 1987)
"Allopurinol has been shown to decrease the gastro-intestinal and bone marrow toxicity of 5-fluorouracil."1.27Allopurinol mouthwashes and 5-fluorouracil induced oral toxicity. ( Clark, PI; Slevin, ML, 1985)
"Thirty patients with squamous cell carcinoma of the head and neck were treated with a combination of cisplatin (20 mg/m2) and 5-FU (400-200 mg/m2) by iv push on Days 1-5 every 21 days."1.27Phase I-II trial with cisplatin and 5-FU in recurrent head and neck cancer: an effective outpatient schedule. ( Grimaldi, A; Margarino, G; Merlano, M; Rosso, R; Tatarek, R, 1985)
"Stomatitis was the predominant dose-limiting toxicity (22% grade 1, 19% grade 2, and 27% grade 3 toxicity)."1.26Allopurinol modulation of fluorouracil toxicity. ( Fox, RM; Piper, AA; Sampson, D; Tattersall, MH; Woods, RL, 1981)

Research

Studies (371)

TimeframeStudies, this research(%)All Research%
pre-199054 (14.56)18.7374
1990's84 (22.64)18.2507
2000's92 (24.80)29.6817
2010's104 (28.03)24.3611
2020's37 (9.97)2.80

Authors

AuthorsStudies
Takeuchi, I5
Tanaka, K1
Makino, K6
Cotomacio, CC2
Calarga, CC1
Yshikawa, BK1
Arana-Chavez, VE3
Simões, A3
Menezes, BC1
Thebit, MM1
Bonela, LAS1
Oliveira, KG1
Gonçalves, WL1
Bissoli, NS1
Sartorio, CL1
Gouvea, SA1
Severo, MLB1
Thieme, S1
Silveira, FM1
Tavares, RPM1
Gonzaga, AKG1
Zucolotto, SM1
de Araújo, AA2
Martins, MAT2
Martins, MD6
da Silveira, ÉJD2
Meirovitz, A1
Baider, L1
Peretz, T1
Stephanos, S1
Barak, V1
Cao, YN1
Wang, Y3
Zhang, L2
Hou, Y1
Shan, J2
Li, M1
Chen, C1
Zhou, Y2
Shan, E2
Wang, J1
Sun, H1
Ma, R1
Zhang, J2
Chen, Y1
Li, X1
Çelebi, A1
Dörtbudak, MB1
Keskinrüzgar, A1
Yüksel, H1
Aksoy, N1
Sen, E1
Sukmasari, S1
Özakpınar, ÖB1
Arıcıoğlu, F1
Yücel, YY1
Dumlu, MR1
Doolaanea, AA1
AbdulRahman, MN1
Olgac, V1
Bozkan, P1
Ozen, B1
Li, L1
Xuan, Y1
Zhu, B1
Wang, X1
Tian, X1
Zhao, L1
Jiang, X2
Wen, N1
Tian, MM1
Wang, YS1
Xiao, HB1
Ogihara, T1
Kagawa, M1
Yamanaka, R1
Imai, S1
Itohara, K1
Hira, D2
Nakagawa, S1
Yonezawa, A1
Ito, M2
Nakagawa, T1
Terada, T2
Matsubara, K1
Zhao, Y1
Mao, R1
Yan, H1
Zhang, Y1
Ma, H1
Tang, Y1
Walladbegi, J4
Dankis, M3
Aydogdu, Ö3
Jontell, M4
Winder, M3
Huang, J2
Hwang, AYM2
Jia, Y2
Kim, B2
Iskandar, M2
Mohammed, AI3
Cirillo, N3
Vaezi, H2
Rabbani, S2
Mortazavi, SA2
Kamalinejad, M2
Haeri, A2
Gomes, JT2
Wanzeler, AMV2
Júnior, SMA2
Soares, RHFC1
Oliveira, CP1
Rodrigues, EM1
Soares, BM2
Alcantara, DDFA1
Burbano, RMR1
Tuji, FM2
Celentano, A1
Paolini, R1
Low, JT1
McCullough, MJ1
O' Reilly, LA1
Yamanobe, H1
Yamamoto, K1
Kishimoto, S1
Nakai, K1
Oseko, F1
Yamamoto, T1
Mazda, O1
Kanamura, N1
Hamidi, SP1
Koohi-Hosseinabadi, O6
Khaksar, S1
Ghanbariasad, A1
Dehghanian, AR1
Dehghan, A1
Haddadi, Z1
Gorgin, R1
Farjam, M1
Alipanah, H1
Hu, Q1
Xu, J1
Ke, J1
Zhang, Z1
Chu, T1
Dilber, M1
Suleyman, B1
Mammadov, R1
Suleyman, Z1
Yavuzer, B1
Gulaboglu, M1
Erhan, E1
Salcan, I1
Suleyman, H1
Choi, S1
Shin, SH1
Lee, HR1
Sohn, KY1
Yoon, SY1
Kim, JW2
Damrongrungruang, T1
Panpitakkul, P1
Somudorn, J1
Sangchart, P1
Mahakunakorn, P2
Uthaiwat, P2
Daduang, J2
Panyatip, P1
Puthongking, P1
Priprem, A2
Jung, H1
Kim, HS1
Lee, JH1
Lee, JJ1
Park, HS1
Kawamata, R1
Cuba, LF1
Salum, FG1
Guimarães, FS1
Cherubini, K1
Borghetti, RL1
de Figueiredo, MAZ1
Settasatian, C1
Chio-Srichan, S1
Lee, YC1
Boonsiri, P1
Ramos, MV2
Freitas, APF1
Leitão, RFC3
Costa, DVS1
Cerqueira, GS1
Martins, DS1
Martins, CS1
Alencar, NMN2
Freitas, LBN1
Brito, GAC5
Yan, P1
Yin, H1
Guo, W1
Sun, X2
Li, F1
Huang, S1
Bian, X1
Wang, F1
Zhang, F1
Wang, B1
Zhou, H1
Zhou, C1
Yin, L1
Jiang, N1
Wu, J2
Liu, J1
Song, D1
He, X1
Tanideh, N7
Badie, A1
Habibagahi, R1
Haghnegahdar, S2
Andisheh-Tadbir, A2
Wagner, AD1
Grothey, A2
Andre, T1
Dixon, JG1
Wolmark, N1
Haller, DG1
Allegra, CJ1
de Gramont, A2
VanCutsem, E1
Alberts, SR1
George, TJ1
O'Connell, MJ3
Twelves, C1
Taieb, J1
Saltz, LB3
Blanke, CD2
Francini, E1
Kerr, R1
Yothers, G1
Seitz, JF2
Marsoni, S1
Goldberg, RM4
Shi, Q1
Gupta, N1
Ferreira, J1
Hong, CHL1
Tan, KS1
Huang, YF2
Liu, SP1
Muo, CH1
Chen, HJ1
Liao, YF1
Chiu, KM1
Chen, CC1
Tsai, CH1
Hong, HH2
Chang, CT2
Rodrigues, AB1
Aguiar, MIF1
Oliveira, PP1
Alves, NP1
Silva, RA1
Vitorino, WO1
Lopes, TSS1
de Morais, EF1
Batista Severo, ML1
Dantas Martins, HD1
Trevizani Martins, MA1
de Almeida Freitas, R1
Al-Taie, A1
Koseoglu, A1
Kim, DR1
Kim, J2
Oh, JY1
Kim, HY2
Kim, YJ1
Chang, MS2
Xing, X1
Meng, F1
Zhong, D1
Falvella, FS1
Luoni, M1
Cheli, S1
Fava, S1
Cergnul, M1
Harada, K1
Ferdous, T1
Kobayashi, H1
Ueyama, Y1
Ranjbar, Z2
Sepehrimanesh, M2
AndisheTadbir, A1
Poorbaghi, SL1
Bahranifard, H1
Koohi-Hosseinabadi, M1
Iraji, A2
Dos Santos Filho, EX1
da Silva, ACG1
de Ávila, RI1
Batista, AC2
Marreto, RN2
Lima, EM1
de Oliveira, CMA1
Mendonça, EF1
Valadares, MC2
Silva, VCD1
Martins, CDS1
Freire, GE1
Aragão, KS1
Wanderley, CWS1
Freitas, MR1
Ribeiro, SB1
Araújo Júnior, RF2
Leitão, RC1
Barbosa, MM1
Garcia, VB2
Medeiros, AC1
Medeiros, CACX2
Sottili, M1
Mangoni, M1
Gerini, C1
Salvatore, G1
Castiglione, F1
Desideri, I1
Bonomo, P1
Meattini, I1
Greto, D1
Loi, M1
Francolini, G1
Perna, M1
Grassi, R1
Biti, G1
Livi, L1
Gouveia, EHH1
Henriques, HYB1
Chaves, RH1
Salgado, HLC1
Santos, AS1
Shimamura, Y2
Terada, H2
Sobue, T2
Bertolini, M1
Thompson, A2
Peterson, DE3
Diaz, PI2
Dongari-Bagtzoglou, A2
Smith, SA1
Grayson, AK1
Murdoch, C1
Colley, HE1
Pastorino, A1
Di Bartolomeo, M1
Maiello, E1
Iaffaioli, V1
Ciuffreda, L1
Fasola, G1
Di Costanzo, F1
Frassineti, GL2
Marchetti, P1
Antoniotti, C1
Leone, F1
Zaniboni, A1
Aprile, G1
Zilocchi, C1
Sobrero, A3
Bordonaro, R1
Kamiki, Y1
Araújo, AA1
Araújo, LS1
Costa, DVDS1
Guerra, GCB1
Lima, MLS1
Idayu Mat Nawi, R1
Lei Chui, P1
Wan Ishak, WZ1
Hsien Chan, CM1
Dote, S1
Itakura, S1
Kamei, K1
Noda, S1
Kobayashi, Y1
Park, JW1
Oh, J1
Ko, SJ1
Okamoto, K1
Ninomiya, I1
Yamaguchi, T5
Terai, S1
Nakanuma, S1
Kinoshita, J1
Makino, I1
Nakamura, K2
Miyashita, T1
Tajima, H1
Takamura, H1
Fushida, S1
Ohta, T1
Schmidt, TR1
Curra, M3
Wagner, VP1
de Oliveira, AC1
Barbosa, SCM1
Pereira, VBM1
Wong, DVT1
Santana, APM1
Lucetti, LT1
Carvalho, LL1
Barbosa, CRN1
Callado, RB1
Silva, CAA1
Lopes, CDH1
Lima-Júnior, RCP1
Alinca, SB1
Saglam, E1
Kandas, NO1
Okcu, O1
Yilmaz, N1
Goncu, B1
Dogan, MA1
Hong, BY1
Choquette, L1
Dupuy, AK1
Burleson, JA1
Salner, AL1
Schauer, PK1
Joshi, P1
Fox, E1
Shin, DG1
Weinstock, GM1
Strausbaugh, LD1
Burns, KE1
Allright, D1
Porter, D1
Findlay, MP1
Helsby, NA1
Schwartzberg, LS1
Tauer, KW1
Hermann, RC1
Makari-Judson, G1
Isaacs, C1
Beck, JT1
Kaklamani, V1
Stepanski, EJ1
Rugo, HS1
Wang, W1
Bell-McGuinn, K1
Kirshner, JJ1
Eisenberg, P1
Emanuelson, R1
Keaton, M1
Levine, E1
Medgyesy, DC1
Qamar, R1
Starr, A1
Ro, SK1
Lokker, NA1
Hudis, CA1
Won, JH1
Ji, JE1
Ahn, KH1
Kim, SK1
Choi, JM1
Ha, HC1
Kim, HM1
Yun, CK1
Han, K1
Kim, DK1
Mazzeo, MA1
Linares, JA1
López, MM1
Bachmeier, E1
Wietz, FM1
Galván, V1
Valentinuzzi, MC1
Riveros, JA1
Finkelberg, A1
Lin, HX2
Hua, YJ1
Chen, QY1
Luo, DH2
Sun, R1
Qiu, F2
Mo, HY1
Mai, HQ1
Guo, X2
Xian, LJ1
Hong, MH2
Guo, L2
Kochi, M1
Akiyama, Y1
Aoki, T1
Hagiwara, K1
Takahashi, T1
Hironaka, K1
Teranishi, F1
Osuka, F1
Takeuchi, M1
Fujii, M2
Nakajima, T1
Davarmanesh, M2
Miri, R1
Tadbir, AA3
Saghiri, MA2
Garcia-Godoy, F2
Asatourian, A1
Scardina, GA1
Cacioppo, A1
Messina, P1
Likhacheva, A1
Jhingran, A1
Bodurka, DC1
Sun, C1
Sam, M1
Eifel, PJ1
Hamaker, ME1
Seynaeve, C1
Wymenga, AN2
van Tinteren, H1
Nortier, JW1
Maartense, E1
de Graaf, H1
de Jongh, FE1
Braun, JJ1
Los, M1
Schrama, JG1
van Leeuwen-Stok, AE1
de Groot, SM1
Smorenburg, CH1
Yoshino, F1
Yoshida, A1
Nakajima, A1
Wada-Takahashi, S1
Takahashi, SS1
Lee, MC1
Saif, MW1
Lee, AM1
Offer, SM1
McConnell, K1
Relias, V1
Diasio, RB1
Liu, Y1
Wu, W1
Hong, W1
Huang, Q1
Horii, K1
Kanayama, T1
Miyamoto, H3
Kohgo, T1
Tsuchimochi, T1
Shigetomi, T1
Yokoi, M1
Karaca, H1
Bozkurt, O1
Ozaslan, E1
Baldane, S1
Berk, V1
Inanc, M1
Duran, AO1
Dikilitas, M2
Er, O1
Ozkan, M1
Namazi, F1
Andisheh Tadbir, A1
Ebrahimi, H1
Yoshida, K1
Yoshioka, M1
Okamura, H1
Moriyama, S1
Kawazoe, K1
Grenier, D1
Hinode, D1
Enami, A1
Masuda, N1
Yamamura, J1
Mizutani, M1
Yasojima, H1
Shikata, A1
Masaoka, M1
Takada, S1
Bamba, N1
Yamamoto, M1
Abe, M1
Makihara, K1
Skeff, MA1
Brito, GA6
de Oliveira, MG1
Braga, CM1
Cavalcante, MM1
Baldim, V1
Holanda-Afonso, RC1
Silva-Boghossian, CM1
Colombo, AP1
Ribeiro, RA6
Moura-Neto, V1
Leitão, RF4
Cruz, Éde P1
Campos, L2
Pereira, Fda S1
Magliano, GC1
Benites, BM1
Ballester, RY1
Takano, H1
Momota, Y1
Kani, K1
Aota, K1
Yamamura, Y1
Yamanoi, T1
Azuma, M1
Lima, Gde M1
Severo, MC1
Santana-Melo, Gde F1
Carvalho, MA1
Vilela-Goulart, Md2
Salgado, MA1
Gomes, MF2
Matsuda, C1
Munemoto, Y1
Mishima, H1
Nagata, N1
Oshiro, M1
Kataoka, M1
Sakamoto, J1
Aoyama, T1
Morita, S1
Kono, T1
Ohnuma, H1
Sato, Y1
Hirakawa, M1
Okagawa, Y1
Osuga, T1
Hayashi, T1
Sato, T1
Miyanishi, K1
Kobune, M1
Takimoto, R1
Sagawa, T1
Hori, M1
Someya, M1
Nakata, K1
Sakata, K1
Takayama, T1
Kato, J1
Hsiang, CY1
Ho, TY1
Wu, CZ1
Mardani, M1
Afra, SM1
Modarresi, F1
Abdel-Rahman, O1
ElHalawani, H1
Essam-Eldin, S1
Riley, P1
Glenny, AM1
Worthington, HV1
Littlewood, A1
Clarkson, JE1
McCabe, MG1
Pellicioli, AC2
Filho, NA1
Ochs, G1
Matte, Ú1
Filho, MS1
Martins, MA3
Yamaguchi, K1
Ono, K1
Hitomi, S1
Nodai, T1
Goto, T1
Harano, N1
Watanabe, S4
Inoue, H1
Miyano, K1
Uezono, Y1
Matoba, M1
Inenaga, K1
Ala, S2
Saeedi, M2
Janbabai, G1
Ganji, R1
Azhdari, E1
Shiva, A1
Molina Prats, P1
Gómez Garcia, F1
Martinez Diaz, F1
Amaral Mendes, R1
Lopez-Jornet, P1
Nakata, Y1
Ijichi, K1
Hanai, N1
Nishikawa, D1
Suzuki, H1
Hirakawa, H1
Kodaira, T1
Fujimoto, Y1
Fujii, T1
Miyazaki, T1
Shimizu, T1
Hasegawa, Y1
Turkeli, M1
Aldemir, MN1
Bingol, F1
Dogan, C1
Kara, A1
Bossi, P1
Bergamini, C1
Miceli, R1
Cova, A1
Orlandi, E1
Resteghini, C1
Locati, L1
Alfieri, S1
Imbimbo, M1
Granata, R1
Mariani, L1
Iacovelli, NA1
Huber, V1
Cavallo, A1
Licitra, L1
Rivoltini, L1
Spivakovsky, S1
Gümüş, S1
Yarıktaş, M1
Nazıroğlu, M1
Uğuz, AC1
Aynali, G1
Başpınar, Ş1
Mehriar, P1
Okada, T1
Nakajima, Y1
Nishikage, T1
Ryotokuji, T1
Miyawaki, Y1
Hoshino, A1
Tokairin, Y1
Kawada, K1
Nagai, K1
Kawano, T1
Nesadal de Souza, D1
Suemaru, K4
Cui, R2
Li, B2
Okihara, K1
Hashimoto, K1
Yamada, H1
Araki, H4
Teixeira, RT1
Rangel, DC1
Niccoli-Filho, W1
Topuz, E1
Derin, D1
Can, G1
Kürklü, E1
Cinar, S1
Aykan, F1
Cevikbaş, A1
Dişçi, R1
Durna, Z1
Sakar, B1
Saglam, S1
Tanyeri, H1
Deniz, G1
Gürer, U1
Taş, F1
Guney, N1
Aydiner, A1
Sacono, NT1
Costa, CA1
Bagnato, VS1
Abreu-e-Lima, FC1
Lopes, NN2
Plapler, H2
Chavantes, MC2
Lalla, RV2
Yoshimura, EM2
Alves, MT2
Lee, YJ1
Lee, HJ1
Jeong, KC1
Kang, JG1
Lee, SH1
Kim, YT1
Maiguma, T1
Kaji, H2
Teshima, D1
Kovács, AF1
Eberlein, K1
Hülsmann, T1
Mignogna, MD1
Fortuna, G1
Falleti, J1
Leuci, S1
Hidaka, N1
Sakanaka, M1
Barker, NP1
Akhmadullina, LI1
Rodionova, I1
Sherman, NZ1
Davidenko, IS1
Rakovskaya, GN1
Gotovkin, EA1
Shinkarev, SA1
Kopp, MV1
Kulikov, EP1
Moiseyenko, VM1
Gertner, JM1
Firsov, I1
Tuleneva, T1
Yarosh, A1
Woon, CW1
Panahi, Y1
Okhovatian, A1
Bazzaz, N1
Naghizadeh, MM1
Buiret, G1
Combe, C1
Favrel, V1
Pommier, P1
Martin, L1
Ecochard, R1
Fayette, J1
Tartas, S1
Ramade, A1
Céruse, P1
Shueng, PW1
Wu, LJ1
Chen, SY3
Hsiao, CH1
Tien, HJ1
Cheng, PW1
Kuo, YS1
Chen, YJ1
Chen, CA1
Hsieh, PY1
Hsieh, CH1
Baena-Cañada, JM1
Martínez, MJ1
García-Olmedo, O1
Jiménez-Bárcenas, R1
Muriel-Cueto, P1
Bin, Q1
Li, J1
Liao, C1
Cao, Y1
Gao, F1
Pavesi, VC2
Lopez, TC1
Sant'Ana Filho, M2
Bussadori, SK1
Fernandes, KP1
Mesquita-Ferrari, RA1
Clavel, S1
Fortin, B1
Després, P1
Donath, D1
Soulières, D1
Khaouam, N1
Charpentier, D1
Bélair, M1
Guertin, L1
Nguyen-Tan, PF1
Rades, D1
Kronemann, S1
Meyners, T1
Bohlen, G1
Tribius, S1
Kazic, N1
Schroeder, U1
Hakim, SG1
Schild, SE1
Dunst, J1
Medeiros, CA1
Macedo, RN1
Barboza, DR1
Gomes, AS1
Nogueira, NA1
Alencar, NM1
da Silva, MA1
Wu, SX1
Cui, TT1
Zhao, C1
Pan, JJ1
Xu, BY1
Tian, Y1
Cui, NJ1
Bhide, SA2
Gulliford, S1
Fowler, J1
Rosenfelder, N1
Newbold, K1
Harrington, KJ2
Nutting, CM2
Fleckenstein, J1
Kühne, M1
Seegmüller, K1
Derschang, S1
Melchior, P1
Gräber, S1
Fricke, A1
Rübe, CE1
Rübe, C1
Isaev, PA1
Medvedev, VS1
Pasov, VV1
Semin, DIu1
Derbugov, DN1
Pol'kin, VV1
Terekhov, OV1
Thukral, A1
Metz, J1
Hwang, WT1
O'Dwyer, P1
Plastaras, J1
Both, S1
Bar-Ad, V1
Ad, VB1
Miah, AB1
Guerrero-Urbano, MT1
Clark, C1
Bidmead, AM1
St Rose, S1
Barbachano, Y1
A'hern, R1
Tanay, M1
Hickey, J1
Nicol, R1
Newbold, KL1
Best, SR1
Ha, PK1
Blanco, RG1
Saunders, JR1
Zinreich, ES1
Levine, MA1
Pai, SI1
Walker, M1
Trachta, J1
Ulmer, K1
Murakami, P1
Thompson, R1
Califano, JA1
Messing, BP1
Sugisaki, T1
Kawakami, K1
Nemoto, M1
Kawata, K1
Ishibashi, M2
Fujiki, Y1
Mishima, Y1
Yokoyama, M1
Takahashi, S2
Hatake, K1
Hama, T1
Winterhalder, R1
Hoesli, P1
Delmore, G1
Pederiva, S1
Bressoud, A1
Hermann, F1
von Moos, R1
Bot, BM1
Thomas, DM1
Bleyer, A1
Kohne, CH1
Seymour, MT2
Sargent, DJ2
Kabeya, M1
Ina, K1
Yuasa, S1
Kikuchi, F1
Tajiri, C1
Kato, T1
Hibi, S1
Minagawa, Y1
Furuta, R1
Kayukawa, S1
Kataoka, T1
Kawai, M1
Yen, SH3
Wang, LW1
Lin, YH1
Jen, YM1
Chung, YL1
Katrancı, N1
Ovayolu, N1
Ovayolu, O1
Sevinc, A2
Cen, P1
Liu, C1
Du, XL1
Sanguineti, G1
Sormani, MP1
Marur, S1
Gunn, GB1
Rao, N1
Cianchetti, M1
Ricchetti, F1
McNutt, T1
Wu, B1
Forastiere, A1
Fukui, T1
Itoh, Y1
Orihara, M1
Yoshizawa, K1
Takeda, H1
Kawada, S1
Yoshioka, T1
Fukazawa, M1
Kawaguchi, H1
Shigematsu, H1
Koga, C1
Mori, E1
Nishimura, S1
Nakamura, Y1
Satou, S1
Sawamura, K1
Kashiwaba, K1
Ohno, S1
Cunha, CB1
Eduardo, FP1
Zezell, DM1
Bezinelli, LM1
Shitara, PP1
Correa, L1
Tomita, M1
Matsuyama, H1
Yamazaki, K1
Sato, K1
Freitas, AP1
Bitencourt, FS1
de Alencar, NM1
Lima-Júnior, RC1
Vale, ML2
Qi, WX1
Tang, LN1
He, AN1
Shen, Z1
Yao, Y1
Aguilar-Ponce, JL1
Granados-García, M1
Cruz López, JC1
Maldonado-Magos, F1
Alvarez-Avitia, MA1
Arrieta, O1
González-Ramírez, I1
Lara-Cruz, G1
Martinez-Juárez, I1
Medina-Santillan, R1
Castillo-Hernández, C1
De la Garza-Salazar, J1
Lauxen, IS1
Carrard, VC1
Miki, I1
Nakamura, T1
Kuwahara, A1
Yamamori, M1
Nishiguchi, K1
Tamura, T1
Okuno, T1
Omatsu, H1
Mizuno, S1
Hirai, M1
Azuma, T1
Sakaeda, T1
Nomura, M1
Kamata, M1
Kojima, H1
Hayashi, K1
Sawada, S1
Tavakoli, P1
Amanat, D1
Samani, SM1
Tamadon, A1
Francois, E1
Bennouna, J1
Chamorey, E1
Etienne-Grimaldi, MC1
Renée, N1
Senellart, H1
Michel, C1
Follana, P1
Mari, V1
Douillard, JY1
Milano, G3
Takechi, K1
Imai, K1
Russo, F1
Linsalata, M1
Clemente, C1
D'Attoma, B1
Orlando, A1
Campanella, G1
Giotta, F1
Riezzo, G1
Clarke, J2
Butler, R1
Howarth, G1
Read, L1
Regester, G2
Takahashi, K3
Mori, T3
Ohue, M1
Mohiuddin, M1
Marks, G1
Marks, J1
Francini, G2
Petrioli, R2
Messinese, S1
Pozzessere, D1
Marsili, S1
Correale, P1
Sabatino, M1
Fiaschi, AI1
Leonard, P1
James, R1
Hochhauser, D1
Ledermann, JA1
Rothenberg, ML1
Nottage, M1
McLachlan, SA1
Brittain, MA1
Oza, A1
Hedley, D1
Feld, R2
Siu, LL1
Pond, G1
Moore, MJ2
van Kuilenburg, AB2
Baars, JW1
Meinsma, R1
van Gennip, AH2
Bocci, G1
Danesi, R1
Allegrini, G1
Innocenti, F2
Di Paolo, A1
Falcone, A2
Conte, PF1
Del Tacca, M1
Okabe, S1
Ishikawa, T1
Tanami, H1
Kuwabara, H1
Fukahara, T1
Udagawa, M1
Ootsukasa, S1
Arai, T1
Maruyama, S1
Murase, N1
Yamashita, H1
Iwai, T1
Rossi, A1
Rosati, G2
Colarusso, D2
Manzione, L2
Tebbutt, NC1
Norman, AR1
Cunningham, D3
Allen, M1
Chau, I1
Oates, J1
Hill, M2
Alvarez, E1
Fey, EG1
Valax, P1
Yim, Z1
Peterson, JD1
Mesri, M1
Jeffers, M1
Dindinger, M1
Twomlow, N1
Ghatpande, A1
LaRochelle, WJ1
Sonis, ST9
Lichenstein, HS1
ANSFIELD, FJ4
CURRERI, AR1
MALKASIAN, GD1
DECKER, DG1
MUSSEY, E1
JOHNSON, CE1
CUDMORE, JT1
GROESBECK, HP1
MOERTEL, CG5
REITEMEIER, RJ2
HAHN, RG3
HURLEY, JD1
Schmidberger, H1
Rave-Fränk, M1
Kim, S1
Hille, A1
Pradier, O1
Hess, CF1
Ura, T1
Shirao, K2
Han, JY1
Lee, DH1
Hong, EK1
Yoon, SM1
Chun, JH1
Lee, HG1
Lee, SY1
Shin, EH1
Lee, JS1
Matsumoto, H2
Arai, K2
Iwasaki, Y2
Katayanagi, S2
Morvan, FO1
Baroukh, B1
Ledoux, D1
Caruelle, JP1
Barritault, D1
Godeau, G1
Saffar, JL1
Schrijvers, D1
Van Herpen, C1
Kerger, J1
Joosens, E1
Van Laer, C1
Awada, A1
Van den Weyngaert, D1
Nguyen, H1
Le Bouder, C1
Castelijns, JA1
Kaanders, J1
De Mulder, P1
Vermorken, JB1
Parulekar, W1
de Marsh, RW1
Wong, R2
Mendenhall, W1
Davey, P1
Zlotecki, R1
Berry, S1
Rout, WR1
Bjarnason, GA1
Sykes, AJ1
Slevin, NJ1
MacDougall, RH1
Ironside, JA1
Mais, KL1
Cohen, SM1
Neugut, AI1
Ghi, MG1
Paccagnella, A2
D'Amanzo, P1
Mione, CA1
Fasan, S1
Paro, S1
Mastromauro, C1
Carnuccio, R1
Turcato, G1
Gatti, C1
Pallini, A1
Nascimben, O1
Biason, R1
Oniga, F1
Medici, M1
Rossi, F1
Fila, G1
Kuehr, T1
Ruff, P1
Rapoport, BL1
Falk, S1
Daniel, F1
Jacobs, C1
Davidson, N1
Thaler, J1
Boussard, B1
Carmichael, J1
Aksungur, P1
Sungur, A1
Unal, S1
Iskit, AB1
Squier, CA1
Senel, S1
Li, FY1
Li, Q1
Tucci, A1
Rinaldi, A1
Pizza, C1
Reggiardo, G1
Marsé, H1
Van Cutsem, E2
Valverde, S1
Sternberg, CN1
Reichardt, P1
Holland, M1
Undevia, SD1
Kindler, HL2
Janisch, L1
Olson, SC1
Schilsky, RL4
Vogelzang, NJ2
Kimmel, KA1
Macek, TA1
Ratain, MJ3
Feng, JF1
Lu, JW1
Sun, XF1
Di Lorenzo, G1
Autorino, R1
Giordano, A1
Giuliano, M1
D'Armiento, M1
Bianco, AR1
De Placido, S1
Franchin, G1
Vaccher, E1
Gobitti, C1
Minatel, E1
Politi, D1
Talamini, R1
Di Gennaro, G1
Savignano, G1
Trovò, MG1
Tirelli, U1
Barzan, L1
Dörr, W1
Bässler, S1
Reichel, S1
Spekl, K1
Nikoletti, S1
Hyde, S1
Shaw, T1
Myers, H1
Kristjanson, LJ1
Lima, V1
Cunha, FQ2
Rebouças, CG1
Falcão, BA1
Augusto, RF1
Souza, ML1
Leitão, BT1
Lin, A1
Jabbari, S1
Worden, FP1
Bradford, CR1
Chepeha, DB1
Teknos, TN1
Liao, JJ1
Nyquist, GG1
Tsien, C1
Schipper, MJ1
Urba, S1
Wolf, GT1
Eisbruch, A1
Baydar, M1
Aydogdu, I1
Yamshita, Y1
Shikimori, M1
Goto, M1
Kwong, DL1
Sham, JS1
Leung, LH1
Cheng, AC1
Ng, WM1
Kwong, PW1
Lui, WM1
Yau, CC1
Wu, PM1
Wei, W1
Au, G1
Cho, SA1
Park, JH2
Seok, SH1
Juhn, JH1
Kim, SJ1
Ji, HJ1
Choo, YS1
Farker, K1
Merkel, U1
Wedding, U1
Hippius, M1
Höffken, K2
Hoffmann, A1
Jones, JA1
Avritscher, EB1
Cooksley, CD1
Michelet, M1
Bekele, BN1
Elting, LS1
Cerchietti, LC1
Navigante, AH1
Lutteral, MA1
Castro, MA1
Kirchuk, R1
Bonomi, M1
Cabalar, ME1
Roth, B1
Negretti, G1
Sheinker, B1
Uchima, P1
Papadeas, E1
Naxakis, S1
Riga, M1
Kalofonos, Ch1
Berg, DT1
Bellaguarda, EA2
Macedo, FD2
Silva, LR2
Oriá, RB1
Choi, K1
Lee, SS1
Oh, SJ1
Lim, SY2
Jeon, WK1
Oh, TY1
Mitsuhashi, H1
Rosen, LS2
Abdi, E1
Davis, ID1
Gutheil, J1
Schnell, FM1
Zalcberg, J1
Cesano, A1
Gayko, U1
Chen, MG1
Clarke, S1
Mauger, CA1
Butler, RN1
Geier, MS1
Tooley, KL1
Howarth, GS1
Lara, RN1
da Guerra, EN1
de Melo, NS1
Lira, AM1
Sousa, RB1
Wilder-Smith, P1
Hammer-Wilson, MJ1
Wang, Q1
Osann, K1
Chen, Z1
Wigdor, H1
Schwartz, J1
Epstein, J1
Larsen, S1
Serup-Hansen, E1
Andersen, LJ1
Lindeløv, B1
McCulloch, T1
Adimi, P1
Bastholt, L1
Haines, IE1
Yamamitsu, S1
Kimura, H1
Yamada, Y1
Inui, N1
Hiyama, S1
Hirata, K1
Kimura, Y1
Shirasaka, T1
Xie, FY1
Qi, SN1
Hu, WH1
Zou, GR1
Peng, M1
Li, JS1
Kim, SG1
Oh, SY1
Kwon, HC1
Lee, S1
Kim, JH1
Kim, SH1
Kim, HJ1
Gong, ZJ1
Ren, JQ1
Kong, G1
Qing, DJ1
Liu, H1
Liang, YQ1
Sorensen, JB1
Skovsgaard, T1
Bork, E1
Damstrup, L1
Ingeberg, S1
Fox, RM2
Woods, RL2
Tattersall, MH1
Piper, AA1
Sampson, D1
Kish, JA2
Weaver, A2
Jacobs, J2
Cummings, G2
Al-Sarraf, M2
Bruckner, HW1
Cohen, J1
Aboud, A1
Buzdar, AU2
Yap, HY1
Hortobagyi, GN2
Blumenschein, GR1
Windschitl, H1
Scott, M1
Schutt, A1
McCormack, G1
Everson, L1
Cullinan, S1
Gerstner, J1
Krook, J1
Laurie, J1
Shreck, R1
Lokich, J4
Bothe, A1
Fine, N1
Perri, J1
Sonis, S1
Muska, A1
O'Brien, J1
Van Vugt, A2
Langer-Safer, P1
Keith, J2
Verdi, CJ1
Garewal, HS1
Koenig, LM1
Vaughn, B1
Burkhead, T1
Chan, AT1
Teo, PM1
Leung, TW1
Leung, SF1
Lee, WY1
Yeo, W1
Choi, PH1
Johnson, PJ1
Greenhouse, JB1
Wasserman, L1
Chi, KH2
Chen, CH1
Chan, WK2
Chow, KC1
Chao, JY1
Chang, CY1
Chen, KY2
Norman, A1
Findlay, M1
Watson, M1
Nicolson, V1
Webb, A1
Middleton, G1
Ahmed, F1
Hickish, T1
Aquino, A1
Gonnelli, S1
Keith, JC1
Albert, L1
Pfeiffer, CJ1
Schaub, RG1
Loprinzi, CL12
Foote, RL1
Michalak, J1
Yamao, T1
Shimada, Y1
Kondo, H1
Yokota, T1
Sugano, K1
Saito, D1
Ohkura, H1
Yoshida, S1
Mochizuki, F1
Tomioka, K1
Mizuno, Y1
Sato, F1
Yamagata, T1
Nagakawa, Y1
Kobari, Y1
Iwai, S1
Tanaka, T1
Mans, DR1
Scaletzky, A1
Becker, D1
de Oliveria, JR1
Pinheiro, CM1
Bittar, C1
Ferreira Filho, A1
Machado, VL1
Ritt, JL1
Jung, FA1
Conti, JA1
Kemeny, NE1
André, AM1
Grossano, DD1
Bertino, JR1
Krause, HH1
Breuning, J1
Sasaki, T1
Ota, K1
Taguchi, T1
Ogawa, N1
Kurihara, M1
Akazawa, S1
Ogawa, M1
Tominaga, T1
Konishi, T1
Kumai, K1
Jebb, SA1
Osborne, RJ1
Maughan, TS1
Mohideen, N1
Mack, P1
Mort, D1
Shelley, MD1
Elia, M1
Fine, S2
Erlichman, C3
Kaizer, L1
Warr, D1
Gadalla, T2
Cascinu, S2
Fedeli, A1
Fedeli, SL1
Catalano, G2
Metzger, G1
Massari, C1
Etienne, MC1
Comisso, M1
Brienza, S1
Touitou, Y1
Bastian, G1
Misset, JL2
Lévi, F2
Leyvraz, S1
Pasche, P1
Bauer, J1
Bernasconi, S1
Monnier, P1
Lindquist, L1
Stewart, AA1
Stam, K1
Qu, GY1
Iwata, KK1
Haley, JD2
Scheithauer, W2
Depisch, D1
Kornek, G1
Pidlich, J1
Rosen, H1
Karall, M1
Prochaska, M1
Ernst, A1
Sebesta, C1
Eckhardt, S1
Porta, C1
Moroni, M1
Nastasi, G1
Rosso, R4
Mazzei, T1
Mini, E1
Cartei, G1
Conte, P1
Labianca, R2
Cartei, F1
Pancera, G1
John, WJ1
Neefe, JR1
Macdonald, JS1
Cantrell, J1
Smith, M1
Tomio, L1
Zorat, PL1
Segati, R1
Loreggian, L1
Lora, O1
Friso, ML1
Chiarion-Sileni, V1
Favaretto, A1
Fede, A1
Rocke, LK1
Lee, JK2
Kunselman, SJ1
Iverson, RK1
Finck, G1
Lifsey, D1
Glaw, KC1
Stevens, BA1
Hatfield, AK2
Adenis, A1
Bonneterre, J1
Pion, JM1
Degardin, M1
Horner, D1
Seiter, K1
Kemeny, N1
Martin, D1
Schneider, A1
Williams, L1
Colofiore, J1
Sawyer, R1
Zalupski, MM1
Baker, LH1
Zalcberg, JR1
Rath, U1
Olver, I1
Svensson, C1
Harper, P1
Kerr, D1
Perez-Manga, G1
Fidler, P1
O'Fallon, JR2
Leitch, JM1
Hayes, DL1
Novotny, P1
Clemens-Schutjer, D2
Bartel, J1
Michalak, JC3
Shu, CH1
Law, CK1
Skubitz, KM1
Anderson, PM1
Del Ferro, E1
Ligi, M1
Cascino, TL1
Veeder, MH2
Buckner, JC1
Wiesenfeld, M1
Levitt, R1
Kuross, SA1
Morton, RF1
Scheithauer, BW1
Cleary, JF1
Arzoomanian, R1
Alberti, D2
Feierabend, C1
Storer, B1
Witt, P1
Carbone, P1
Wilding, G2
Ghosh, C1
Camoriano, J1
Sloan, J1
Steen, PD1
Schaefer, PL1
Novotny, PJ3
Gerstner, JB1
White, DF1
Quella, SK1
Van Vugt, AG2
Brien, JP1
Muska, AD1
Bruskin, AM1
Rose, A1
Blijham, GH1
Sato, A1
Kumagai, S1
Sakaki, K1
Morikawa, H1
Song, ST1
Mori, S1
McDonald, J1
Dotoli, E1
Schwertschlag, U1
Szklut, P1
Zambetti, M1
Demicheli, R1
De Candis, D1
Antonelli, G1
Giacobone, A1
Terenziani, M1
Laffranchi, A1
Garbagnati, F1
Biasi, S1
Bonadonna, G1
van der Graaf, WT1
Spijkervet, FL1
Timens, W1
Timmer-Bosscha, H1
Sluiter, WJ1
de Vries, EG1
Mulder, NH1
Fujii, K1
Nakashima, K1
Ohno, T1
Anai, H1
Cao, S1
Troutt, AB1
Rustum, YM2
Chiara, S1
Nobile, MT2
Vincenti, M1
Lionetto, R1
Gozza, A1
Barzacchi, MC1
Sanguineti, O1
Repetto, L1
Spijkervet, FK1
McCarthy, GM2
Awde, JD1
Ghandi, H1
Vincent, M1
Kocha, WI1
Hudes, GR2
Lipsitz, S1
Grem, J1
Morrisey, M1
Weiner, L1
Kugler, JW1
Benson, A1
Loury, D1
Embree, JR1
Steinberg, DA1
Fiddes, JC1
Okuno, SH1
Woodhouse, CO1
Sloan, JA3
LaVasseur, BI1
Swan, D1
Axvig, C1
Ebbert, LP1
Tirona, MR1
Pierson, N1
Focan, C1
Kreutz, F1
Focan-Henrard, D1
Lobelle, JP1
Adam, R1
Dallemagne, B1
Jehaes, C1
Markiewicz, S1
Weerts, J1
Bismuth, H1
Jasmin, C1
Edwards, B1
Srpek, L1
Wang, HM2
Wang, CH2
Chen, JS2
Su, CL1
Liao, CT1
Chen, IH2
Colevas, AD1
Norris, CM1
Tishler, RB1
Fried, MP1
Gomolin, HI1
Amrein, P1
Nixon, A1
Lamb, C1
Costello, R1
Barton, J1
Read, R1
Adak, S1
Posner, MR1
Altmann, S1
Hoffmanns, H1
Okuno, S1
Nair, S2
Barton, DL1
Riva, C1
Lavieille, JP1
Schmerber, S1
Cuisnie, O1
Reyt, E1
Meropol, NJ1
Creaven, PJ1
Blumenson, LE1
Frank, C1
Cox, JV1
Blanke, C1
Fehrenbacher, L1
Maroun, JA2
Ackland, SP1
Locker, PK1
Pirotta, N1
Elfring, GL1
Miller, LL1
Knox, JJ1
Puodziunas, AL1
Hoff, PM1
Ansari, R1
Batist, G1
Cox, J1
Kocha, W1
Kuperminc, M1
Maroun, J1
Walde, D1
Weaver, C1
Harrison, E1
Burger, HU1
Osterwalder, B1
Wong, AO1
Guglielmi, A2
Cirillo, M1
Recaldin, E1
Aschele, C1
Ravaioli, A1
Testore, P1
Caroti, C1
Gallo, L2
Pessi, MA1
Cortesi, E1
Turci, D1
Grossi, F1
Ng, SH1
Liaw, CT1
Yang, TS1
Melichar, B1
Kohout, P1
Brátová, M1
Solichová, D1
Králícková, P1
Zadák, Z1
Au, E1
Koo, WH1
Lee, KS1
Chua, EJ1
Soo, KC1
Seow-Choen, F1
Low, CH1
Ng, BK1
Hoe, M1
Magné, N1
Pivot, X1
Marcy, PY1
Chauvel, P2
Courdi, A1
Dassonville, O1
Poissonnet, G1
Vallicioni, J1
Ettore, F1
Falewee, MN1
Santini, J1
Lagrange, JL1
Schneider, M3
Demard, F3
Bensadoun, RJ1
Raida, M1
Schwabe, W1
Häusler, P1
Behnke, D1
Hejna, M1
Köstler, WJ1
Raderer, M1
Steger, GG2
Brodowicz, T1
Wiltschke, C1
Zielinski, CC2
Bell, KA1
Perna, AG1
Hsu, S1
Wenzel, C1
Locker, GJ1
Schmidinger, M1
Mader, R1
Kramer, G1
Marberger, M1
Rauchenwald, M1
Bertucci, D1
Vargas-Chanes, D1
Cha, SS1
Poon, MA1
Ito, A1
Hanawa, T1
Fujii, E1
Jian, JJ1
Cheng, SH1
Tsai, SY1
Yen, KC1
Chu, NM1
Chan, KY1
Tan, TD1
Cheng, JC1
Lin, YC1
Leu, SY1
Hsieh, CI1
Tsou, MH1
Lin, CY1
Huang, AT1
Lindquist, SF1
Hickey, AJ1
Drane, JB1
Tattersall, HN1
Brodie, GW1
Stanford, JR1
King, D1
Carey, L1
Anderson, G2
Scialla, SJ1
Miskoff, RA1
Rees, GJ1
Bugaighis, A1
Skillings, JR1
Steinberg, J1
Wong, A1
Weh, HJ1
Platz, D1
Braumann, D1
Buggisch, P1
Eckardt, N1
Schmiegel, WH1
Drescher, S1
Kleeberg, UR1
Müllerleile, U1
Crone-Munzebrock, W1
Sertoli, MR1
Rubagotti, A1
Vidili, MG1
Venturini, M1
Canobbio, L1
Fassio, T1
Ciais, G2
Namer, M2
Pourreau-Schneider, N2
Martin, PM2
Soudry, M2
Franquin, JC2
Zattara, H2
Pazdur, R1
Ajani, JJ1
Abbruzzese, JL1
Belt, RJ1
Dakhil, SR1
Dubovsky, D1
Graham, S1
Pilat, S1
Winn, R1
Levin, B1
Weinberger, H1
Costa, JW1
Evitts, SM1
Lindquist, LE1
Nicolson, M1
Vokes, EE2
Haraf, DJ1
Panje, WR2
Weichselbaum, RR2
Bailey, H1
Tutsch, KD2
Arzoomanian, RZ1
Tombes, MB1
Grem, JL1
Spriggs, DR1
Monnet, I1
Chariot, P1
Azli, N1
Ruffié, P1
Voisin, S1
Saltiel, JC1
de Cremoux, H1
Cvitkovic, E1
Pfeiffer, P1
Madsen, EL1
Hansen, O1
May, O1
Tsavaris, NB1
Komitsopoulou, P1
Tzannou, I1
Loucatou, P1
Tsaroucha-Noutsou, A1
Kilafis, G1
Kosmidis, P2
Grunberg, SM1
Clay, C1
Spicer, DV1
Anderson, N2
Bern, M2
Coco, F1
Zipoli, T1
Moore, C2
Gonsalves, L1
Elzawawy, A1
Saphner, T1
Tormey, DC1
Albertini, M1
Trump, DL1
Egorin, MJ1
Forrest, A1
Willson, JK1
Remick, S1
Mahood, DJ1
Dose, AM4
Athmann, LM2
Therneau, TM2
Sorensen, JM1
Gainey, DK2
Mailliard, JA1
Gusa, NL1
Denham, JW1
Abbott, RL1
Cianflone, SG1
Etzell, PS1
Burnham, NL1
Hagen, L1
Cross, M1
Evans, WK1
Wierzbicki, R1
Shepherd, FA1
Rusthoven, J1
Stewart, DJ1
Aitken, SE1
Ezzat, A1
Tracey, C1
Shklar, G1
Jenson, J1
Florine, D1
Wallach, S1
Williams, D1
LaCreta, F1
DeLap, RJ1
Grillo-Lopez, AJ1
Catalano, R1
Comis, RL1
Chaffey, J1
Neptune, W1
Olver, IN1
Dalley, D1
Woods, R1
Aroney, R1
Hughes, P1
Bishop, JF1
Cruickshank, D1
Miser, AW1
Kardinal, C1
Everson, LK1
Ahlquist, DA1
Dozono, H1
Motoya, T1
Nakamura, S1
Shinmura, R1
Miwa, K1
Nagata, Y1
Mick, R1
Awan, AM1
Moran, WJ1
Goldman, MD1
Tybor, AG1
Burnham, N1
Jabboury, K1
Holmes, FA1
Hortobagyi, G1
Van der Vliet, W1
Elhakim, T1
Frye, D1
Ewer, MS1
Fraschini, G1
Hug, V1
Ames, F1
Montague, E1
Carrasco, CH1
Mackay, B1
Legha, SS1
Dimery, IW1
Rubin, J1
Schutt, AJ2
Wieand, HS1
Becouarn, Y1
Calabet, J1
Brunet, R1
Caballero, GA1
Ausman, RK1
Quebbeman, EJ1
Tsavaris, N1
Caragiauris, P1
Bertrand, M1
Doroshow, JH1
Multhauf, P1
Blayney, DW1
Carr, BI1
Cecchi, G1
Goldberg, D1
Leong, L1
Margolin, K1
Metter, G1
Barone, C1
Astone, A1
Garufi, C1
Grieco, A1
Cavallaro, A1
Netri, G1
Rossi, S1
Cassano, A1
Ricevuto, E1
Noviello, MR1
Ensley, JF1
Clark, PI1
Slevin, ML1
Merlano, M1
Tatarek, R1
Grimaldi, A1
Margarino, G1
Lokich, JJ1
Phillips, D1
Green, R1
Paul, S1
Sonneborn, H1
Zipoli, TE1
Curt, G1
Byfield, JE1
Frankel, SS1
Hornbeck, CL1
Sharp, TR1
Callipari, FB1
Floyd, RA1
Levantine, A1
Almeyda, J1
Ellerby, RA1
Davis, HL1
Ramirez, G1
Ahmann, DL1
Bisel, HF1
Dines, DE1
Nadler, SH2
Moore, GE1
Miller, E1
Carter, AC1
Goldenberg, IS1
Segaloff, A1
Piro, AJ1
Wilson, RE1
Hall, TC1
Aliapoulios, MA1
Nevinny, HB1
Moore, FD1
Hill, GJ1
Grage, TB1
Wilson, W1
Karev, NI1
Blokhina, NG1
Vozny, EK1
Pershin, MP1
White, RS1
Fuqua, WB1
Barrett, O1
Cohen, JL1
Krant, MJ1
Shnider, BI1
Matias, PI1
Horton, J2
Baxter, D1
Olson, KB1
Hosley, HF1
Brincker, H1

Clinical Trials (34)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer[NCT06115174]Phase 444 participants (Anticipated)Interventional2023-11-01Not yet recruiting
A Double-Blind, Randomized Phase 2b Study of Sorafenib Compared to Placebo When Administered in Combination With Chemotherapy for Patients With Locally Advanced or MBC That Has Progressed During or After Bevacizumab Therapy[NCT00493636]Phase 2160 participants (Actual)Interventional2007-06-30Completed
Prevention of Post-sphincterotomy Bleeding by Endoscopic Tranexamic Acid and Sucralfate Administration: A Randomized Controlled Trial[NCT06107504]60 participants (Anticipated)Interventional2023-11-01Not yet recruiting
Precise Administration of Sucralfate Powder in Prevention of Delayed Polypectomy Bleeding: a Randomized Clinical Trial[NCT05817656]Phase 1160 participants (Anticipated)Interventional2023-05-15Recruiting
Microbiota, Inflammatory Environment, Clinical and Radiomic Features as Predictors of Normal Tissue Response in Radiotherapy for Prostate and Head-and-neck Cancer[NCT03294122]400 participants (Anticipated)Observational2017-02-02Recruiting
A Polychromatic Light Emitting Diode System to Deliver Low Dose Light Directly Into a Peripheral Intravascular Catheter: A Pain Reduction Study[NCT03246282]Early Phase 1150 participants (Anticipated)Interventional2017-02-08Suspended (stopped due to Lack of Funding)
The Influence of Glutamine on the Side Effects of Chemo-radiation in Head and Neck Cancer Patients - A Randomized Controlled Trial[NCT02282839]Phase 360 participants (Anticipated)Interventional2015-01-31Recruiting
Quarterback 22: A Phase II Clinical Trial of Sequential Therapy and De-Intensified Chemoradiotherapy for Locally Advanced HPV Positive Oropharynx Cancer[NCT02945631]43 participants (Actual)Interventional2016-04-25Active, not recruiting
The Quarterback Trial: A Randomized Phase III Clinical Trial Comparing Reduced and Standard Radiation Therapy Doses for Locally Advanced HPV Positive Oropharynx Cancer[NCT01706939]Phase 323 participants (Actual)Interventional2012-09-01Active, not recruiting
Impacts of Oral Supplement With L-Glutamine on the Radiation-induced Toxicity and Nutritional Status of Head and Neck Cancer Patients Under Radiotherapy[NCT03015077]59 participants (Actual)Interventional2014-07-31Completed
A Multicenter and Prospective Clinical Trial of Gemcitabine-based Induction Chemotherapy Combined With Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma[NCT04522050]Phase 165 participants (Anticipated)Interventional2018-10-01Recruiting
Evaluation of Dyspeptic Symptoms in Oncological Frail Patients With Extraintestinal Cancer in Chemotherapy. Assessment of Circulating Levels of Glucagon-like Peptide 2 (GLP-2) in Relation to Mucositis[NCT01382667]70 participants (Actual)Observational2011-07-31Completed
Phase Ⅱ Clinical Study of RALOX or CAPOX Combined With Bevacizumab in the First-line Treatment of Advanced Colorectal Cancer[NCT03813641]Phase 2100 participants (Anticipated)Interventional2019-01-28Recruiting
The Effect of Topical Chamomile in the Prevention of Chemotherapy-induced Oral Mucositis (a Randomized Controlled Clinical Trial)[NCT04317183]Phase 245 participants (Anticipated)Interventional2019-05-15Recruiting
A Randomized Study of a New Medical Device for Oral Mucositis (MDOM Trial)[NCT05104268]Phase 1/Phase 2100 participants (Anticipated)Interventional2021-11-30Not yet recruiting
A Phase 1/Phase 2 Study for the Prevention of Oral Mucositis (SPOM)[NCT05338398]Phase 1/Phase 2100 participants (Anticipated)Interventional2022-04-15Enrolling by invitation
Phase I Study of Multiple Ascending Dose, to Investigate the Safety and Tolerability of the Use of Copaiba in Patients With Oral Cancer Submitted to Radiotherapy[NCT05308732]Phase 136 participants (Anticipated)Interventional2021-05-11Recruiting
Long-term Results of Plasma Epstein-Barr Virus DNA Monitoring In Nasopharyngeal Carcinoma After Curative Treatment[NCT03973723]441 participants (Actual)Observational2011-08-01Completed
trūFreeze® Spray Cryotherapy Patient Registry[NCT01802203]275 participants (Actual)Observational [Patient Registry]2013-04-30Completed
A Phase I Trial of ZD1694 (TOMUDEX® (Registered Trademark)), an Inhibitor of Thymidylate Synthase, in Pediatric Patients With Advanced Neoplastic Disease[NCT00001341]Phase 160 participants Interventional1993-09-30Completed
Randomized Evaluation of a Phytopharmaceutical in Prevention of Severe Oral Mucositis in Patients Receiving Radiotherapy for Oral Cavity, Oropharynx, Hypopharynx, or Cavum Cancer[NCT01066741]Phase 378 participants (Actual)Interventional2009-05-31Terminated (stopped due to insufficient recruitment, the planed sample size appears not achievable)
Genetic Variants and the Efficacy or Severe Adverse Reactions of CPT-11 Based Regimens in mCRC[NCT01282658]200 participants (Anticipated)Observational2010-11-30Recruiting
A Randomized, Placebo-controlled, Double-blind Multicenter Phase II Study to Investigate the Protectivity and Efficacy of Metformin Against Steatosis in Combination With FOLFIRI and Cetuximab in Subjects With First-line Palliative Treated, KRAS-Wild-Type,[NCT01523639]Phase 28 participants (Actual)Interventional2012-04-30Terminated (stopped due to Prematurely due to slow recruitment (07/08/2013). Newly defined study end=LPLV=05/11/2013. ABCSG guaranteed completed treatment period for ethical reasons.)
A Randomised Phase-III Study Comparing Cytoreductive Surgery Plus Intraperitoneal Chemotherapy Versus Modern Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis.[NCT01524094]Phase 349 participants (Actual)Interventional2003-06-30Completed
Phase 1 Study of Postoperative Capecitabine With Concurrent Radiation in Elderly With Stage II/III Rectal Cancer[NCT01268943]Phase 118 participants (Actual)Interventional2010-11-30Completed
A Pilot Study Using Neoadjuvant Proton Beam Radiation Therapy and Chemotherapy for Marginally Resectable Carcinoma of the Pancreas[NCT00763516]8 participants (Actual)Interventional2009-02-28Completed
Randomized Trial to Evaluate Therapeutic Gain by Changing Chemoradiotherapy From Concurrent-adjuvant to Induction-concurrent Sequence, and Radiotherapy From Conventional to Accelerated Fractionation for Advanced Nasopharyngeal Carcinoma[NCT00379262]Phase 3803 participants (Actual)Interventional2006-09-30Completed
A Study Using Photon/Proton Beam Radiation Therapy and Chemotherapy for Unresectable Carcinoma of the Pancreas[NCT00685763]13 participants (Actual)Interventional2008-03-31Completed
A Pilot Study- Prevention of Capecitabine Induced Hand and Foot Syndrome[NCT01291628]10 participants (Anticipated)Interventional2012-01-31Not yet recruiting
Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320]Phase 2200 participants (Actual)Interventional2015-10-05Active, not recruiting
Phase I Study of Preoperative Concurrent Chemo-radiation With Capecitabine in Elderly Rectal Cancer Patients[NCT01584544]Phase 124 participants (Actual)Interventional2011-01-31Completed
Laser Therapy Associated With Photodynamic Therapy in the Treatment of Oral Mucositis Induced by Chemotherapy in Young Patients: Randomized Blind Clinical Trial[NCT02555501]Phase 318 participants (Actual)Interventional2014-10-31Completed
Multiple Centre, Randomised, Controlled Trial of Hyperfractionated IMRT and Conventional Fraction IMRT for Patients With Loco-regionally Recurrent Nasopharyngeal Carcinoma.[NCT02456506]142 participants (Anticipated)Interventional2015-06-30Active, not recruiting
Randomized Phase II Study of Recombinant Human Epidermal Growth Factor (rhEGF) on Oral Mucositis Induced by Intensive Chemotherapy for Hematologic Malignancies[NCT00845819]Phase 2138 participants (Actual)Interventional2009-02-28Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Duration of Overall Response

Duration of overall response was calculated as the time (days) from first documentation of CR or PR (whichever status is recorded first) until the first date that recurrent or progressive disease (PD) or death is objectively documented. Response was evaluated via changes from baseline in radiological tumor measurements using RECIST version 1.0 guidelines, where complete response (CR) is the disappearance of all target lesions; partial response (PR) is >=30% decrease in the sum of the longest diameter (LD) of target lesions; Stable Disease (SD) is neither sufficient shrinkage in sum of LD of target lesions to be PR nor increase of >=20%; Progressive Disease (PD) is the increase in existing lesions or new lesions. (NCT00493636)
Timeframe: Period measured from the first documentation of complete or partial response (whichever status is recorded first) until the first date that recurrent or progressive disease or death is objectively documented.

InterventionDays (Median)
A (Sorafenib + Gemcitabine or Capecitabine)94
B (Placebo + Gemcitabine or Capecitabine)147

Overall Response Rate

Overall response rate was defined as the proportion of participants experiencing complete response (CR) and partial response (PR) as best overall response. Response was evaluated via changes from baseline in radiological tumor measurements using RECIST version 1.0 guidelines, where complete response (CR) is the disappearance of all target lesions; partial response (PR) is >=30% decrease in the sum of the longest diameter (LD) of target lesions; Stable Disease (SD) is neither sufficient shrinkage in sum of LD of target lesions to be PR nor increase of >=20%; Progressive Disease (PD) is the increase in existing lesions or new lesions. (NCT00493636)
Timeframe: The overall tumor burden at baseline will be compared with subsequent measurements up to the date of first documented disease progression or the date of death due to any cause, if before progression, assessed up to 39 months.

Interventionpercentage of participants (Number)
A (Sorafenib + Gemcitabine or Capecitabine)19.8
B (Placebo + Gemcitabine or Capecitabine)12.7

Overall Survival

(NCT00493636)
Timeframe: From the date of randomization to date of death due to any cause, assessed up to 56 months.

InterventionDays (Median)
A (Sorafenib + Gemcitabine or Capecitabine)407
B (Placebo + Gemcitabine or Capecitabine)348

Progression Free Survival

(NCT00493636)
Timeframe: From the date of randomization to date of first documented disease progression (i.e., the date on which a radiologic procedure or clinical evaluation was performed) or the date of death due to any cause, if before progression, assessed up to 39 months.

InterventionDays (Median)
A (Sorafenib + Gemcitabine or Capecitabine)103
B (Placebo + Gemcitabine or Capecitabine)81

Time to Progression

(NCT00493636)
Timeframe: Calculated as the time (days) from date of randomization to date of first observed disease progression (radiological or clinical, whichever is earlier), assessed up to 39 months.

InterventionDays (Median)
A (Sorafenib + Gemcitabine or Capecitabine)111
B (Placebo + Gemcitabine or Capecitabine)82

Biomarkers Predictive of Failure

To determine biomarkers predictive of failure with either reduced or standard dose radiotherapy. (NCT01706939)
Timeframe: at 5 years

Interventionbiomarkers (Number)
Reduced Dose Radiation0
Standard Dose Radiation0

Change in MD Anderson Dysphagia Inventory (MDADI) From Baseline

MDADI is a questionnaire of 20 questions and contains a global subscale, and three other categories of questions (emotional, functional, and physical). The scores are summed and a mean score is calculated. This mean score was multiplied by 20 to obtain a score, with a range of 0 (extremely low functioning) to 100 (high functioning). Thus, a higher MDADI score represented better day-to-day functioning and better QOL. (NCT01706939)
Timeframe: Baseline and 5 years

Interventionscore on a scale (Mean)
Reduced Dose Radiation-8.12
Standard Dose Radiation-8.93

Change in Xerostomia Questionnaire (XQ)

XQ is a nine questions survey developed specifically for xerostomia symptoms. The scores are summed and a mean score is calculated on a scale of 0 (low xerostomia interference) to 10 (high xerostomia interference). A lower or negative score reflects a better quality of life compared to baseline. (NCT01706939)
Timeframe: Baseline and 5 years

Interventionscore on a scale (Mean)
Reduced Dose Radiation2.18
Standard Dose Radiation4.38

Number of Participants With Acute Toxicity of Chemoradiotherapy (CRT)

Number of participants with acute toxicity treated with reduced or standard dose CRT. (NCT01706939)
Timeframe: at 5 years

InterventionParticipants (Count of Participants)
Reduced Dose Radiation3
Standard Dose Radiation1

Number of Participants With Local-regional Control

Local-regional control (LRC) at 3 years in patients with advanced HPV related oropharynx cancer or unknown primary treated with reduced or standard dose radiation. (NCT01706939)
Timeframe: at 3 years

InterventionParticipants (Count of Participants)
Reduced Dose Radiation10
Standard Dose Radiation7

Number of Participants With Overall Survival at 5 Years

Overall Survival (OS) 5 years treated with reduced or standard dose CRT. (NCT01706939)
Timeframe: at 5 years

InterventionParticipants (Count of Participants)
Reduced Dose Radiation10
Standard Dose Radiation7

Change in European Organization for Research and Treatment of Cancer Questionnaire for Head and Neck (EORTC HN)

The EORTC Head and Neck module was specifically designed and validated for head and neck cancer patients. This 35-item questionnaire contains 7 symptom scales (pain, swallowing, senses, speech, social eating, social contact, and sexuality), 6 single-item scales (difficulties of teeth, mouth opening, dry mouth, sticky saliva, coughing, and feeling ill), and 5 items about the additional use of pain medicine, nutritional supplements, and feeding tube and changes in body weight. All items were transformed to scales from 0 to 100, and divided into respective sub-scores of global health (GHS), functional (FS), and symptom scale (SS). Subscales from 0-100. A high score on global health and functional scale represents a better level of functioning, whereas a high score on a symptom scale and head and neck module indicates more severe symptoms. (NCT01706939)
Timeframe: Baseline and 5 years

,
Interventionscore on a scale (Mean)
EORTC GHSEORTC FSEORTC SSEORTC HN
Reduced Dose Radiation5.955.14-3.91-2.80
Standard Dose Radiation-30.56-6.3314.978.97

Change in MD Anderson Symptom Inventory Symptom Inventory and Severity (MDASI-HN SI and SS)

"MD Anderson Symptom Inventory Symptom Inventory and Severity (MDASI-HN SI and SS) MDASI Head and Neck is a site-specific MDASI module which includes the core MDASI 13 symptom severity items (SS) and 6 symptom interference items (SI), alongside 9 items relevant to head and neck cancer. The scores are summed and a mean score is calculated on a scale of 0 (low severity or interference) to 10 (high severity or complete interference). In order to calculate the mean score, a majority of the subscale's items must have been completed.~A lower or negative score reflects a better quality of life compared to baseline." (NCT01706939)
Timeframe: Baseline and 5 years

,
Interventionscore on a scale (Mean)
MDASI-HN SIMDASI-HN SS
Reduced Dose Radiation0.640.52
Standard Dose Radiation1.561.48

Number of Participants With Progression Free Survival (PFS)

Progression free survival (PFS) at 5 years in patients with advanced HPV related oropharynx cancer, nasopharynx cancer or unknown primary treated with reduced or standard dose radiation. (NCT01706939)
Timeframe: at 3 and 5 years

,
InterventionParticipants (Count of Participants)
at 3 yearsat 5 years
Reduced Dose Radiation1010
Standard Dose Radiation77

Dose Related Toxicity

dose related toxicity is defined as follows:1. WBC damage >= grade 3; granular cell decrease >= grade 3; hemoglobin >= grade 2; platelet >= grade 2;SGPT/SGOT elevation >= grade 2; ALP >= grade 2; GGT >= grade 2; Tbil >= grade 2;renal function damage: BUN/Cr elevation >= grade 2;Non-gradular cell decreased fever >= grade 2;nausea/vomiting >= grade 2; fatigue >= grade 3; weight loss >= grade 3;gastritis >= grade 3; dairrea >= grade 3; abdominal pain >= grade 3; pancreatitis >= grade 2; upper gastrointestinal bleeding >= grade 2;other toxic reaction >= grade 3;KPS < 50 during the treatment (NCT01268943)
Timeframe: up to 9 weeks

Interventionevent (Number)
1000mg1
1200mg0
1400mg0
1500mg3

Cumulative Incidence of grade3+ Bowel Perforation, Grade 3+ Bleeding (Ocurring Withing 1 Years) and grade4+ Nonhematologic Acute Adverse Events (Limited to Within 90 Days of Treatment Start)

(NCT00685763)
Timeframe: 1 year following the completion of radiation therapy

Interventionparticipants (Number)
Proton Radiation and Chemotherapy0

Number of Participants Experienced Dose Limited Toxicity

Dose related toxicity is defined as follows:1. luecopenia > grade 2; granular cell decrease > grade 2; anemia > grade 1; platelet > grade 1;SGPT/SGOT elevation > grade 1; ALP > grade 1; GGT > grade 1; Tbil > grade 1;renal function damag > grade 2;Non-gradular cell decreased fever > grade 1;nausea/vomiting > grade 1; fatigue > grade 2; weight loss > grade 2;gastritis > grade 2; dairrea > grade 2; abdominal pain > grade 2; upper gastrointestinal bleeding > grade 1;other toxic reaction > grade 2;KPS < 50 during the treatment (NCT01584544)
Timeframe: up to 7 weeks from start of the treatment

Interventionparticipants (Number)
1000mg0
1200mg1
1350mg1
1500mg0
1650mg1

Reviews

26 reviews available for fluorouracil and Stomatitis

ArticleYear
Experimental Chemotherapy-Induced Mucositis: A Scoping Review Guiding the Design of Suitable Preclinical Models.
    International journal of molecular sciences, 2022, Dec-06, Volume: 23, Issue:23

    Topics: Animals; Antineoplastic Agents; Fluorouracil; Humans; Irinotecan; Methotrexate; Mice; Mucositis; Rab

2022
Experimental Chemotherapy-Induced Mucositis: A Scoping Review Guiding the Design of Suitable Preclinical Models.
    International journal of molecular sciences, 2022, Dec-06, Volume: 23, Issue:23

    Topics: Animals; Antineoplastic Agents; Fluorouracil; Humans; Irinotecan; Methotrexate; Mice; Mucositis; Rab

2022
Experimental Chemotherapy-Induced Mucositis: A Scoping Review Guiding the Design of Suitable Preclinical Models.
    International journal of molecular sciences, 2022, Dec-06, Volume: 23, Issue:23

    Topics: Animals; Antineoplastic Agents; Fluorouracil; Humans; Irinotecan; Methotrexate; Mice; Mucositis; Rab

2022
Experimental Chemotherapy-Induced Mucositis: A Scoping Review Guiding the Design of Suitable Preclinical Models.
    International journal of molecular sciences, 2022, Dec-06, Volume: 23, Issue:23

    Topics: Animals; Antineoplastic Agents; Fluorouracil; Humans; Irinotecan; Methotrexate; Mice; Mucositis; Rab

2022
S-1 and 5-Fluorouracil-related adverse events in patients with advanced gastric cancer: A meta-analysis.
    PloS one, 2023, Volume: 18, Issue:8

    Topics: Fluorouracil; Humans; Hypokalemia; Hypophosphatemia; Inflammation; Stomach Neoplasms; Stomatitis

2023
Effectiveness of phytotherapeutics in the prevention and treatment of 5-fluorouracil-induced oral mucositis in animal models: A systematic review.
    Archives of oral biology, 2021, Volume: 123

    Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Antioxidants; Cricetinae; Fluorouracil; Ma

2021
Oral fluoropyrimidine versus intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: Meta-analysis.
    Journal of gastroenterology and hepatology, 2018, Volume: 33, Issue:1

    Topics: Administration, Oral; Antineoplastic Agents; Colorectal Neoplasms; Databases, Bibliographic; Disease

2018
Raltitrexed-based chemotherapy for advanced colorectal cancer.
    Clinics and research in hepatology and gastroenterology, 2014, Volume: 38, Issue:2

    Topics: Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Chemical and Drug Induce

2014
S-1-based regimens and the risk of oral and gastrointestinal mucosal injury: a meta-analysis with comparison to other fluoropyrimidines.
    Expert opinion on drug safety, 2016, Volume: 15, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Combinations; Fluorouracil; Humans; I

2016
Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy.
    The Cochrane database of systematic reviews, 2015, Dec-23, Issue:12

    Topics: Adult; Antineoplastic Agents; Cryotherapy; Fluorouracil; Hematopoietic Stem Cell Transplantation; Hu

2015
Interaction between capecitabine and brivudin in a patient with breast cancer.
    Nature reviews. Clinical oncology, 2010, Volume: 7, Issue:1

    Topics: Aged; Anemia, Aplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc

2010
Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials.
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2011, Volume: 13, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Fluorouracil; Humans

2011
Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jul-10, Volume: 29, Issue:20

    Topics: Adolescent; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemo

2011
Comparison between doublet agents versus single agent in metastatic breast cancer patients previously treated with an anthracycline and a taxane: a meta-analysis of four phase III trials.
    Breast (Edinburgh, Scotland), 2013, Volume: 22, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Anthracyclines; Antineoplastic Combined Chemotherapy Protoco

2013
Current status of capecitabine in the treatment of colorectal cancer.
    Oncology (Williston Park, N.Y.), 2002, Volume: 16, Issue:12 Suppl N

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherap

2002
[Toxicities associated with chemotherapy in colorectal cancer].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 7

    Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Clinical Trials a

2003
Adjuvant therapy for rectal cancer in the elderly.
    Drugs & aging, 2004, Volume: 21, Issue:7

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cli

2004
Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda).
    European journal of oncology nursing : the official journal of European Oncology Nursing Society, 2004, Volume: 8 Suppl 1

    Topics: Alopecia; Ambulatory Care; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colonic

2004
Development of and clinical experience with capecitabine (Xeloda) in the treatment of solid tumours.
    European journal of oncology nursing : the official journal of European Oncology Nursing Society, 2004, Volume: 8 Suppl 1

    Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Clin

2004
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2006, Volume: 14, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms

2006
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2006, Volume: 14, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms

2006
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2006, Volume: 14, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms

2006
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2006, Volume: 14, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms

2006
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2006, Volume: 14, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms

2006
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2006, Volume: 14, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms

2006
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2006, Volume: 14, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms

2006
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2006, Volume: 14, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms

2006
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2006, Volume: 14, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms

2006
Capecitabine: a new adjuvant option for colorectal cancer.
    Clinical journal of oncology nursing, 2006, Volume: 10, Issue:4

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Cause of Death; Colorectal Neop

2006
Alleviation of cytotoxic therapy-induced normal tissue damage.
    Seminars in oncology, 1995, Volume: 22, Issue:2 Suppl 3

    Topics: Chlorhexidine; Clinical Trials as Topic; Cryotherapy; Dermatitis; Esophagitis; Eye Diseases; Fluorou

1995
Unexpected fatal toxicity related to low-dose leucovorin with 5-fluorouracil treatment in metastatic colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1993, Volume: 4, Issue:2

    Topics: Aged; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Pneumonia, Staphylococcal; Sto

1993
New frontiers in the management of chemotherapy-induced mucositis.
    Current opinion in oncology, 1998, Volume: 10 Suppl 1

    Topics: Adult; Animals; Antineoplastic Agents; Cell Division; Child; Cricetinae; Drug Evaluation, Preclinica

1998
Sex differences in fluorouracil-induced stomatitis.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Female; Fluorouracil; Humans; Incidence; Male; Middle

2000
Chemotherapy-induced oral mucositis. Prevention and management.
    Drugs & aging, 2000, Volume: 17, Issue:4

    Topics: Antineoplastic Agents; Cryotherapy; Fluorouracil; Humans; Mouth Mucosa; Oral Hygiene; Randomized Con

2000
Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Mar-15, Volume: 20, Issue:6

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Incidence; Logi

2002
Drug reactions. XXIV. Cutaneous reactions to cytostatic agents.
    The British journal of dermatology, 1974, Volume: 90, Issue:2

    Topics: Alopecia; Aminopterin; Antineoplastic Agents; Asparaginase; Azathioprine; Bleomycin; Busulfan; Chlor

1974
The metabolism and pharmacology of 5-fluorouracil.
    Journal of surgical oncology, 1971, Volume: 3, Issue:3

    Topics: Adenocarcinoma; Alopecia; Animals; Breast Neoplasms; Carbon Isotopes; Cell Division; Chromosome Aber

1971

Trials

128 trials available for fluorouracil and Stomatitis

ArticleYear
Effect of pentoxifylline on colon cancer patients treated with chemotherapy (Part I).
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2021, Volume: 43, Issue:1

    Topics: Aged; Antineoplastic Agents; Cachexia; Colonic Neoplasms; Disease Progression; Female; Fluorouracil;

2021
The chromatographic constitution of andiroba oil and his healing effects, compared to the LLLT outcomes, in oral mucositis induced in golden Syrian hamsters: a new treatment option.
    Oncotarget, 2023, 01-12, Volume: 14

    Topics: Animals; Cicatrix; Cricetinae; Fluorouracil; Low-Level Light Therapy; Mesocricetus; Stomatitis

2023
Raltitrexed versus 5-fluorouracil with cisplatin and concurrent radiotherapy for locally advanced nasopharyngeal carcinoma: An open labeled, randomized, controlled, and multicenter clinical trial.
    Cancer medicine, 2020, Volume: 9, Issue:17

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chemoradiotherapy; Chi-Squ

2020
Effect of cryotherapy in preventing mucositis associated with the use of 5-fluorouracil.
    Revista latino-americana de enfermagem, 2020, Volume: 28

    Topics: Antineoplastic Agents; Cryotherapy; Fluorouracil; Humans; Mucositis; Stomatitis

2020
Potential therapeutic effects of different mouthwashes for alleviation and treatment of oral complications of 5-fluorouracil-based chemotherapy in patients with colon cancer.
    European journal of hospital pharmacy : science and practice, 2023, Volume: 30, Issue:4

    Topics: Benzydamine; Colonic Neoplasms; Fluorouracil; Glutamine; Humans; Mouthwashes; Pain; Prospective Stud

2023
Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study.
    Clinical colorectal cancer, 2018, Volume: 17, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Cohort Studies; Colore

2018
Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, May-15, Volume: 19, Issue:10

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2013
Randomized study of sinusoidal chronomodulated versus flat intermittent induction chemotherapy with cisplatin and 5-fluorouracil followed by traditional radiotherapy for locoregionally advanced nasopharyngeal carcinoma.
    Chinese journal of cancer, 2013, Volume: 32, Issue:9

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease-Free Survival;

2013
FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study.
    Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplas

2013
Protective effect of bilberry extract as a pretreatment on induced oral mucositis in hamsters.
    Oral surgery, oral medicine, oral pathology and oral radiology, 2013, Volume: 116, Issue:6

    Topics: Animals; Cricetinae; Fluorouracil; Photomicrography; Phytotherapy; Plant Extracts; Stomatitis; Vacci

2013
Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists' group.
    Breast (Edinburgh, Scotland), 2014, Volume: 23, Issue:1

    Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antineoplastic Agents; Body Mass Index; Breast

2014
Double-blind, placebo-controlled, randomized phase II study of TJ-14 (Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer chemotherapy-induced oral mucositis.
    Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal

2015
A Phase 1/2 Study of Definitive Chemoradiation Therapy Using Docetaxel, Nedaplatin, and 5-Fluorouracil (DNF-R) for Esophageal Cancer.
    International journal of radiation oncology, biology, physics, 2015, Oct-01, Volume: 93, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Disease-Free Survival; Doce

2015
Efficacy of Sucralfate Mouth Wash in Prevention of 5-fluorouracil Induced Oral Mucositis: A Prospective, Randomized, Double-Blind, Controlled Trial.
    Nutrition and cancer, 2016, Volume: 68, Issue:3

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Female

2016
Efficacy of Sucralfate Mouth Wash in Prevention of 5-fluorouracil Induced Oral Mucositis: A Prospective, Randomized, Double-Blind, Controlled Trial.
    Nutrition and cancer, 2016, Volume: 68, Issue:3

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Female

2016
Efficacy of Sucralfate Mouth Wash in Prevention of 5-fluorouracil Induced Oral Mucositis: A Prospective, Randomized, Double-Blind, Controlled Trial.
    Nutrition and cancer, 2016, Volume: 68, Issue:3

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Female

2016
Efficacy of Sucralfate Mouth Wash in Prevention of 5-fluorouracil Induced Oral Mucositis: A Prospective, Randomized, Double-Blind, Controlled Trial.
    Nutrition and cancer, 2016, Volume: 68, Issue:3

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Female

2016
Treatment results of alternating chemoradiotherapy with early assessment for advanced laryngeal cancer: A multi-institutional phase II study.
    Auris, nasus, larynx, 2017, Volume: 44, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C

2017
Effect of oral administration of kefir on serum proinflammatory cytokines on 5-FU induced oral mucositis in patients with colorectal cancer.
    Investigational new drugs, 2008, Volume: 26, Issue:6

    Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Cultured M

2008
Organ preservation treatment using TPF-a pilot study in patients with advanced primary and recurrent cancer of the oral cavity and the maxillary sinus.
    Oral and maxillofacial surgery, 2009, Volume: 13, Issue:2

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P

2009
Phase II, randomized, double-blind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fluorouracil-based chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Sep-10, Volume: 27, Issue:26

    Topics: Abdominal Pain; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea

2009
Allopurinol mouth rinse for prophylaxis of fluorouracil-induced mucositis.
    European journal of cancer care, 2010, Volume: 19, Issue:3

    Topics: Adult; Allopurinol; Antimetabolites, Antineoplastic; Double-Blind Method; Female; Fluorouracil; Huma

2010
A prospective, randomized, multi-center trial to investigate Actovegin in prevention and treatment of acute oral mucositis caused by chemoradiotherapy for nasopharyngeal carcinoma.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2010, Volume: 97, Issue:1

    Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chi-Square Distri

2010
Characteristics of response of oral and pharyngeal mucosa in patients receiving chemo-IMRT for head and neck cancer using hypofractionated accelerated radiotherapy.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2010, Volume: 97, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous

2010
Dose-escalated intensity-modulated radiotherapy is feasible and may improve locoregional control and laryngeal preservation in laryngo-hypopharyngeal cancers.
    International journal of radiation oncology, biology, physics, 2012, Feb-01, Volume: 82, Issue:2

    Topics: Adult; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell;

2012
[Preventive effect of polaprezinc suspension dispersed in sodium alginate solution (P-AG) for stomatitis induced by Docetaxel/Cisplatin/Fluorouracil (DCF) chemotherapy in patients with head and neck cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:5

    Topics: Adult; Aged; Alginates; Antineoplastic Combined Chemotherapy Protocols; Carnosine; Cisplatin; Doceta

2011
[Pilot study on clinical effects of rebamipide gargle against oral mucositis induced by fluoropyrimidines].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:7

    Topics: Alanine; Antimetabolites, Antineoplastic; Colonic Neoplasms; Fluorouracil; Humans; Mouthwashes; Pilo

2011
Phenylbutyrate mouthwash mitigates oral mucositis during radiotherapy or chemoradiotherapy in patients with head-and-neck cancer.
    International journal of radiation oncology, biology, physics, 2012, Mar-15, Volume: 82, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Double-Blind Method; E

2012
Evaluation of the effect of cryotherapy in preventing oral mucositis associated with chemotherapy - a randomized controlled trial.
    European journal of oncology nursing : the official journal of European Oncology Nursing Society, 2012, Volume: 16, Issue:4

    Topics: Antineoplastic Agents; Cryotherapy; Female; Fluorouracil; Humans; Leucovorin; Male; Neoplasms; Stoma

2012
Effect of irradiation with red and infrared laser in the treatment of oral mucositis: a pilot study with patients undergoing chemotherapy with 5-FU.
    Lasers in medical science, 2012, Volume: 27, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouracil; Humans; Infra

2012
Irsogladine maleate reduces the incidence of fluorouracil-based chemotherapy-induced oral mucositis.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Drug-Related Side

2013
Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study.
    Chemotherapy, 2012, Volume: 58, Issue:5

    Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capeci

2012
The effects of fluorouracil, epirubicin, and cyclophosphamide (FEC60) on the intestinal barrier function and gut peptides in breast cancer patients: an observational study.
    BMC cancer, 2013, Feb-04, Volume: 13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemoth

2013
Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens.
    Cancer chemotherapy and pharmacology, 2002, Volume: 50, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression;

2002
Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer.
    British journal of cancer, 2002, Nov-18, Volume: 87, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia

2002
Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2003, Volume: 11, Issue:1

    Topics: Administration, Oral; Aged; Anti-Ulcer Agents; Antimetabolites, Antineoplastic; Double-Blind Method;

2003
Investigation into the usefulness and adverse events of CDDP, 5-fU and dl-leucovorin (PFL-therapy) for advanced colorectal cancer.
    Journal of medical and dental sciences, 2002, Volume: 49, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Cisp

2002
Subcutaneous granulocyte-macrophage colony-stimulating factor in mucositis induced by an adjuvant 5-fluorouracil plus leucovorin regimen. A phase II study and review of the literature.
    Oncology, 2003, Volume: 64, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop

2003
A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma.
    Cancer, 2003, Nov-01, Volume: 98, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Capecitabine; Carcinoma, Non-

2003
Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docet

2004
Phase I study of 5-fluorouracil and leucovorin by continuous infusion chronotherapy and pelvic radiotherapy in patients with locally advanced or recurrent rectal cancer.
    International journal of radiation oncology, biology, physics, 2004, Apr-01, Volume: 58, Issue:5

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chronotherapy; Combined Modality Therapy; Diarrhea; Di

2004
Results of a phase I study to determine the maximum tolerated dose of capecitabine when given concurrently with radical radiotherapy in the treatment of squamous cell carcinoma of the head and neck.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2004, Volume: 71, Issue:1

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Combi

2004
Neoadjuvant docetaxel, cisplatin, 5-fluorouracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: a phase II feasibility study.
    International journal of radiation oncology, biology, physics, 2004, Jun-01, Volume: 59, Issue:2

    Topics: Adult; Aged; Anemia; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality

2004
Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer.
    BMC cancer, 2004, Jul-16, Volume: 4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms;

2004
Chitosan delivery systems for the treatment of oral mucositis: in vitro and in vivo studies.
    Journal of controlled release : official journal of the Controlled Release Society, 2004, Aug-11, Volume: 98, Issue:2

    Topics: Adult; Animals; Antifungal Agents; Biological Availability; Body Weight; Chitosan; Cricetinae; Cross

2004
[Phase I study of capecitabine with concurrent radiotherapy in early-stage nasopharyngeal carcinoma].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2004, Volume: 26, Issue:4

    Topics: Adult; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Dose

2004
A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
    Oncology, 2004, Volume: 66, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia

2004
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:11

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols

2004
Neoadjuvant accelerated chemotherapy followed by hyperfractionated radiation therapy in patients with operable, locally advanced head and neck carcinoma.
    Oral oncology, 2005, Volume: 41, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy,

2005
Comparison of plain ice and flavoured ice for preventing oral mucositis associated with the use of 5 fluorouracil.
    Journal of clinical nursing, 2005, Volume: 14, Issue:6

    Topics: Antimetabolites, Antineoplastic; Attitude to Health; Clinical Nursing Research; Cross-Over Studies;

2005
[Clinical trial of chemotherapy by superselective intra-arterial infusion of nedaplatin combined with radiotherapy for advanced oral cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:9

    Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell;

2005
Chronomodulated chemotherapy with oxaliplatin, 5-FU and sodium folinate in metastatic gastrointestinal cancer patients: original analysis of non-hematological toxicity and patient characteristics in a pilot investigation.
    International journal of clinical pharmacology and therapeutics, 2006, Volume: 44, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Chronotherapy; Diarrhe

2006
Double-blinded, placebo-controlled trial on intravenous L-alanyl-L-glutamine in the incidence of oral mucositis following chemoradiotherapy in patients with head-and-neck cancer.
    International journal of radiation oncology, biology, physics, 2006, Aug-01, Volume: 65, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dipeptides; Double-Blind Met

2006
Prevention of 5-fluorouracil-related stomatitis by oral cryotherapy: a randomized controlled study.
    European journal of oncology nursing : the official journal of European Oncology Nursing Society, 2007, Volume: 11, Issue:1

    Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Attitude to Health;

2007
The effect of oral glutamine on 5-fluorouracil/leucovorin-induced mucositis/stomatitis assessed by intestinal permeability test.
    Clinical nutrition (Edinburgh, Scotland), 2007, Volume: 26, Issue:1

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chromi

2007
Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-20, Volume: 24, Issue:33

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Drug Administr

2006
A phase II study using vinorelbine and continuous 5-fluorouracil in patients with advanced head and neck cancer.
    Acta oncologica (Stockholm, Sweden), 2007, Volume: 46, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Catheterizati

2007
[Comparison of efficacy of docetaxel combined cisplatin (TP regimen) and cisplatin combined 5-fluorouracil (PF regimen) on locally advanced nasopharyngeal carcinoma].
    Ai zheng = Aizheng = Chinese journal of cancer, 2007, Volume: 26, Issue:8

    Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin;

2007
A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer.
    Japanese journal of clinical oncology, 2007, Volume: 37, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; F

2007
[Impact of perioperative chemotherapy on prognosis of colorectal cancer: a report of 82 cases].
    Ai zheng = Aizheng = Chinese journal of cancer, 2007, Volume: 26, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva

2007
Double-blind, placebo-controlled, randomized study of chlorhexidine prophylaxis for 5-fluorouracil-based chemotherapy-induced oral mucositis with nonblinded randomized comparison to oral cooling (cryotherapy) in gastrointestinal malignancies.
    Cancer, 2008, Apr-01, Volume: 112, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva

2008
Randomized phase II studies in advanced colorectal carcinoma: a North Central Cancer Treatment Group study.
    Cancer treatment reports, 1983, Volume: 67, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea; Drug Evalu

1983
A double-blind, randomized, placebo-controlled, crossover trial of pentoxifylline for the prevention of chemotherapy-induced oral mucositis.
    Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 1995, Volume: 80, Issue:1

    Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cross-Over St

1995
A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma.
    International journal of radiation oncology, biology, physics, 1995, Oct-15, Volume: 33, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplati

1995
Robust Bayesian methods for monitoring clinical trials.
    Statistics in medicine, 1995, Jun-30, Volume: 14, Issue:12

    Topics: Bayes Theorem; Clinical Trials as Topic; Data Collection; Data Interpretation, Statistical; Extracor

1995
Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:10

    Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo

1995
Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:9

    Topics: Adolescent; Adult; Aged; Alopecia; Chi-Square Distribution; Colorectal Neoplasms; Combined Modality

1995
Clinical trial of continuous infusion of 5-fluorouracil using an ambulatory pump for metastatic colorectal cancer.
    Japanese journal of clinical oncology, 1995, Volume: 25, Issue:2

    Topics: Adult; Aged; Catheters, Indwelling; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusion Pum

1995
Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer.
    Cancer, 1995, Feb-01, Volume: 75, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

1995
[A randomized early phase II study of l-leucovorin and 5-fluorouracil in gastric cancer. l-Leucovorin and 5-FU Study Group].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Administration

1995
5-fluorouracil and folinic acid-induced mucositis: no effect of oral glutamine supplementation.
    British journal of cancer, 1994, Volume: 70, Issue:4

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Double-Bli

1994
Phase II trial of 5-fluorouracil and folinic acid in the treatment of advanced breast cancer.
    Breast cancer research and treatment, 1994, Volume: 30, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Diarrhea; Female; Fluor

1994
Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis.
    European journal of cancer. Part B, Oral oncology, 1994, Volume: 30B, Issue:4

    Topics: Adult; Aged; Cryotherapy; Female; Fluorouracil; Humans; Male; Middle Aged; Smoking; Stomatitis

1994
Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in patients with cancer.
    Clinical pharmacology and therapeutics, 1994, Volume: 56, Issue:2

    Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Circadian Rhythm;

1994
Rapidly alternating chemotherapy and hyperfractionated radiotherapy in the management of locally advanced head and neck carcinoma: four-year results of a phase I/II study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co

1994
Randomized comparison of fluorouracil and leucovorin therapy versus fluorouracil, leucovorin, and cisplatin therapy in patients with advanced colorectal cancer.
    Cancer, 1994, Mar-15, Volume: 73, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Colonic Neoplasms

1994
Allopurinol mouthwashes in the treatment of 5-fluorouracil-induced stomatitis.
    American journal of clinical oncology, 1994, Volume: 17, Issue:3

    Topics: Adult; Aged; Allopurinol; Double-Blind Method; Fluorouracil; Humans; Middle Aged; Mouthwashes; Stoma

1994
Phase II trial of 5-fluorouracil and the natural l isomer of folinic acid in the treatment of advanced colorectal carcinoma.
    European journal of cancer (Oxford, England : 1990), 1994, Volume: 30A, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Female;

1994
5-fluorouracil and interferon-alpha-2a in advanced colorectal cancer. Results of two treatment schedules.
    Cancer, 1993, Dec-01, Volume: 72, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Catheters, Indwelling; Colonic Neoplasms; Drug Admin

1993
A randomized clinical trial of two different durations of oral cryotherapy for prevention of 5-fluorouracil-related stomatitis.
    Cancer, 1993, Oct-01, Volume: 72, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cryosurgery; Female;

1993
Low-dose, continuous infusion 5-fluorouracil and oral etoposide for the treatment of advanced sarcomas.
    The Journal of infusional chemotherapy, 1995,Summer, Volume: 5, Issue:3

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Administration

1995
'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The 'Tomudex' Colorectal Cancer Study Group.
    European journal of cancer (Oxford, England : 1990), 1995, Volume: 31A, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dr

1995
Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis.
    Cancer, 1996, Feb-01, Volume: 77, Issue:3

    Topics: Antimetabolites, Antineoplastic; Chamomile; Double-Blind Method; Female; Flavonoids; Fluorouracil; H

1996
Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis.
    Cancer, 1996, Feb-01, Volume: 77, Issue:3

    Topics: Antimetabolites, Antineoplastic; Chamomile; Double-Blind Method; Female; Flavonoids; Fluorouracil; H

1996
Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis.
    Cancer, 1996, Feb-01, Volume: 77, Issue:3

    Topics: Antimetabolites, Antineoplastic; Chamomile; Double-Blind Method; Female; Flavonoids; Fluorouracil; H

1996
Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis.
    Cancer, 1996, Feb-01, Volume: 77, Issue:3

    Topics: Antimetabolites, Antineoplastic; Chamomile; Double-Blind Method; Female; Flavonoids; Fluorouracil; H

1996
Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis.
    Cancer, 1996, Feb-01, Volume: 77, Issue:3

    Topics: Antimetabolites, Antineoplastic; Chamomile; Double-Blind Method; Female; Flavonoids; Fluorouracil; H

1996
Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis.
    Cancer, 1996, Feb-01, Volume: 77, Issue:3

    Topics: Antimetabolites, Antineoplastic; Chamomile; Double-Blind Method; Female; Flavonoids; Fluorouracil; H

1996
Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis.
    Cancer, 1996, Feb-01, Volume: 77, Issue:3

    Topics: Antimetabolites, Antineoplastic; Chamomile; Double-Blind Method; Female; Flavonoids; Fluorouracil; H

1996
Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis.
    Cancer, 1996, Feb-01, Volume: 77, Issue:3

    Topics: Antimetabolites, Antineoplastic; Chamomile; Double-Blind Method; Female; Flavonoids; Fluorouracil; H

1996
Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis.
    Cancer, 1996, Feb-01, Volume: 77, Issue:3

    Topics: Antimetabolites, Antineoplastic; Chamomile; Double-Blind Method; Female; Flavonoids; Fluorouracil; H

1996
Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma.
    Cancer, 1995, Dec-01, Volume: 76, Issue:11

    Topics: Adult; Aged; Ambulatory Care; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Ant

1995
Oral glutamine to prevent chemotherapy induced stomatitis: a pilot study.
    The Journal of laboratory and clinical medicine, 1996, Volume: 127, Issue:2

    Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Antineoplastic Combined Chemotherapy Proto

1996
A phase I trial of 5-fluorouracil, leucovorin and interferon-alpha 2b administered by 24 h infusion in metastatic colorectal carcinoma.
    Anti-cancer drugs, 1996, Volume: 7, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma; Colorectal Neopl

1996
Phase II study of 5-fluorouracil and leucovorin in recurrent primary brain tumor.
    Journal of neuro-oncology, 1996, Volume: 30, Issue:3

    Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Astrocytoma; Brain Neoplasms; Female; Fluor

1996
A phase I study of 5-fluorouracil, leucovorin and levamisole.
    Cancer chemotherapy and pharmacology, 1997, Volume: 39, Issue:4

    Topics: Adjuvants, Immunologic; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Colonic Neoplasms;

1997
Phase III controlled evaluation of sucralfate to alleviate stomatitis in patients receiving fluorouracil-based chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:3

    Topics: Anti-Ulcer Agents; Antimetabolites, Antineoplastic; Double-Blind Method; Fluorouracil; Humans; Prosp

1997
The EORTC GI group experience with high-dose infusional 5-FU in colorectal cancer.
    The Journal of infusional chemotherapy, 1996,Summer, Volume: 6, Issue:3

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol

1996
[Inhibition of 5-fluorouracil-cisplatin-induced stomatitis by oral cryotherapy: use of an ice-bar containing fibrinolysin and deoxyribonuclease combine (Elase)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:9

    Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Cryotherapy; Deoxyribonucleases; Drug Combinations

1997
Five-day infusion fluorouracil plus vinorelbine i.v. in metastatic pretreated breast cancer patients.
    Breast cancer research and treatment, 1997, Volume: 44, Issue:3

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb

1997
A new in vitro assay for quantitation of chemotherapy-induced mucositis.
    British journal of cancer, 1997, Volume: 76, Issue:8

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cyclophosphami

1997
[Evaluation of 5-fluorouracil concentration in peripheral blood and side effects in continuous hepatic arterial infusion chemotherapy for patients with unresectable liver cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:12

    Topics: Abdominal Pain; Aged; Anorexia; Antimetabolites, Antineoplastic; Drug Administration Schedule; Femal

1997
Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy.
    Cancer chemotherapy and pharmacology, 1998, Volume: 42, Issue:4

    Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe

1998
A phase II study of 5-fluorouracil, leucovorin, and interferon-alpha in the treatment of patients with metastatic or recurrent gastric carcinoma: an Eastern Cooperative Oncology Group study (E5292).
    Cancer, 1999, Jan-15, Volume: 85, Issue:2

    Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil;

1999
Phase III controlled evaluation of glutamine for decreasing stomatitis in patients receiving fluorouracil (5-FU)-based chemotherapy.
    American journal of clinical oncology, 1999, Volume: 22, Issue:3

    Topics: Administration, Oral; Administration, Topical; Aged; Antimetabolites, Antineoplastic; Antineoplastic

1999
Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion.
    Anti-cancer drugs, 1999, Volume: 10, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Clocks; Colonic Neoplasms; C

1999
Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co

1999
[Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors].
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1999, Volume: 175 Suppl 4

    Topics: Adult; Aged; Amifostine; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Comb

1999
Phase II trial of cisplatin, 5-fluorouracil and folinic acid using a weekly 24-h infusion schedule for locally advanced head and neck cancer: a pharmacokinetic and clinical survey.
    International journal of oncology, 2000, Volume: 17, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy,

2000
Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant.
    Cancer investigation, 1999, Volume: 17, Issue:1

    Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Bone Marrow Diseases; Cohort Studies; Diarr

1999
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
    The New England journal of medicine, 2000, Sep-28, Volume: 343, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother

2000
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
    The New England journal of medicine, 2000, Sep-28, Volume: 343, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother

2000
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
    The New England journal of medicine, 2000, Sep-28, Volume: 343, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother

2000
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
    The New England journal of medicine, 2000, Sep-28, Volume: 343, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother

2000
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
    The New England journal of medicine, 2000, Sep-28, Volume: 343, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother

2000
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
    The New England journal of medicine, 2000, Sep-28, Volume: 343, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother

2000
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
    The New England journal of medicine, 2000, Sep-28, Volume: 343, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother

2000
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
    The New England journal of medicine, 2000, Sep-28, Volume: 343, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother

2000
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
    The New England journal of medicine, 2000, Sep-28, Volume: 343, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother

2000
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer.
    British journal of cancer, 2001, Apr-20, Volume: 84, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Conjunctivitis; D

2001
Intra-arterial plus i.v. chemotherapy for advanced bulky squamous cell carcinoma of the buccal mucosa.
    Anti-cancer drugs, 2001, Volume: 12, Issue:4

    Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis

2001
Decrease of duration and symptoms in chemotherapy-induced oral mucositis by topical GM-CSF: results of a prospective randomised trial.
    European journal of cancer (Oxford, England : 1990), 2001, Volume: 37, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Amphotericin B; Antimetabolites, Antineoplastic; Drug Administration

2001
Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2002, Volume: 39, Issue:1

    Topics: Aged; Anemia; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; D

2002
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jan-15, Volume: 20, Issue:2

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplasti

2002
[The preventive effect of allopurinol spray on stomatitis induced by anti-cancer drugs].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:4

    Topics: Aerosols; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplas

2002
Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid.
    European journal of cancer (Oxford, England : 1990), 1992, Volume: 28A, Issue:11

    Topics: Adult; Aged; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotr

1992
Phase II trial of 5-fluorouracil and recombinant interferon alfa-2B in metastatic colorectal carcinoma.
    European journal of cancer (Oxford, England : 1990), 1992, Volume: 28A, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Drug Ev

1992
Randomised comparison of weekly bolus 5-fluorouracil with or without leucovorin in metastatic colorectal carcinoma.
    European journal of cancer (Oxford, England : 1990), 1992, Volume: 28A, Issue:11

    Topics: Adult; Aged; Colorectal Neoplasms; Conjunctivitis; Diarrhea; Drug Administration Schedule; Female; F

1992
Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinoma.
    Cancer, 1992, Oct-15, Volume: 70, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Dru

1992
Chemo-related stomatitis on ice.
    The American journal of nursing, 1992, Volume: 92, Issue:11

    Topics: Fluorouracil; Humans; Ice; Stomatitis

1992
A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions.
    Cancer chemotherapy and pharmacology, 1992, Volume: 30, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dipyridamole; Dose-Response Relationshi

1992
Effect of prophylactic sucralfate suspension on stomatitis induced by cancer chemotherapy. A randomized, double-blind cross-over study.
    Acta oncologica (Stockholm, Sweden), 1990, Volume: 29, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Double-Blind Meth

1990
Decreased oral toxicity with the local use of allopurinol in patients who received high dose 5-fluorouracil.
    Selective cancer therapeutics, 1991,Fall, Volume: 7, Issue:3

    Topics: Allopurinol; Fluorouracil; Humans; Mouth Mucosa; Mouthwashes; Stomatitis

1991
Dual modulation of 5-fluorouracil using leucovorin and hydroxyurea. A phase I trial.
    Cancer, 1991, Aug-15, Volume: 68, Issue:4

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols

1991
Continuous infusion 5-fluorouracil with escalating doses of intermittent cisplatin and etoposide. A phase I study.
    Cancer, 1991, Dec-01, Volume: 68, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Dose-Respo

1991
Inhibition of fluorouracil-induced stomatitis by oral cryotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:3

    Topics: Administration, Oral; Cryosurgery; Drug Synergism; Fluorouracil; Humans; Leucovorin; Mouth Mucosa; P

1991
A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5-fluorouracil-induced stomatitis.
    Cancer, 1990, Apr-15, Volume: 65, Issue:8

    Topics: Allopurinol; Colorectal Neoplasms; Consumer Behavior; Double-Blind Method; Fluorouracil; Humans; Leu

1990
5-Fluorouracil with folinic acid is not effective against metastatic adenocarcinoma of the lung.
    Cancer investigation, 1990, Volume: 8, Issue:3-4

    Topics: Adenocarcinoma; Adult; Aged; Allopurinol; Anorexia; Antineoplastic Combined Chemotherapy Protocols;

1990
Concomitant 5-fluorouracil infusion and high-dose radiation for stage III non-small cell lung cancer.
    Cancer, 1989, Sep-01, Volume: 64, Issue:5

    Topics: Aged; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Esophagit

1989
Cancer control research in the North Central Cancer Treatment Group (NCCTG).
    Progress in clinical and biological research, 1989, Volume: 293

    Topics: Allopurinol; Anorexia; Antineoplastic Agents; Cachexia; Clinical Trials as Topic; Colorectal Neoplas

1989
[Prevention of stomatitis induced by anti-cancer drugs].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:10

    Topics: Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophospham

1989
A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck.
    Cancer, 1985, Dec-15, Volume: 56, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials

1985
Phase I clinical trial of combined therapy with 5-FU (NSC 19893) and CIS-platinum (II) diaminedichloride (NSC 119875).
    Cancer, 1974, Volume: 34, Issue:4

    Topics: Audiometry; Cisplatin; Clinical Trials as Topic; Deafness; Digestive System; Drug Evaluation; Drug T

1974
A controlled evaluation of 5-fluorouracil utilizing a single injection technique.
    Oncology, 1974, Volume: 29, Issue:2

    Topics: Adenocarcinoma; Alopecia; Evaluation Studies as Topic; Fluorouracil; Gastrointestinal Diseases; Huma

1974
A clinical study of fluorouracil.
    Surgery, gynecology & obstetrics, 1968, Volume: 127, Issue:6

    Topics: Adult; Aged; Clinical Trials as Topic; Diarrhea; Female; Fluorouracil; Follow-Up Studies; Humans; Le

1968
Corticosteroids and fluorouracil toxicity.
    Archives of internal medicine, 1966, Volume: 117, Issue:6

    Topics: Bone Marrow; Clinical Trials as Topic; Diarrhea; Digestive System; Fluorouracil; Humans; Injections,

1966

Other Studies

217 other studies available for fluorouracil and Stomatitis

ArticleYear
Therapeutic Effects of GGsTop
    Anticancer research, 2021, Volume: 41, Issue:9

    Topics: Aminobutyrates; Animals; Antimetabolites, Antineoplastic; Body Weight; Collagen; Disease Models, Ani

2021
Wound healing process with different photobiomodulation therapy protocols to treat 5-FU-induced oral mucositis in hamsters.
    Archives of oral biology, 2021, Volume: 131

    Topics: Animals; Cricetinae; Fluorouracil; Low-Level Light Therapy; Mouth Mucosa; Mucositis; Stomatitis; Wou

2021
Laser Therapy as a Preventive Approach for Oral Mucositis in Cancer Patients Undergoing Chemotherapy: The Potential Role of Superoxide Dismutase.
    Asian Pacific journal of cancer prevention : APJCP, 2021, Oct-01, Volume: 22, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2021
Comparative study of royal jelly, propolis, and photobiomodulation therapies in 5-fluorouracil-related oral mucositis in rats.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2022, Volume: 30, Issue:3

    Topics: Animals; Fatty Acids; Fluorouracil; Humans; Low-Level Light Therapy; Male; Propolis; Rats; Rats, Wis

2022
Protective effect of endoplasmic reticulum stress inhibition on 5-fluorouracil-induced oral mucositis.
    European journal of pharmacology, 2022, Mar-15, Volume: 919

    Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Endoplasmic Reticulum Stress; Fluorouracil;

2022
Metformin protects 5-Fu-induced chemotherapy oral mucositis by reducing endoplasmic reticulum stress in mice.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2022, Jun-01, Volume: 173

    Topics: Animals; Antineoplastic Agents; Apoptosis; Diabetes Mellitus, Type 2; Endoplasmic Reticulum Stress;

2022
The therapeutic effect of bovine colostrum on 5-Fluorouracil-Induced oral mucositis in rats.
    Journal of stomatology, oral and maxillofacial surgery, 2022, Volume: 123, Issue:6

    Topics: Animals; Cattle; Colostrum; Female; Fluorouracil; Humans; Male; Mouth Mucosa; Pregnancy; Rats; Rats,

2022
Investigation of the protective effect of gel incorporating Eugenia jambolana leaf extract on 5-fluorouracil-induced oral mucositis: an animal study.
    Journal of cancer research and clinical oncology, 2022, Volume: 148, Issue:8

    Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Fluorouracil; Gels; Mucositis; Plant Extracts; Rats

2022
Protective Effects of Cannabidiol on Chemotherapy-Induced Oral Mucositis via the Nrf2/Keap1/ARE Signaling Pathways.
    Oxidative medicine and cellular longevity, 2022, Volume: 2022

    Topics: Animals; Antineoplastic Agents; Antioxidants; Cannabidiol; Fluorouracil; Heme Oxygenase-1; Humans; K

2022
Dual roles of ANGPTL4 in multiple inflammatory responses in stomatitis mice.
    Molecular biology reports, 2022, Volume: 49, Issue:10

    Topics: Angiopoietin-Like Protein 4; Angiopoietins; Animals; Cytokines; Fluorouracil; Inflammation; Interleu

2022
Preparation and pharmaceutical properties of Hangeshashinto oral ointment and its safety and efficacy in Syrian hamsters with 5-fluorouracil-induced oral mucositis.
    Journal of natural medicines, 2023, Volume: 77, Issue:1

    Topics: Animals; Cricetinae; Fluorouracil; Male; Mesocricetus; Mucositis; Ointments; Stomatitis

2023
Sprayable NAHAO® hydrogel alleviates pain and accelerates rat oral mucositis wound healing.
    Journal of stomatology, oral and maxillofacial surgery, 2023, Volume: 124, Issue:1S

    Topics: Animals; Capsaicin; Cyclooxygenase 2; Dinoprostone; Fluorouracil; Humans; Hydrogels; Male; Matrix Me

2023
Moderate temperature reduction is sufficient for prevention of 5-fluorouracil-induced oral mucositis: an experimental in vivo study in rats.
    Cancer chemotherapy and pharmacology, 2023, Volume: 91, Issue:1

    Topics: Animals; Antineoplastic Agents; Fluorouracil; Interleukin-6; Male; Mucositis; Rats; Rats, Sprague-Da

2023
Moderate temperature reduction is sufficient for prevention of 5-fluorouracil-induced oral mucositis: an experimental in vivo study in rats.
    Cancer chemotherapy and pharmacology, 2023, Volume: 91, Issue:1

    Topics: Animals; Antineoplastic Agents; Fluorouracil; Interleukin-6; Male; Mucositis; Rats; Rats, Sprague-Da

2023
Moderate temperature reduction is sufficient for prevention of 5-fluorouracil-induced oral mucositis: an experimental in vivo study in rats.
    Cancer chemotherapy and pharmacology, 2023, Volume: 91, Issue:1

    Topics: Animals; Antineoplastic Agents; Fluorouracil; Interleukin-6; Male; Mucositis; Rats; Rats, Sprague-Da

2023
Moderate temperature reduction is sufficient for prevention of 5-fluorouracil-induced oral mucositis: an experimental in vivo study in rats.
    Cancer chemotherapy and pharmacology, 2023, Volume: 91, Issue:1

    Topics: Animals; Antineoplastic Agents; Fluorouracil; Interleukin-6; Male; Mucositis; Rats; Rats, Sprague-Da

2023
Fabrication, in Vitro, and in Vivo Characterization of Mucoadhesive Berberine-Loaded Blended Wafers for Treatment of Chemotherapy-Induced Oral Mucositis.
    AAPS PharmSciTech, 2022, Dec-16, Volume: 24, Issue:1

    Topics: Alginates; Animals; Antineoplastic Agents; Berberine; Chitosan; Fluorouracil; Hypromellose Derivativ

2022
Fabrication, in Vitro, and in Vivo Characterization of Mucoadhesive Berberine-Loaded Blended Wafers for Treatment of Chemotherapy-Induced Oral Mucositis.
    AAPS PharmSciTech, 2022, Dec-16, Volume: 24, Issue:1

    Topics: Alginates; Animals; Antineoplastic Agents; Berberine; Chitosan; Fluorouracil; Hypromellose Derivativ

2022
Fabrication, in Vitro, and in Vivo Characterization of Mucoadhesive Berberine-Loaded Blended Wafers for Treatment of Chemotherapy-Induced Oral Mucositis.
    AAPS PharmSciTech, 2022, Dec-16, Volume: 24, Issue:1

    Topics: Alginates; Animals; Antineoplastic Agents; Berberine; Chitosan; Fluorouracil; Hypromellose Derivativ

2022
Fabrication, in Vitro, and in Vivo Characterization of Mucoadhesive Berberine-Loaded Blended Wafers for Treatment of Chemotherapy-Induced Oral Mucositis.
    AAPS PharmSciTech, 2022, Dec-16, Volume: 24, Issue:1

    Topics: Alginates; Animals; Antineoplastic Agents; Berberine; Chitosan; Fluorouracil; Hypromellose Derivativ

2022
Characterization of a novel dual murine model of chemotherapy-induced oral and intestinal mucositis.
    Scientific reports, 2023, 01-25, Volume: 13, Issue:1

    Topics: Animals; Antimetabolites, Antineoplastic; Diarrhea; Disease Models, Animal; Fluorouracil; Intestinal

2023
Anti-Inflammatory Effects of β-Cryptoxanthin on 5-Fluorouracil-Induced Cytokine Expression in Human Oral Mucosal Keratinocytes.
    Molecules (Basel, Switzerland), 2023, Mar-24, Volume: 28, Issue:7

    Topics: Anti-Inflammatory Agents; Beta-Cryptoxanthin; Cytokines; Fluorouracil; Humans; Interleukin-6; Interl

2023
Evaluation of the topical gel and oral administration of Punica Granatum Var Pleniflora on oral mucositis induced by 5-Fluorouracil in golden hamsters.
    BMC complementary medicine and therapies, 2023, Jul-07, Volume: 23, Issue:1

    Topics: Administration, Oral; Animals; Cricetinae; Fluorouracil; Male; Mesocricetus; Pomegranate; Stomatitis

2023
The role of Hippophae rhamnoides L. on 5-fluorouracil-ınduced oral mucositis in rats.
    Pakistan journal of pharmaceutical sciences, 2023, Volume: 36, Issue:5

    Topics: Animals; Antioxidants; Fluorouracil; Hippophae; Interleukin-6; Intestinal Mucosa; Oxidants; Rats; St

2023
1-Palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol ameliorates chemoradiation-induced oral mucositis.
    Oral diseases, 2020, Volume: 26, Issue:1

    Topics: Animals; Chemokine CXCL2; Chemoradiotherapy; Diglycerides; Fluorouracil; Interleukin-6; Male; Mice;

2020
Glutaryl Melatonin Niosome Gel for Topical Oral Mucositis: Anti- Inflammatory and Anticandidiasis.
    Current drug delivery, 2020, Volume: 17, Issue:3

    Topics: Administration, Topical; Anhydrides; Animals; Anti-Inflammatory Agents; Antifungal Agents; Candida a

2020
Wound Healing Promoting Activity of Tonsil-Derived Stem Cells on 5-Fluorouracil-Induced Oral Mucositis Model.
    Tissue engineering and regenerative medicine, 2020, Volume: 17, Issue:1

    Topics: Animals; Child; Cricetinae; Culture Media, Conditioned; Disease Models, Animal; Female; Fluorouracil

2020
A Rat Model of Oral Mucositis Induced by Cancer Chemotherapy for Quantitative Experiments.
    Anticancer research, 2020, Volume: 40, Issue:5

    Topics: Animals; Antineoplastic Agents; Body Weight; Disease Models, Animal; Fluorouracil; Leukocyte Count;

2020
Cannabidiol on 5-FU-induced oral mucositis in mice.
    Oral diseases, 2020, Volume: 26, Issue:7

    Topics: Animals; Cannabidiol; Disease Models, Animal; Fluorouracil; Intestinal Mucosa; Mice; Mucositis; Stom

2020
Topical Melatonin Niosome Gel for the Treatment of 5-FU-Induced Oral Mucositis in Mice.
    Current drug delivery, 2021, Volume: 18, Issue:2

    Topics: Animals; Fluorouracil; Liposomes; Melatonin; Mice; Mice, Inbred ICR; Quality of Life; Stomatitis

2021
Anti-inflammatory latex proteins of the medicinal plant Calotropis procera: a promising alternative for oral mucositis treatment.
    Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2020, Volume: 69, Issue:9

    Topics: Animals; Anti-Inflammatory Agents; Calotropis; Fluorouracil; Latex; Male; Mesocricetus; Plant Protei

2020
Effect of Topical 2% Eucalyptus Extract on 5-FU-Induced Oral Mucositis in Male Golden Hamsters.
    Brazilian dental journal, 2020, Volume: 31, Issue:3

    Topics: Animals; Cricetinae; Eucalyptus; Fluorouracil; Male; Mesocricetus; Mouth Mucosa; Mucositis; Plant Ex

2020
Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database.
    Journal of the National Cancer Institute, 2021, 04-06, Volume: 113, Issue:4

    Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Camptothecin; Capecit

2021
Lactobacillus reuteri DSM 17938 and ATCC PTA 5289 ameliorates chemotherapy-induced oral mucositis.
    Scientific reports, 2020, 10-01, Volume: 10, Issue:1

    Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Female; Fluorouracil; Inflammation;

2020
The impact of timing and modalities of dental prophylaxis on the risk of 5-fluorouracil-related oral mucositis in patients with head and neck cancer: a nationwide population-based cohort study.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2021, Volume: 29, Issue:6

    Topics: Adult; Aged; Cohort Studies; Cross-Sectional Studies; Dental Prophylaxis; Female; Fluorouracil; Head

2021
Protective effect of Salvia miltiorrhiza Bunge on 5-fluorouracil-induced oral mucositis.
    International journal of molecular medicine, 2017, Volume: 40, Issue:1

    Topics: Animals; Cell Line; Fluorouracil; Humans; Male; Mesocricetus; Plant Extracts; Salvia miltiorrhiza; S

2017
Fluoropyrimidine-Associated Toxicity in Two Gastrointestinal Cancer Patients: Potential Role of Common DPYD Polymorphisms.
    Chemotherapy, 2017, Volume: 62, Issue:5

    Topics: Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Dihydrouracil Dehydrogenase (NADP); F

2017
Elemental Diet Accelerates the Recovery From Oral Mucositis and Dermatitis Induced by 5-Fluorouracil Through the Induction of Fibroblast Growth Factor 2.
    Integrative cancer therapies, 2018, Volume: 17, Issue:2

    Topics: Animals; Dermatitis; Female; Fibroblast Growth Factor 2; Fluorouracil; Food, Formulated; Glutamine;

2018
Biochemical, hematological, and pathological related healing effects of Elaeagnus angustifolia hydroalcoholic extract in 5-fluorouracil-induced oral mucositis in male golden hamster.
    Environmental science and pollution research international, 2017, Volume: 24, Issue:31

    Topics: Animals; Antimetabolites, Antineoplastic; Elaeagnaceae; Fluorouracil; Male; Mesocricetus; Plant Extr

2017
Chemopreventive effects of FITOPROT against 5-fluorouracil-induced toxicity in HaCaT cells.
    Life sciences, 2018, Jan-15, Volume: 193

    Topics: Anticarcinogenic Agents; Antioxidants; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Surviva

2018
Role of the route of leukotrienes in an experimental model of oral mucositis induced by 5-fluorouracil 1.
    Acta cirurgica brasileira, 2017, Volume: 32, Issue:9

    Topics: Animals; Cricetinae; Cysteine; Cytokines; Disease Models, Animal; Fluorouracil; Immunohistochemistry

2017
Protective effect of dexamethasone on 5-FU-induced oral mucositis in hamsters.
    PloS one, 2017, Volume: 12, Issue:10

    Topics: Animals; Cricetinae; Cyclooxygenase 2; Cytokines; Dexamethasone; Fluorouracil; Male; Matrix Metallop

2017
Peroxisome proliferator activated receptor-gamma stimulation for prevention of 5-fluorouracil-induced oral mucositis in mice.
    Head & neck, 2018, Volume: 40, Issue:3

    Topics: Animals; Blotting, Western; Cytokines; Fluorouracil; Mice; Mice, Inbred C57BL; Mouth Mucosa; PPAR ga

2018
Therapeutic effect of andiroba oil (Carapa guianensis Aubl.) against oral mucositis: an experimental study in golden Syrian hamsters.
    Clinical oral investigations, 2018, Volume: 22, Issue:5

    Topics: Animals; Disease Models, Animal; Fluorouracil; Male; Meliaceae; Mesocricetus; Plant Oils; Random All

2018
A Mouse Model for Oral Mucositis Induced by Cancer Chemotherapy.
    Anticancer research, 2018, Volume: 38, Issue:1

    Topics: Acetic Acid; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Disease Models, Animal; Fluor

2018
Chemotherapy-induced oral mucositis and associated infections in a novel organotypic model.
    Molecular oral microbiology, 2018, Volume: 33, Issue:3

    Topics: Adherens Junctions; Apoptosis; Bacteria; Biofilms; Cadherins; Cell Line; Cell Proliferation; Cytokin

2018
Cooling of the oral mucosa to prevent adverse effects of chemotherapeutic agents: An in vitro study.
    Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2018, Volume: 47, Issue:5

    Topics: Antineoplastic Agents; Cell Survival; Cold Temperature; Cryotherapy; Dose-Response Relationship, Dru

2018
Therapeutic efficacy of rebamipide-loaded PLGA nanoparticles coated with chitosan in a mouse model for oral mucositis induced by cancer chemotherapy.
    Colloids and surfaces. B, Biointerfaces, 2018, Jul-01, Volume: 167

    Topics: Alanine; Animals; Anti-Ulcer Agents; Chitosan; Coated Materials, Biocompatible; Drug Liberation; Flu

2018
Protective effect of angiotensin II receptor blocker against oxidative stress and inflammation in an oral mucositis experimental model.
    Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2018, Volume: 47, Issue:10

    Topics: Angiotensin Receptor Antagonists; Animals; Antimetabolites, Antineoplastic; Cricetinae; Cytokines; F

2018
Oral Cryotherapy: Prevention of Oral Mucositis and Pain Among Patients With Colorectal Cancer Undergoing Chemotherapy.
    Clinical journal of oncology nursing, 2018, 10-01, Volume: 22, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics; Antifungal Agents; Antineoplastic Agents; Co

2018
Oral mucositis associated with anti-EGFR therapy in colorectal cancer: single institutional retrospective cohort study.
    BMC cancer, 2018, Oct-05, Volume: 18, Issue:1

    Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Camptoth

2018
Effects of Onchung-eum, an Herbal Prescription, on 5-Fluorouracil-Induced Oral Mucositis.
    Integrative cancer therapies, 2018, Volume: 17, Issue:4

    Topics: Animals; Cell Death; Cell Survival; Cytokines; Fluorouracil; Herbal Medicine; Humans; Inflammation;

2018
Therapeutic Effect of GGsTop, Selective Gamma-glutamyl Transpeptidase Inhibitor, on a Mouse Model of 5-Fluorouracil-induced Oral Mucositis.
    Anticancer research, 2019, Volume: 39, Issue:1

    Topics: Aminobutyrates; Animals; Disease Models, Animal; Fluorouracil; gamma-Glutamyltransferase; Humans; Mi

2019
Oral cryotherapy for prophylaxis of oral mucositis caused by docetaxel, cisplatin, and fluorouracil chemotherapy for esophageal cancer.
    Esophagus : official journal of the Japan Esophageal Society, 2019, Volume: 16, Issue:2

    Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cryotherapy;

2019
Mucoadhesive formulation containing Curcuma longa L. reduces oral mucositis induced by 5-fluorouracil in hamsters.
    Phytotherapy research : PTR, 2019, Volume: 33, Issue:4

    Topics: Animals; Cricetinae; Curcuma; Drug Compounding; Fluorouracil; Male; Mesocricetus; Plant Extracts; St

2019
Amifostine reduces inflammation and protects against 5-fluorouracil-induced oral mucositis and hyposalivation.
    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2019, Feb-25, Volume: 52, Issue:3

    Topics: Amifostine; Animals; Cricetinae; Disease Models, Animal; Fluorouracil; Inflammation; Male; Protectiv

2019
Comparison of the efficacy of low-level laser therapy and photodynamic therapy on oral mucositis in rats.
    Lasers in medical science, 2019, Volume: 34, Issue:7

    Topics: Animals; Becaplermin; Body Weight; Fibroblast Growth Factor 2; Fluorouracil; Low-Level Light Therapy

2019
Chemotherapy-induced oral mucositis is associated with detrimental bacterial dysbiosis.
    Microbiome, 2019, 04-25, Volume: 7, Issue:1

    Topics: Antineoplastic Agents; Bacteria; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Dysb

2019
A simple ex vivo bioassay for 5-FU transport into healthy buccal mucosal cells.
    Cancer chemotherapy and pharmacology, 2019, Volume: 84, Issue:4

    Topics: Antimetabolites, Antineoplastic; Biological Transport, Active; Biological Variation, Population; Fem

2019
Effect of rice cell-derived human granulocyte-macrophage colony-stimulating factor on 5-fluorouracil-induced mucositis in hamsters.
    Biological & pharmaceutical bulletin, 2013, Volume: 36, Issue:3

    Topics: Animals; Antimetabolites, Antineoplastic; Cricetinae; Fluorouracil; Granulocyte-Macrophage Colony-St

2013
Analysis of saliva samples from oncological patients treated with 5-fluorouracil and leucovorin calcium by scanning electron microscopy with energy dispersive system.
    Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2013, Volume: 42, Issue:10

    Topics: Administration, Intravenous; Adult; Antimetabolites, Antineoplastic; Calcium; Carcinoma; Colonic Neo

2013
Changes of oral microcirculation in chemotherapy patients: A possible correlation with mucositis?
    Clinical anatomy (New York, N.Y.), 2014, Volume: 27, Issue:3

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Fema

2014
Prospective study of symptom assessment among patients with cervical cancer during concurrent chemoradiotherapy with weekly cisplatin or every-3-week cisplatin and 5-fluorouracil.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2013, Volume: 23, Issue:8

    Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Anxiety; Carcinoma; Chemoradiotherapy; Cispl

2013
Alteration of the redox state with reactive oxygen species for 5-fluorouracil-induced oral mucositis in hamsters.
    PloS one, 2013, Volume: 8, Issue:12

    Topics: Animals; Cyclic N-Oxides; Disease Models, Animal; Fluorouracil; Kinetics; Male; Malondialdehyde; Mes

2013
A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach.
    Mayo Clinic proceedings, 2014, Volume: 89, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Colonic N

2014
Platelet-rich fibrin has a healing effect on chemotherapy-induced mucositis in hamsters.
    Oral surgery, oral medicine, oral pathology and oral radiology, 2014, Volume: 117, Issue:4

    Topics: Administration, Topical; Animals; Blood Platelets; Cricetinae; Disease Models, Animal; Fibrin; Fluor

2014
Positive effects of oral β-glucan on mucositis and leukopenia in colorectal cancer patients receiving adjuvant FOLFOX-4 combination chemotherapy.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; b

2014
Comparative assessment of the therapeutic effects of the topical and systemic forms of Hypericum perforatum extract on induced oral mucositis in golden hamsters.
    International journal of oral and maxillofacial surgery, 2014, Volume: 43, Issue:10

    Topics: Administration, Oral; Administration, Topical; Animals; Antimetabolites, Antineoplastic; Fluorouraci

2014
Preventive effect of Daiokanzoto (TJ-84) on 5-fluorouracil-induced human gingival cell death through the inhibition of reactive oxygen species production.
    PloS one, 2014, Volume: 9, Issue:11

    Topics: Caspase 1; Cell Death; Drugs, Chinese Herbal; Fluorouracil; Gingiva; Humans; Medicine, Kampo; Reacti

2014
[Therapeutic effect of rebamipide for oral mucositis associated with FEC therapy for breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:11

    Topics: Adult; Aged; Alanine; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophospha

2014
S-nitrosoglutathione accelerates recovery from 5-fluorouracil-induced oral mucositis.
    PloS one, 2014, Volume: 9, Issue:12

    Topics: Administration, Topical; Animals; Cricetinae; Disease Models, Animal; Fluorouracil; Gene Expression

2014
Clinical, biochemical and histological study of the effect of antimicrobial photodynamic therapy on oral mucositis induced by 5-fluorouracil in hamsters.
    Photodiagnosis and photodynamic therapy, 2015, Volume: 12, Issue:2

    Topics: Animals; Anti-Infective Agents; Antineoplastic Agents; Cricetinae; Female; Fluorouracil; Low-Level L

2015
γ-Tocotrienol prevents 5-FU-induced reactive oxygen species production in human oral keratinocytes through the stabilization of 5-FU-induced activation of Nrf2.
    International journal of oncology, 2015, Volume: 46, Issue:4

    Topics: Antimetabolites, Antineoplastic; Antioxidants; Cell Line; Cell Nucleus; Cell Proliferation; Fluorour

2015
Amniotic membrane as a biological dressing for 5-fluoruracil-induced oral mucositis in rats.
    International journal of oral and maxillofacial surgery, 2015, Volume: 44, Issue:7

    Topics: Amnion; Animals; Biological Dressings; Biomarkers; CD4 Lymphocyte Count; CD8 Antigens; Cell Prolifer

2015
Comprehensive Assessment of Host Responses to 5-Fluorouracil-Induced Oral Mucositis through Transcriptomic Analysis.
    PloS one, 2015, Volume: 10, Issue:8

    Topics: Animals; Chitinases; Fluorouracil; Glycoproteins; Interleukin-1beta; Male; Mice; Mice, Inbred BALB C

2015
Hydroalcoholic extract of Carum carvi L. in oral mucositis: a clinical trial in male golden hamsters.
    Oral diseases, 2016, Volume: 22, Issue:1

    Topics: Animals; Anti-Infective Agents; Carum; Cricetinae; Double-Blind Method; Fluorouracil; Glutathione; M

2016
Photobiomodulation reduces oral mucositis by modulating NF-kB.
    Journal of biomedical optics, 2015, Volume: 20, Issue:12

    Topics: Animals; Antimetabolites, Antineoplastic; Blotting, Western; Cricetinae; Drug Administration Schedul

2015
Distinct TRPV1- and TRPA1-based mechanisms underlying enhancement of oral ulcerative mucositis-induced pain by 5-fluorouracil.
    Pain, 2016, Volume: 157, Issue:5

    Topics: Acetanilides; Anesthetics, Local; Animals; Anti-Bacterial Agents; Antimetabolites; Carcinosarcoma; C

2016
The therapeutic effects of apigenin and dexamethasone on 5-fluorouracil-induced oral mucositis - a pilot study using a Syrian hamster model.
    Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2017, Volume: 46, Issue:2

    Topics: Animals; Anti-Inflammatory Agents; Apigenin; Dexamethasone; Disease Models, Animal; Fluorouracil; Ma

2017
A morphometric study of the protective effect of cryotherapy on oral mucositis in cancer patients treated with 5-fluorouracil.
    Biotechnic & histochemistry : official publication of the Biological Stain Commission, 2016, Volume: 91, Issue:7

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Cryotherapy; Female; Fluorouracil; Humans; Male; Middl

2016
Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy.
    International journal of radiation oncology, biology, physics, 2016, 12-01, Volume: 96, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Carcinoma,

2016
Oral cryotherapy reduced oral mucositis in patients having cancer treatments.
    Evidence-based dentistry, 2016, Volume: 17, Issue:3

    Topics: Cryosurgery; Cryotherapy; Fluorouracil; Humans; Neoplasms; Stomatitis; United States

2016
Effect of a corticosteroid (triamcinolone) and chlorhexidine on chemotherapy-induced oxidative stress in the buccal mucosa of rats.
    Ear, nose, & throat journal, 2016, Volume: 95, Issue:12

    Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Chlorhexidine; Female; Fluorouracil; Mouth

2016
Healing acceleration of oral mucositis induced by 5-fluorouracil with Pistacia atlantica (bene) essential oil in hamsters.
    Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2017, Volume: 46, Issue:9

    Topics: Administration, Topical; Animals; Cricetinae; Fluorouracil; Male; Oils, Volatile; Phytotherapy; Pist

2017
A prospective study of nutritional supplementation for preventing oral mucositis in cancer patients receiving chemotherapy.
    Asia Pacific journal of clinical nutrition, 2017, Volume: 26, Issue:1

    Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Diarrhea; Esophageal Neoplasms; Fe

2017
Dosimetric study of photobiomodulation therapy in 5-FU-induced oral mucositis in hamsters.
    Journal of biomedical optics, 2017, 01-01, Volume: 22, Issue:1

    Topics: Animals; Cricetinae; Fluorouracil; Low-Level Light Therapy; Stomatitis; Wound Healing

2017
Topical application of royal jelly has a healing effect for 5-fluorouracil-induced experimental oral mucositis in hamsters.
    Methods and findings in experimental and clinical pharmacology, 2008, Volume: 30, Issue:2

    Topics: Administration, Topical; Animals; Cricetinae; Fatty Acids; Fluorouracil; Growth Substances; Honey; M

2008
Homogenous amniotic membrane as a biological dressing for oral mucositis in rats: histomorphometric analysis.
    Archives of oral biology, 2008, Volume: 53, Issue:12

    Topics: Acetic Acid; Amnion; Animals; Antimetabolites, Antineoplastic; Biological Dressings; Female; Fluorou

2008
Light-emitting diode therapy in chemotherapy-induced mucositis.
    Lasers in surgery and medicine, 2008, Volume: 40, Issue:9

    Topics: Animals; Antineoplastic Agents; Cheek; Cricetinae; Disease Models, Animal; Fluorouracil; Male; Mesoc

2008
Cyclooxygenase-2 and vascular endothelial growth factor expression in 5-fluorouracil-induced oral mucositis in hamsters: evaluation of two low-intensity laser protocols.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2009, Volume: 17, Issue:11

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cheek; Cri

2009
An unusual presentation of hand-foot syndrome at the hidden area: the scrotum and penis.
    Acta oncologica (Stockholm, Sweden), 2009, Volume: 48, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration Schedul

2009
Protective effects of amifostine and cyclooxygenase-1 inhibitor against normal human epidermal keratinocyte toxicity induced by methotrexate and 5-fluorouracil.
    Basic & clinical pharmacology & toxicology, 2009, Volume: 105, Issue:1

    Topics: Allopurinol; Amifostine; Antimetabolites, Antineoplastic; Calcium; Cell Line; Cell Proliferation; Ce

2009
Capecitabine-induced stomatitis: a likely pathogenetic mechanism of oral lichenoid mucositis.
    European journal of clinical pharmacology, 2009, Volume: 65, Issue:10

    Topics: Administration, Buccal; Antimetabolites, Antineoplastic; Betamethasone; Breast Neoplasms; Capecitabi

2009
Effect of oral mucosal adhesive films containing ginsenoside Rb1 on 5-fluorouracil-induced oral mucositis in hamsters.
    European journal of pharmacology, 2009, Aug-15, Volume: 616, Issue:1-3

    Topics: Adhesives; Administration, Topical; Alginates; Animals; Antineoplastic Agents; Chitosan; Cricetinae;

2009
A retrospective, multicenter study of the tolerance of induction chemotherapy with docetaxel, Cisplatin, and 5-Fluorouracil followed by radiotherapy with concomitant cetuximab in 46 cases of squamous cell carcinoma of the head and neck.
    International journal of radiation oncology, biology, physics, 2010, Jun-01, Volume: 77, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2010
Concurrent chemoradiotherapy with helical tomotherapy for oropharyngeal cancer: a preliminary result.
    International journal of radiation oncology, biology, physics, 2010, Jul-01, Volume: 77, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined

2010
Healing action of topical chamomile on 5-fluoracil induced oral mucositis in hamster.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2011, Volume: 19, Issue:5

    Topics: Administration, Topical; Animals; Antimetabolites, Antineoplastic; Betamethasone; Cricetinae; Female

2011
Enteral feeding during chemoradiotherapy for advanced head-and-neck cancer: a single-institution experience using a reactive approach.
    International journal of radiation oncology, biology, physics, 2011, Mar-01, Volume: 79, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Squa

2011
Comparison of four cisplatin-based radiochemotherapy regimens for nonmetastatic stage III/IV squamous cell carcinoma of the head and neck.
    International journal of radiation oncology, biology, physics, 2011, Jul-15, Volume: 80, Issue:4

    Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp

2011
Effect of atorvastatin on 5-fluorouracil-induced experimental oral mucositis.
    Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:5

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Atorvastatin; Bac

2011
Effects of low-level laser therapy on collagen expression and neutrophil infiltrate in 5-fluorouracil-induced oral mucositis in hamsters.
    Lasers in surgery and medicine, 2010, Volume: 42, Issue:6

    Topics: Animals; Antimetabolites, Antineoplastic; Collagen; Cricetinae; Female; Fluorouracil; Low-Level Ligh

2010
The impact of individual in vivo repair of DNA double-strand breaks on oral mucositis in adjuvant radiotherapy of head-and-neck cancer.
    International journal of radiation oncology, biology, physics, 2011, Dec-01, Volume: 81, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemoradiotherapy; Cisplati

2011
[Early-onset radiation complications and tissue damage in the treatment of head and neck tumors].
    Voprosy onkologii, 2010, Volume: 56, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Chemotherapy, Adjuvant;

2010
Toxicity data for preoperative concurrent chemoradiotherapy with oxaliplatin and continuous infusion 5-fluorouracil for locally advanced esophageal cancer.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2011, Volume: 24, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju

2011
Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma.
    Head & neck, 2011, Volume: 33, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali

2011
Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma.
    Head & neck, 2011, Volume: 33, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali

2011
Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma.
    Head & neck, 2011, Volume: 33, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali

2011
Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma.
    Head & neck, 2011, Volume: 33, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali

2011
Self-reported compliance with capecitabine: findings from a prospective cohort analysis.
    Oncology, 2011, Volume: 80, Issue:1-2

    Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Fema

2011
Comparison of toxicity profiles of fluorouracil versus oxaliplatin regimens in a large population-based cohort of elderly patients with colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:6

    Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Beva

2012
Effect of radiotherapy and chemotherapy on the risk of mucositis during intensity-modulated radiation therapy for oropharyngeal cancer.
    International journal of radiation oncology, biology, physics, 2012, May-01, Volume: 83, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2012
[Elental prevented and reduced oral mucositis during chemotherapy in patients esophageal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:13

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Female; Fluor

2011
[High incidence-rate of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy (FEC100)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:3

    Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclo

2012
[Concurrent chemoradiotherapy with either CDDP or CDGP, plus 5-FU for squamous cell carcinoma of the oropharynx and hypopharynx].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous

2012
Protein fraction of Calotropis procera latex protects against 5-fluorouracil-induced oral mucositis associated with downregulation of pivotal pro-inflammatory mediators.
    Naunyn-Schmiedeberg's archives of pharmacology, 2012, Volume: 385, Issue:10

    Topics: Animals; Antimetabolites, Antineoplastic; Calotropis; Cricetinae; Cyclooxygenase 2; Cytokines; Disea

2012
Alternating chemotherapy: gemcitabine and cisplatin with concurrent radiotherapy for treatment of advanced head and neck cancer.
    Oral oncology, 2013, Volume: 49, Issue:3

    Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy

2013
Effect of topical chamomile on immunohistochemical levels of IL-1β and TNF-α in 5-fluorouracil-induced oral mucositis in hamsters.
    Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:2

    Topics: Administration, Topical; Animals; Antimetabolites, Antineoplastic; Chamomile; Cricetinae; Female; Fl

2013
THRB genetic polymorphisms can predict severe myelotoxicity after definitive chemoradiotherapy in patients with esophageal squamous cell carcinoma.
    International journal of medical sciences, 2012, Volume: 9, Issue:9

    Topics: 3' Untranslated Regions; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcino

2012
Healing acceleration in hamsters of oral mucositis induced by 5-fluorouracil with topical Calendula officinalis.
    Oral surgery, oral medicine, oral pathology and oral radiology, 2013, Volume: 115, Issue:3

    Topics: Abscess; Animals; Antimetabolites, Antineoplastic; Calendula; Carboxymethylcellulose Sodium; Criceti

2013
Oral mucosal adhesive films containing royal jelly accelerate recovery from 5-fluorouracil-induced oral mucositis.
    Journal of pharmacological sciences, 2013, Volume: 121, Issue:2

    Topics: Adhesives; Animals; Cheek; Cricetinae; Fatty Acids; Fibroblast Growth Factor 7; Fluorouracil; Free R

2013
Exposure of oral mucosa to bioactive milk factors reduces severity of chemotherapy-induced mucositis in the hamster.
    Oral oncology, 2002, Volume: 38, Issue:5

    Topics: Animals; Antimetabolites, Antineoplastic; Cell Division; Cheek; Cricetinae; Dose-Response Relationsh

2002
[The prevention of negative side effects in homeochemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:7

    Topics: Abdominal Pain; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neop

2002
Long-term results of reirradiation for patients with recurrent rectal carcinoma.
    Cancer, 2002, Sep-01, Volume: 95, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2002
Lethal 5-fluorouracil toxicity associated with a novel mutation in the dihydropyrimidine dehydrogenase gene.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:2

    Topics: Adult; Alopecia; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto

2003
Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report.
    European journal of clinical pharmacology, 2002, Volume: 58, Issue:9

    Topics: Alopecia; Antimetabolites, Antineoplastic; Area Under Curve; Diarrhea; Drug Eruptions; Female; Fever

2002
Analysis of the time course and prognostic factors determining toxicity due to infused fluorouracil.
    British journal of cancer, 2003, May-19, Volume: 88, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Databases, Factual; Diarrhea; Drug

2003
Preclinical characterization of CG53135 (FGF-20) in radiation and concomitant chemotherapy/radiation-induced oral mucositis.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Aug-15, Volume: 9, Issue:9

    Topics: Animals; Bromodeoxyuridine; Cheek; Coloring Agents; Cricetinae; Dose-Response Relationship, Drug; Fi

2003
FURTHER CLINICAL COMPARISON BETWEEN 5-FLUOROURACIL (5-FU) AND 5-FLUORO-2' -DEOXYURIDINE (5-FUDR).
    Cancer chemotherapy reports, 1963, Volume: 32

    Topics: Brain Neoplasms; Breast Neoplasms; Diarrhea; Floxuridine; Fluorouracil; Geriatrics; Humans; Liver Ne

1963
PRELIMINARY OBSERVATIONS ON CARCINOMA OF THE CERVIX TREATED WITH 5-FLUOROURACIL.
    American journal of obstetrics and gynecology, 1964, Jan-01, Volume: 88

    Topics: Carcinoma; Female; Fluorouracil; Humans; Injections, Intravenous; Mortality; Neoplasms; Stomatitis;

1964
COMPARISON OF HIGH-DOSAGE AND LOW-DOSAGE-MAINTENANCE THERAPY WITH 5-FLUOROURACIL IN SOLID TUMORS.
    Cancer, 1964, Volume: 17

    Topics: Diarrhea; Fluorouracil; Humans; Nausea; Neoplasms; Stomatitis; Toxicology; Vomiting

1964
FLUORINATED PYRIMIDINE THERAPY OF ADVANCED GASTROINTESTINAL CANCER.
    Gastroenterology, 1964, Volume: 46

    Topics: Alopecia; Colonic Neoplasms; Drug Eruptions; Esophagitis; Fluorouracil; Gallbladder Neoplasms; Human

1964
TREATMENT OF ADVANCED CANCER WITH 5-FLUOROURACIL.
    Acta - Unio Internationalis Contra Cancrum, 1964, Volume: 20

    Topics: Alopecia; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Drug Eruptions; Fluorouracil; Humans; Leuko

1964
[Radiation-induced mucositis and neutrophil granulocytes in oral mucosa].
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2003, Volume: 179, Issue:10

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Combined Modality Therapy

2003
[A new systemic combination chemotherapy to be provided at home for patients with unresectable recurrent colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug Administration

2003
An engineered biopolymer prevents mucositis induced by 5-fluorouracil in hamsters.
    The American journal of pathology, 2004, Volume: 164, Issue:2

    Topics: Animals; Antimetabolites, Antineoplastic; Basement Membrane; Biopolymers; Blotting, Western; Criceti

2004
[A new systemic combination chemotherapy to be provided at home for patients with unresectable recurrent colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:1 Suppl

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasm

2003
[Biweekly regimen of high dose of leucovorin, 5-fluorouracil, and paclitaxel for patients with advanced gastric cancer].
    Ai zheng = Aizheng = Chinese journal of cancer, 2004, Volume: 23, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch

2004
FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder.
    Japanese journal of clinical oncology, 2004, Volume: 34, Issue:12

    Topics: Aged; Aged, 80 and over; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bi

2004
Reduction of radiochemotherapy-induced early oral mucositis by recombinant human keratinocyte growth factor (palifermin): experimental studies in mice.
    International journal of radiation oncology, biology, physics, 2005, Jul-01, Volume: 62, Issue:3

    Topics: Animals; Cisplatin; Dose Fractionation, Radiation; Drug Evaluation, Preclinical; Fibroblast Growth F

2005
Effects of the tumour necrosis factor-alpha inhibitors pentoxifylline and thalidomide in short-term experimental oral mucositis in hamsters.
    European journal of oral sciences, 2005, Volume: 113, Issue:3

    Topics: Abscess; Animals; Antimetabolites, Antineoplastic; Cricetinae; Disease Models, Animal; Edema; Erythe

2005
Metabolic abnormalities associated with weight loss during chemoirradiation of head-and-neck cancer.
    International journal of radiation oncology, biology, physics, 2005, Dec-01, Volume: 63, Issue:5

    Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Blood Urea Nitrogen; Cisplatin

2005
Prevention of oral mucositis due to 5-fluorouracil treatment with oral cryotherapy.
    Journal of the National Medical Association, 2005, Volume: 97, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cryotherapy; F

2005
Preliminary results of radiation dose escalation for locally advanced nasopharyngeal carcinoma.
    International journal of radiation oncology, biology, physics, 2006, Feb-01, Volume: 64, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality

2006
Effect of granulocyte macrophage-colony stimulating factor (GM-CSF) on 5-FU-induced ulcerative mucositis in hamster buccal pouches.
    Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie, 2006, Volume: 57, Issue:4

    Topics: Administration, Topical; Animals; Anti-Ulcer Agents; Biomarkers; Cricetinae; Disease Models, Animal;

2006
Role of nitric oxide on pathogenesis of 5-fluorouracil induced experimental oral mucositis in hamster.
    Cancer chemotherapy and pharmacology, 2007, Volume: 59, Issue:5

    Topics: Animals; Antineoplastic Agents; Cricetinae; Enzyme Inhibitors; Fluorouracil; Guanidines; Immunohisto

2007
Evaluation of topical external medicine for 5-fluorouracil-induced oral mucositis in hamsters.
    European journal of pharmacology, 2006, Dec-03, Volume: 551, Issue:1-3

    Topics: Administration, Topical; Alginates; Analysis of Variance; Animals; Anti-Inflammatory Agents; Anti-Ul

2006
Probiotic effects on 5-fluorouracil-induced mucositis assessed by the sucrose breath test in rats.
    Digestive diseases and sciences, 2007, Volume: 52, Issue:3

    Topics: Animals; Bifidobacterium; Breath Tests; Disease Models, Animal; Female; Fluorouracil; Ileum; Immunos

2007
Macroscopic and microscopic effects of GaAIAs diode laser and dexamethasone therapies on oral mucositis induced by fluorouracil in rats.
    Oral health & preventive dentistry, 2007, Volume: 5, Issue:1

    Topics: Aluminum; Animals; Anti-Inflammatory Agents; Antimetabolites; Arsenicals; Biofilms; Dexamethasone; D

2007
Glutamine and alanyl-glutamine accelerate the recovery from 5-fluorouracil-induced experimental oral mucositis in hamster.
    Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:2

    Topics: Animals; Antimetabolites, Antineoplastic; Cricetinae; Dipeptides; Fluorouracil; Glutamine; Glutathio

2008
In vivo imaging of oral mucositis in an animal model using optical coherence tomography and optical Doppler tomography.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Apr-15, Volume: 13, Issue:8

    Topics: Animals; Blood Flow Velocity; Cricetinae; Disease Models, Animal; Fluorouracil; Mesocricetus; Mouth

2007
Questions about the role of palifermin in fluorouracil-based therapy for metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Jul-01, Volume: 25, Issue:19

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cryotherapy; Data Interpretati

2007
[The second report from Sapporo Tsukisamu hospital--chemotherapy for patients with advanced colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:8

    Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplas

2007
Allopurinol modulation of fluorouracil toxicity.
    Cancer chemotherapy and pharmacology, 1981, Volume: 5, Issue:3

    Topics: Allopurinol; Drug Eruptions; Drug Therapy, Combination; Fluorouracil; Hematologic Diseases; Humans;

1981
Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck.
    Cancer, 1984, May-01, Volume: 53, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Squamous Ce

1984
MTX/5-FU trials in gastrointestinal and other cancers.
    Seminars in oncology, 1983, Volume: 10, Issue:2 Suppl 2

    Topics: Aged; Anemia; Conjunctivitis; Drug Evaluation; Drug Therapy, Combination; Fluorouracil; Gastrointest

1983
Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate.
    Journal of surgical oncology, 1984, Volume: 26, Issue:3

    Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Breast Neoplasms; Cy

1984
Phase I study of protracted venous infusion of 5-fluorouracil.
    Cancer, 1981, Dec-15, Volume: 48, Issue:12

    Topics: Adult; Aged; Catheters, Indwelling; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Admini

1981
Alteration in the frequency, severity and duration of chemotherapy-induced mucositis in hamsters by interleukin-11.
    European journal of cancer. Part B, Oral oncology, 1995, Volume: 31B, Issue:4

    Topics: Animals; Antimetabolites, Antineoplastic; Bone Marrow; Cricetinae; Dose-Response Relationship, Drug;

1995
Advanced breast cancer treatment with folinic acid, 5-fluorouracil, and mitomycin C.
    Cancer chemotherapy and pharmacology, 1993, Volume: 32, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Drug Evalua

1993
IL-11, a pleiotropic cytokine: exciting new effects of IL-11 on gastrointestinal mucosal biology.
    Stem cells (Dayton, Ohio), 1994, Volume: 12 Suppl 1

    Topics: Acetates; Acetic Acid; Animals; Animals, Genetically Modified; beta 2-Microglobulin; Colitis; Cricet

1994
[Two patients with far advanced gastric cancer responding to combination chemotherapy with 5-FU and CDDP].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo

1995
Two new cases of hyperpyrimidinuria associated with excessive 5-fluorouracil toxicity.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1994, Volume: 5, Issue:8

    Topics: Adult; Aged; Female; Fluorouracil; Humans; Leukopenia; Mouth Mucosa; Pyrimidines; Stomatitis

1994
[Allopurinol].
    Deutsche medizinische Wochenschrift (1946), 1995, Feb-17, Volume: 120, Issue:7

    Topics: Allopurinol; Fluorouracil; Humans; Mouth Mucosa; Stomatitis

1995
Prevention of chemotherapy-induced ulcerative mucositis by transforming growth factor beta 3.
    Cancer research, 1994, Mar-01, Volume: 54, Issue:5

    Topics: Animals; Cell Cycle; Cell Division; CHO Cells; Cricetinae; Disease Models, Animal; DNA; Epithelial C

1994
A pilot study of concomitant radiation and chemotherapy in patients with locally advanced head and neck cancer.
    American journal of clinical oncology, 1993, Volume: 16, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, S

1993
Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin.
    Cancer, 1993, Mar-01, Volume: 71, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Diarrhea; Drug Synergism

1993
Transforming growth factor-beta 3 mediated modulation of cell cycling and attenuation of 5-fluorouracil induced oral mucositis.
    Oral oncology, 1997, Volume: 33, Issue:1

    Topics: Administration, Topical; Animals; Antimetabolites, Antineoplastic; Biomarkers; Cell Division; Cricet

1997
Mitigating effects of interleukin 11 on consecutive courses of 5-fluorouracil-induced ulcerative mucositis in hamsters.
    Cytokine, 1997, Volume: 9, Issue:8

    Topics: Animals; Blood Cell Count; Bone Marrow Cells; Cricetinae; Fluorouracil; Interleukin-11; Male; Mesocr

1997
Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer.
    Cancer research, 1998, Apr-15, Volume: 58, Issue:8

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Female; Flu

1998
Risk factors associated with mucositis in cancer patients receiving 5-fluorouracil.
    Oral oncology, 1998, Volume: 34, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cohort Studies; Digestive System Ne

1998
Effect of local application of the antimicrobial peptide IB-367 on the incidence and severity of oral mucositis in hamsters.
    Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 1999, Volume: 87, Issue:5

    Topics: Animals; Anti-Infective Agents, Local; Antimicrobial Cationic Peptides; Bacillus; Colony Count, Micr

1999
Evaluation of bovine lactoferrin as a topical therapy for chemotherapy-induced mucositis in the golden Syrian hamster.
    Oral oncology, 1999, Volume: 35, Issue:2

    Topics: Animals; Antimetabolites, Antineoplastic; Cheek; Cricetinae; Drug Evaluation; Fluorouracil; Immunoco

1999
Impact of oral submucous fibrosis on chemotherapy-induced mucositis for head and neck cancer in a geographic area in which betel quid chewing is prevalent.
    American journal of clinical oncology, 1999, Volume: 22, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Areca; Asia, Southeastern; Cisplatin; F

1999
Intestinal permeability in patients with chemotherapy-induced stomatitis.
    Journal of cancer research and clinical oncology, 2001, Volume: 127, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Digestive System Neoplasms

2001
Adjuvant postoperative 5-fluorouracil chemotherapy combined with pelvic radiation for rectal cancer: results from an Asian population.
    Cancer investigation, 2001, Volume: 19, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Agranulocytosis; Antimetabolites, Antineoplastic; Ch

2001
[Concomitant bifractionated radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in locally progressive, non-resectable epidermoid carcinomas of the pharynx: ten years experience at the Antoine Lacassagne center].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2001, Volume: 5, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co

2001
Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:9

    Topics: Adult; Aged; Alternative Splicing; Antimetabolites, Antineoplastic; Breast Neoplasms; Colonic Neopla

2001
Mucositis as a treatment-limiting side effect in the use of capecitabine for the treatment of metastatic breast cancer.
    Journal of the American Academy of Dermatology, 2001, Volume: 45, Issue:5

    Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil

2001
Correspondence re: Raida, M. et al., prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:5

    Topics: Alternative Splicing; Antimetabolites, Antineoplastic; Diarrhea; Dihydrouracil Dehydrogenase (NADP);

2002
Improvement of local control of T3 and T4 nasopharyngeal carcinoma by hyperfractionated radiotherapy and concomitant chemotherapy.
    International journal of radiation oncology, biology, physics, 2002, Jun-01, Volume: 53, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D

2002
Effect of oral hygiene on stomatitis in patients receiving cancer chemotherapy.
    The Journal of prosthetic dentistry, 1978, Volume: 40, Issue:3

    Topics: Breast Neoplasms; Cyclophosphamide; Dental Plaque; Doxorubicin; Female; Fluorouracil; Humans; Inject

1978
Allopurinol modulation of high-dose fluorouracil toxicity.
    Cancer treatment reviews, 1979, Volume: 6 Suppl

    Topics: Allopurinol; Drug Therapy, Combination; Fluorouracil; Gastrointestinal Neoplasms; Humans; Leukopenia

1979
The adverse effects of elemental diets on tolerance for 5-FU toxicity in the rat.
    Journal of surgical oncology, 1977, Volume: 9, Issue:5

    Topics: Amino Acids, Essential; Animals; Blood; Blood Proteins; Body Weight; Colon; Diarrhea; Diet; Dietary

1977
Basal-cell carcinoma. A case unmasked by systemic fluorouracil therapy.
    JAMA, 1976, May-31, Volume: 235, Issue:22

    Topics: Administration, Topical; Carcinoma, Basal Cell; Diarrhea; Fluorouracil; Humans; Injections, Intraven

1976
Treatment of advanced bronchogenic carcinoma with adriamycin and 5-fluorouracil.
    British journal of diseases of the chest, 1975, Volume: 69

    Topics: Alopecia; Carcinoma, Bronchogenic; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Hum

1975
Orofacial complications of chemotherapy for breast cancer.
    Oral surgery, oral medicine, and oral pathology, 1992, Volume: 74, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Candidiasis, Oral; Chi-Squa

1992
[Laser therapy in the prevention and treatment of mucositis caused by anticancer chemotherapy].
    Bulletin du cancer, 1992, Volume: 79, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans; Laser Thera

1992
Cryotherapy used to reduce stomatitis.
    Oncology nursing forum, 1992, Volume: 19, Issue:9

    Topics: Cryosurgery; Fluorouracil; Humans; Incidence; Research Design; Stomatitis

1992
Effect of epidermal growth factor on ulcerative mucositis in hamsters that receive cancer chemotherapy.
    Oral surgery, oral medicine, and oral pathology, 1992, Volume: 74, Issue:6

    Topics: Animals; Cell Division; Cricetinae; Epidermal Growth Factor; Epithelial Cells; Epithelium; Fluoroura

1992
Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer.
    Seminars in oncology, 1992, Volume: 19, Issue:3 Suppl 9

    Topics: Administration, Oral; Bone Marrow; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Fluorouracil; H

1992
Severe mucositis after chemotherapy with vinorelbine, 5-fluorouracil, leucovorin and cisplatin.
    European journal of cancer (Oxford, England : 1990), 1991, Volume: 27, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Fluoroura

1991
Soft-laser therapy for iatrogenic mucositis in cancer patients receiving high-dose fluorouracil: a preliminary report.
    Journal of the National Cancer Institute, 1992, Mar-04, Volume: 84, Issue:5

    Topics: Female; Fluorouracil; Humans; Iatrogenic Disease; Laser Therapy; Male; Middle Aged; Mouth Mucosa; Ne

1992
Tolerance of extended (28 day) continuous infusion of 5-fluorouracil in advanced head and neck cancer.
    Selective cancer therapeutics, 1991,Spring, Volume: 7, Issue:1

    Topics: Adult; Aged; Drug Eruptions; Drug Tolerance; Female; Fluorouracil; Head and Neck Neoplasms; Humans;

1991
Treatment of 5-fluorouracil-induced stomatitis by allopurinol mouthwashes.
    Oncology, 1991, Volume: 48, Issue:4

    Topics: Allopurinol; Fluorouracil; Gastrointestinal Neoplasms; Humans; Mouthwashes; Stomatitis

1991
Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:11

    Topics: Bone Marrow Diseases; Dipyridamole; Dose-Response Relationship, Drug; Drug Interactions; Fluorouraci

1991
Concurrent cisplatin, infusional fluorouracil, and conventionally fractionated radiation therapy in head and neck cancer: dose-limiting mucosal toxicity.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D

1991
An animal model for mucositis induced by cancer chemotherapy.
    Oral surgery, oral medicine, and oral pathology, 1990, Volume: 69, Issue:4

    Topics: Animals; Cricetinae; Disease Models, Animal; Epithelium; Fluorouracil; Leukopenia; Male; Mesocricetu

1990
Studies on the prevention of 5-fluorouracil-induced oral mucositis.
    NCI monographs : a publication of the National Cancer Institute, 1990, Issue:9

    Topics: Allopurinol; Cryosurgery; Fluorouracil; Humans; Mouth Mucosa; Mouthwashes; Stomatitis

1990
A phase I clinical trial of combined fluoropyrimidines with leucovorin in a 14-day infusion. Demonstration of biochemical modulation.
    Cancer, 1989, Jan-15, Volume: 63, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Admin

1989
Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil.
    Cancer chemotherapy and pharmacology, 1989, Volume: 24, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Proteins; Chro

1989
Carboplatin and continuous infusion 5-fluorouracil for advanced head and neck cancer.
    European journal of cancer & clinical oncology, 1989, Volume: 25, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell;

1989
Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1989, Volume: 7, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcino

1989
Allopurinol mouthwash as prophylactic therapy for 5-fluorouracil-induced mucositis.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 1989, Volume: 15, Issue:3

    Topics: Administration, Oral; Allopurinol; Fluorouracil; Humans; Mouth Mucosa; Stomatitis

1989
5-Fluorouracil rechallenge by protracted infusion in refractory breast cancer.
    Cancer, 1989, Aug-15, Volume: 64, Issue:4

    Topics: Adult; Aged; Breast Neoplasms; Fluorouracil; Hematologic Diseases; Humans; Infusions, Intravenous; M

1989
Allopurinol mouthwash for prevention of fluorouracil-induced stomatitis.
    Clinical pharmacy, 1989, Volume: 8, Issue:9

    Topics: Allopurinol; Breast Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Mouthwashes;

1989
Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma.
    Cancer, 1989, Jan-01, Volume: 63, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiomyopathies; Cyc

1989
High-dose cisplatin administration without hypertonic saline: observation of disabling neurotoxicity.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1985, Volume: 3, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carcinoma, Squamo

1985
A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1986, Volume: 4, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellul

1986
Phase II study of a 5-fluorouracil, teniposide and mitomycin-C combination chemotherapy in advanced colorectal carcinomas.
    Tumori, 1988, Feb-29, Volume: 74, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Colonic Neoplasms; Diarrhea; D

1988
Long-term, ambulatory, continuous IV infusion of 5-FU for the treatment of advanced adenocarcinomas.
    Cancer treatment reports, 1985, Volume: 69, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Breast Neoplasms; Drug Eruptions; Female; Fluorouracil

1985
Reduction of oral toxicity of 5-fluorouracil by allopurinol mouthwashes.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 1988, Volume: 14, Issue:5

    Topics: Allopurinol; Fluorouracil; Gastrointestinal Neoplasms; Humans; Mouth Mucosa; Mouthwashes; Stomatitis

1988
High-dose continuous infusion folinic acid and bolus 5-fluorouracil in patients with advanced colorectal cancer: a phase II study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1986, Volume: 4, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Fem

1986
High-dose folinic acid (HDFA) combined with 5-fluorouracil (5-FU) in first line chemotherapy of advanced large bowel cancer.
    European journal of cancer & clinical oncology, 1987, Volume: 23, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea; Female; Fl

1987
Allopurinol mouthwashes and 5-fluorouracil induced oral toxicity.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 1985, Volume: 11, Issue:3

    Topics: Allopurinol; Colonic Neoplasms; Fluorouracil; Humans; Intestinal Mucosa; Mouth Mucosa; Mouthwashes;

1985
Phase I-II trial with cisplatin and 5-FU in recurrent head and neck cancer: an effective outpatient schedule.
    Cancer treatment reports, 1985, Volume: 69, Issue:9

    Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Ce

1985
5-Fluorouracil and methotrexate administered simultaneously as a continuous infusion. A phase I study.
    Cancer, 1985, Nov-15, Volume: 56, Issue:10

    Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sc

1985
Phase I and pharmacologic study of 72-hour infused 5-fluorouracil in man.
    American journal of clinical oncology, 1985, Volume: 8, Issue:5

    Topics: Drug Evaluation; Female; Fluorouracil; Humans; Infusions, Parenteral; Male; Nausea; Neoplasms; Neutr

1985
Combination chemotherapy in gastrointestinal cancer.
    Cancer research, 1970, Volume: 30, Issue:5

    Topics: Adenocarcinoma; Adult; Alopecia; Appendiceal Neoplasms; Diarrhea; Drug Eruptions; Fluorouracil; Gall

1970
Phase I study of phenesterin (NSC-104469).
    Cancer chemotherapy reports, 1971, Volume: 55, Issue:3

    Topics: Administration, Oral; Adult; Aged; Androgens; Antineoplastic Agents; Blood Cell Count; Blood Platele

1971
Toxicity studies of fluorouracil used with adrenalectomy in breast cancer.
    Archives of surgery (Chicago, Ill. : 1960), 1972, Volume: 105, Issue:1

    Topics: Adrenalectomy; Adult; Aged; Alopecia; Ataxia; Blood Platelet Disorders; Breast Neoplasms; Diarrhea;

1972
5-fluorouracil intravenous infusion for 48 hours, repeated every two weeks.
    Journal of surgical oncology, 1972, Volume: 4, Issue:1

    Topics: Adult; Aged; Breast Neoplasms; Diarrhea; Evaluation Studies as Topic; Female; Fluorouracil; Gastroin

1972
Experience with ftorafur treatment in breast cancer.
    Neoplasma, 1972, Volume: 19, Issue:4

    Topics: Breast Neoplasms; Diarrhea; Female; Fluorouracil; Furans; Humans; Injections, Intravenous; Leukopeni

1972
The effect of 5-fluorouracil on small bowel mucosa.
    Journal of surgical oncology, 1971, Volume: 3, Issue:5

    Topics: Adult; Aged; Biopsy; Diarrhea; Duodenum; Female; Fluorouracil; Humans; Intestinal Mucosa; Intestine,

1971
Radiation plus 5-fluorouracil (NSC-19893): clinical demonstration of an additive effect in bronchogenic carcinoma.
    Cancer chemotherapy reports, 1971, Volume: 55, Issue:3

    Topics: Adenocarcinoma; Aged; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Female; Fluorouracil; Human

1971
[Combined cytostatic treatment of solid tumours with cyclophosphamide (Endoxan), vincristine, methylaminopterin (Methotrexate) and 5-fluorouracil].
    Ugeskrift for laeger, 1971, May-14, Volume: 133, Issue:19

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow; Child; Child, Preschool; Cyclophosphami

1971
Oral administration of fluorouracil. A preliminary trial.
    Archives of surgery (Chicago, Ill. : 1960), 1968, Volume: 97, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Alopecia; Bile Duct Neoplasms; Colonic Neoplasms; Diarrhea; Fluorouraci

1968